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EVALUATION OF QUANTITATIVE ELECTROENCEPHALOGRAPHY FOR 
ASSESSMENT OF CENTRAL NERVOUS SYSTEM STIMULANT RESPONSE 
ABSTRACT 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University . 
Patricia W. Slattum ,  Pharm .D. , Ph . D .  
Medical College o f  Virginia--Virginia Commonwealth University, 1992 
Major Director: Dr. William H .  Barr 
The objective of this investigation was to evaluate quantitat.ive 
electroencephalography (EEG) as a measure of CNS stimulation . The reproducibility 
and sensitivity of quantitative EEG was compared to neuroendocrine, mood , and 
psychomotor performance measures. 
The study was conducted in two parts . The first part investigated the inter- and 
intra-individual variability associated with a series of pharmacological response 
measures under baseline (no drug) conditions .  It was an open-label pilot study in  
which eight healthy male volunteers underwent a series of tests (EEG , visual 
continuous performance task (CPT) , a finger tapping task, and self-rated mood scales) 
repeated eight ti mes over a 1 2  hour period on three occasions, one week apart. The 
second part evaluated the sensitivity of quantitative EEG to dextroamphetamine (DA) 
compared to other response measures. It was a double-blind , placebo-controlled , 
four-period crossover study in eight healthy male volunteers . Subjects received 5 mg , 
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10 mg, or 20 mg DA or placebo orally, and underwent the same series of tests as 
well as blood collection for serum prolactin and DA determination , eight times over a 
1 2  hour period . A GC method allowing quantitation of 2ng/mL DA in serum was 
developed. 
The greatest between-day, within-day , and intrasubject variability was associated 
with quantitative EEG. Learning effects were observed for the psychometric tests, 
and first session effects were apparent for several of the tests including the EEG . 
EEG response to DA was observed only in the 3 subjects who had baseline alpha 
activity greater than 35 % .  There was a statistically significant decrease in serum 
prolactin levels after DA administration, with the largest decrease observed after the 5 
mg dose. Mood scales showed that 3 of 9 subjects experienced dysphoria after DA 
dosing. The effect on mood was generally greater as the dose increased. One subject 
was discontinued from the study because he experienced intense dysphoria after the 5 
mg dose. Doses could not be distinguished based on the results of the psychometric 
tests. Effects on mood , serum prolactin levels, and performance as measured by CPT 
and finger tapping were not correlated with the EEG changes observed . 
Pharmacokinetic evaluation showed that the rate of DA absorption appears to decrease 
as the dose increases. 
Quantitative EEG conducted under our study conditions and study population 
was not more sensitive for the assessment of CNS stimulation than the other response 
measures evaluated . The sensitivity may be improved by screening volunteers to 
select subjects with higher background alpha activity . 
CHAPTER 1 
Introduction 
Accurate and reproducible measures of drug effect on the central nervous 
system (CNS) are needed in order to study the pharmacodynamics of centrally-acting 
drugs. I Pharmacodynamics, or the relationship between drug concentration in the 
systemic circulation and pharmacologic effect, is important because it contributes to 
the interindividual variability observed in drug response. Determining the association 
between drug concentration and subsequent response is necessary for optimizing drug 
therapy . Studies of the pharmacodynamics of centrally-acting drugs have been limited 
primarily by the difficulty in obtaining quantitative measures of CNS response . 2  
Ideal ly,  a measure of drug effect used in pharmacodynamic studies should be 
quantitative, objective, and non-invasive. General ly ,  there should be a gradual , rather 
than an all-or-none, change in the response measure with changing drug 
concentration . The measure should be sensitive to small differences in drug 
concentration . The pharmacodynamic measure should be reproducible both within 
and between individuals .  It is important to be able to measure the response 
repeatedly in the same individual without changes occurring due to learning or 
tolerance. Lastly ,  the response measure should be meaningful ;  the measured response 
should relate to the therapeutic or toxic clinical effects of the drug. 2.3 
Various psychometric tests, ranging from self-rating scales of psychologic state 
to computerized performance tasks, have been used to assess the pharmacodynamics 
of centrally-acting drugs.2.4•s Psychometric tests are noninvasive and the response 
can be quantitated. However, these tests are not ideal pharmacodynamic measures. 
Although some tests can measure certain aspects of behavior as a function of drug 
response, they are more or less subjective and may not be reproducible. Many 
psychometric tests are not suitable for repeated measures, since learning and 
motivational factors influence the results of subsequent tests. These limitations may 
contribute to insensitivity of the measures to small changes in serum drug 
concentrations. The relationship of performance on psychometric tests to the "real 
life" behavioral and psychologic effects of drugs are also difficult to define. 
Therefore, psychometric tests are not entirely acceptable as eNS response measures. 
More recently ,  quantitative EEG has been employed to measure eNS 
pharmacodynamics. 2.6 Many studies using EEG to profile or classify psychoactive 
drugs have been conducted , but few studies have attempted to correlate EEG 
parameters with concurrently measured drug concentrations and response to 
psychometric tests. Pharmacodynamic modeling of the EEG effects of eNS 
depressants such as anesthetic agents7.8·9. IO and benzodiazepinesl l . 12 . 1 3 . 1 4  has 
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been performed successfully. Quantitative EEG is objective, noninvasive, and derived 
parameters change gradually with changes in plasma drug concentration. Repeated or 
continuous measures of the EEG can be made, although a familiarization session 
before the study is advisable to avoid a first-session effect due to anxiety. IS 
Learning effects on the EEG have not been reported.2 Recording of the EEG also 
requires less subject cooperation than completion of psychometric tests. The 
reproducibility and sensitivity of quantitative EEG parameters however, requires 
further evaluation. The behavioral or psychologic meaning of changes in EEG 
parameters is also unclear. If these issues can be addressed , quantitative EEG may 
become a preferred measure of CNS pharmacodynamic response. 
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This study was designed to evaluate quantitative EEG as a pharmacodynamic 
tool to measure CNS stimulation. Dextroamphetamine was chosen as the model 
compound for this evaluation. Dextroamphetamine is a sympathomimetic amine 
known to have potent CNS stimulant effects. The d isomer of amphetamine is 3 to 4 
times more potent in exciting the CNS than the I isomer. 16 Single doses have been 
administered safely to normal volunteers. Its concentration in the systemic circulation 
can be measured adequately by gas chromatographic assay methods and it does not 
have active metabolites that play a clinically significant role after single doses. 17 
The renal excretion of dextroamphetamine is dependent on urinary pH and volume, so 
acidifying the urine will result in constantly enhanced excretion. When urine pH is 
maintained between 5 and 5.5, the elimination half-life of dextroamphetamine is 
approximately 7 hours. I S  Dextroamphetamine has been reported to decrease delta 
activity and increase alpha and beta activity on the EEG . 19.20 Mood changes after 
dextroamphetamine have been measured using a variety of rating 
scales .2 1 .22.23.24.25 It also produces measurable effects on performance 
tasks .26.27.2s.29.30 Dextroamphetamine affects the neurotransmitters dopamine, 
norepinephrine, and serotonin. 3 1  Changes in these neurotransmitter systems result in 
changes in the release of hormones such as prolactin. The prolactin release after 
dextroamphetamine administration could also be used in this study as a 
pharmacodynamic response measure. Based on these characteristics, 
dextroamphetamine was chosen as a model compound to test the sensitivity of 
quantitative EEG as a pharmacodynamic measure of eNS stimulation. 
1 . 1  Objectives 
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These studies were designed to test the following hypotheses: 1 )  quantitative 
EEG is a sensitive and reproducible measure of the eNS 's response to 
sympathomimetic drugs as compared to more widely used methods such as 
psychometric testing, subjective rating scales, or neuroendocrine tests and 2) changes 
in the EEG after sympathomimetic drug administration are related to the behavioral , 
psychological and neuroendocrine effects observed as well as the plasma concentration 
of the drug. 
Two studies were conducted. The purpose of the first study was to investigate 
the inter- and intra-individual variability associated with a series of potential eNS 
pharmacodynamic response measures, including quantitative EEG , under baseline (no 
drug) conditions.  Results from this study were used to design a study of quantitative 
EEG as a pharmacodynamic measure for eNS stimulation . The second study was 
designed to examine the relationship between EEG changes after administration of 
dextroamphetamine and 1) performance on automated psychometric tests, 2) serum 
prolactin levels, 3) subjective response as assessed by self-rated mood scales, and 4) 
serum concentration of dextroamphetamine. The sensitivity of EEG parameters to 
dextroamphetamine concentration in serum was compared with that of more subjective 
measures. 
1 . 2 Rationale 
It is necessary to understand the pharmacodynamic and pharmacokinetic factors 
influencing the response to a drug to optimize drug therapy for the individual patient 
and to support efficient and rational development of new drugs. 32 To accomplish 
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this task, quantitative, sensitive, accurate, and reproducible measures of drug effect 
are needed. Identification of a suitable measure of the eNS 's  response to drugs has 
proven to be particularly difficult. EEG has been used to qualitatively describe the 
effects of drugs on the eNS since its development by Hans Berger in 1929.33 With 
the advent of the Fast Fourier transform and advanced digital computing, EEG has 
become a quantitative as well as a qualitative descriptor of brain electrical activity . 
The sensitivity and reproducibility of the EEG as a pharmacodynamic measure 
requires further evaluation. In addition, the behavioral and psychological meaning of 
drug-induced EEG changes remains unclear . These studies were designed to evaluate 
the sensitivity and reproducibility of EEG as a response measure compared to 
psychometric tests that are more often used , and to provide a better understanding of 
the relationship of the EEG to the clinical effects of the drug. A more sensitive, 
reproducible measure of eNS response is necessary to evaluate the effects of the 
aging process and various disease states on the pharmacodynamics of centrally-acting 
drugs. In addition , an improved eNS response measure for sympathomimetic drugs 
is needed to evaluate the eNS-stimulating properties of drugs such as 
phenylpropanolamine, where the degree of eNS stimulation and its potential clinical 
significance in man is controversial .34  
CHAPTER 2 
Literature Review 
2.1 Quantitative Electroencephalography 
EEG is the recording of changes in the electrical potential of various regions of 
the brain as measured by electrodes placed on the scalp. These fluctuating electrical 
potentials or brain waves can be characterized by their voltage or amplitude, and 
frequency. Brain wave patterns vary depending on the region of the brain being 
measured , the level of consciousness of the subject, and the age of the subject. EEG 
is used to record the spontaneous background activity of the brain or the activity 
evoked by external sensory stimulation.  
Attempts to quantitate the patterns observed in  the EEG began with the earliest 
EEG recordings. 35 The EEG tracing shows fairly irregular patterns, and cannot 
easily be described by explicit mathematical relationships. Rather, it is characterized 
in  statistical terms, by probability distributions and averages . 36 As advances in  
computing technology have developed , a variety of techniques have become available 
for analyzing EEG data quantitatively .  Some of these include frequency or spectral 
analysis ,  bispectral analysis, topographic mapping,  compressed spectral arrays,  and 
significance probability mapping.35.37 EEG signals are processed by Fast Fourier 
transformation , aperiodic analysis, wavelet analysis, and other techniques. 38 EEG 
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measurements can be described by various scores (dependent variables) in various 
domains (independent variables). Domains include the time domain (score versus 
time), the frequency domain (score versus frequency) and the spatial domain (score 
versus electrode location) .  A wide range of  scores have been used, including 
intensity or amplitude, power or the square of the amplitude, coherence, z-scores, 
relative power, peak frequency, frequency ratios, functions from discriminant 
analysis, slope descriptors (activity, mobility and complexity) , values from period and 
zero-crossing analysis, and parameters from autoregressive modeling or spectral 
parameter analysis. Quantitative analysis of the EEG results in a massive amount of 
information and some sort of data reduction is usually necessary. 36 Various statistical 
descriptors have been employed for this purpose. A number of computerized systems 
for quantitative EEG analysis are now commercially available. 
Many potential problems in the techniques and the interpretation of quantitative 
EEG have been identified . The functional significance of changes in quantitative EEG 
parameters is largely unknown . The role of quantitative EEG in diagnosing 
conditions affecting the brain and monitoring response to treatment is 
controversial . 39•35 A considerable amount of research employing quantitative EEG 
techniques is currently being conducted , but the clinical utility of quantitative EEG 
remains to be confirmed. Despite the current limitations of quantitative EEG 
technology and our incomplete understanding of the meaning of quantitative EEG 
data, it is still one of the only ways to continuously and noninvasively examine the 
functioning brain with fraction-of-a-second temporal resolution.4o Significant 
technological developments, such as computerized tomography and magnetic 
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resonance imaging provide superior structural resolution, but do not evaluate dynamic 
brain activity . Positron emission tomography and single-photon emission 
computerized tomography examine brain function by tracking blood flow and local 
cerebral metabolism, but lack the temporal resolution of EEG. Interest in the use of 
quantitative EEG to understand brain physiology and behavior, to diagnose brain 
dysfunction and to monitor the effects of therapeutic interventions continues. 
2 . 1 . 1  Use of Quantitative EEG in Drug Research 
Evidence of eNS activity for many compounds ranging from aspirin to 
hormones has been provided by EEG studies.4 1  The EEG has been used to examine 
the effects of drugs on the central nervous system since Hans Berger' s  descriptions of 
EEG changes following cocaine, scopolamine, morphine and barbiturate 
administration in the 1 930s .33 It was not until the 1 950s however, that systematic 
studies of the effects of medications on the EEG were conducted by Bente, Iti l ,  Fink 
and others. 42 As computer technology and its applications in EEG analysis grew, 
investigators in the 1 960s began using quantitative EEG patterns in an attempt to 
classify psychoactive compounds and predict responders to therapy. 33.41 Early studies 
relating EEG changes after drug administration to effects on behavior were not 
entirely successful, and apparent dissociations between the EEG and behavior resulted 
in waning interest in the utility of EEG in psychopharmacology from the mid 1 960s 
until the mid 1 970s. In the 1 970s, renewed interest in EEG and drug research 
developed . 33 S ince that time, technology for quantitating EEG has also grown 
tremendously.  Use of quantitative techniques to examine drug effects has proven 
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much more useful than visual inspection of EEG records because drugs induce 
changes in the EEG following acute administration of therapeutic doses that are within 
normal variability . 41  Controlled experiments and mathematical signal analysis are 
needed to identify drug-induced EEG changes. 
Quantitative EEG has been employed in a wide variety of applications in clinical 
psychopharmacology including classification of psychoactive drugs42,43, prediction 
and investigation of CNS activity early in a drug ' s  development',45,46, 
examination of the CNS toxicity of drugs whose primary action is outside the 
CNS47.48.49, comparison of the bioavailability of various dosage forms of 
psychoactive drugs42.50.5 1 .52, and investigation of the pharmacodynamics of 
centrally-acting drugs. Quantitative EEG has not proved to be as useful to study drug 
abuse or to predict responders to drug treatment.41  The use of quantitative EEG to 
evaluate pharmacodynamic relationships will be reviewed in more detail below. 
Pharmacodynamic studies examine the relationship between drug concentration 
in the systemic circulation and pharmacologic effect. Pharmacodynamic studies 
employing EEG as a measure of pharmacologic effect have investigated the time 
course , peak effect, and duration of CNS activity for many psychoactive drugs.41 
Because the psychological and behavioral meaning of EEG changes following drug 
administration is not well defined , the EEG is considered to be a surrogate measure of 
drug effect. 53,54 The clinical relevancy of EEG changes has not been established. 
Quantitative EEG has been used most successfully to establish pharmacokinetic­
pharmacodynamic relationships for two groups of drugs--anesthetic agents and the 
benzodiazepines. 
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Anesthetic drugs cause profound effects on the EEG as subjects progress from 
consciousness to unconsciousness. 54 By quantitating these EEG effects and applying 
pharmacodynamic modelling procedures, much has been learned about the clinical 
pharmacology of anesthetic agents. Quantitative EEG techniques have been used to 
investigate intravenous anesthetics (thiopental , etomidate, methohexital , and propofol) ,  
opiates (fentanyl , alfentanil , sufentanil ,  and morphine) , dissociative anesthetics 
(ketamine) and benzodiazepines (midazolam) . 54  Pharmacodynamic studies of 
thiopental using the spectral edge of the EEG as a response measure have examined 
the rate of equilibration of thiopental between the blood and the sites of action , 
individual eNS sensitivity to thiopental , and whether acute tolerance to the drug 
develops during repeated infusions. 8.7 Studies of the EEG effects of fentanyl and 
alfentanil have found that the differences in the time course of the clinical effects of 
these opioids can be explained by differences in the rate of equilibration between 
effect site and plasma concentrations. 55 Using the median frequency of the EEG 
power spectrum as a response measure, investigators have also employed 
pharmacodynamic modelling to examine differences in the eNS activity of the 
enantiomers of ketamine.9 Parameters from aperiodic analysis of the EEG were found 
to be suitable for measuring the pharmacodynamic effects of midazolam during 
anesthesia, I3 .56 and EEG effects have been used to compare the eNS potencies of 
benzodiazepines . 14 Pharmacodynamic modelling of EEG effects has also been used to 
examine the effect of age on the pharmacodynamics of thiopental .57.58 The use of 
quantitative EEG in pharmacodynamic investigations has been most successful with 
the anesthetic agents, perhaps due to the alterations in consciousness and associated 
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substantial EEG changes produced by these drugs . There is also some evidence that 
the EEG changes observed with anesthetic agents are related to the depth of anesthesia 
achieved ,8  so the EEG changes may also be a clinically meaningful response measure. 
Pharmacodynamic studies using quantitative EEG have also been productive for 
the benzodiazepines when the drugs are given in doses and by routes of administration 
that do not result in loss of consciousness . S9 EEG changes have been used to study 
tolerance to a1prazolam in healthy volunteers , 1 2  the time course of eNS activity after 
loprazolam administration in the elderly,60 and the circadian variation in the eNS 
effects of midazolam .61  Measures that have been used to describe benzodiazepine 
effects on the EEG include percent alpha activity,61 total amplitude in the 1 3  - 30 Hz 
range, I I  and spectral edge. 12 Quantitative EEG is an objective measure of the effects 
of benzodiazepines , and EEG changes may correspond to changes in sedation , mood , 
psychomotor performance, and memory. S9 
Much work still remains in realizing the potential of EEG in drug research.  
Investigations in  drug classification with EEG is  continuing .62.63 Quantitative EEG 
is an objective, noninvasive, continuous response measure which shows promise for 
understanding the pharmacodynamics of eNS-active drugs . Quantitative EEG has 
been used most successfully to study the pharmacodynamics of anesthetics and 
benzodiazepines , but its utility for other drugs requires further work. The 
relationship between EEG changes and important aspects of performance, mood, and 
cognition is unclear. The utility of EEG compared to other eNS response measures 
also requires further investigation . 
2 . 1 .2 Methodology in Pharmaco-EEG Studies 
A number of methodological issues are important in the studies incorporating 
quantitative EEG as a response measure. They have been raised by investigators in 
pharmaco-EEG and quantitative EEG more generally . The quantitative EEG 
parameters obtained at the end of a study lie at the end of a long chain of 
physiological , technical , and mathematical steps that are all susceptible to error and 
artifact. Careful control of experimental conditions in pharmaco-EEG studies is 
essential . This review will address subject screening, the testing environment, 
familiarization sessions, control of vigilance, artifact minimization , choice of 
reference electrode, number of EEG channels recorded , length of data sample, 
stimulation modalities, definition of classic frequency bands, and choice of EEG­
derived parameters for measuring response. 
Careful subject screening to ensure a homogenous subject group is essential. 
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Demographic, physical , and psychological attributes can influence the EEG and the 
response to psychoactive drugs. The EEG depends on factors other than the drug 
under study, including age, gender, and medical history.4 1  Smoking and smoking 
withdrawal can also alter the EEG. 41 Correlations between quantitative EEG and the 
menstrual cycle have been described . 41 The EEG response to drugs is influenced by 
the emotional status and neuropsychological traits of the subject, and the baseline 
EEG pattern prior to drug administration.41 .64 Some studies require screening EEGs 
to contain a certain level of alpha activity for example, for the subject to be eligible 
for entry into the study.65.66 Drug effects on mood, performance, and the EEG 
have been shown to depend on psychological selection criteria. 67 Some investigators 
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recommend that subjects be interviewed before beginning each study period 
concerning the quality and duration of their sleep the night before dosing . 67 If the 
sleep is more than one hour under the average length of sleep for the subject, the 
investigation is delayed by one week. Guidelines for conducting Pharmaco-EEG 
studies in man suggested by an expert group organized at the Federal Health Office of 
the Institute for Drugs (Berlin) state that subjects should be as homogeneous as 
possible with respect to demographic characteristics, medical status, sleep history, use 
of tobacco, personality characteristics (such as emotional lability, neuroticism , and 
extroversion/introversion) , and reaction to stress . 68 If these variables cannot be 
controlled , they should as least be documented . 
Careful control of the testing environment is critical to the success of pharmaco­
EEG studies. The setting in which experiments are conducted and procedures used to 
collect pharmacodynamic data can affect the EEG .41  EEG changes can occur with 
changes in blood pressure, heart rate, sleep habits, and blood sugar.41  Stressful 
testing situations can trigger neurohormonal changes that can affect the EEG .41  
Unsystematic changes in the testing environment are particularly problematic and can 
affect the data enough to alter the results of statistical analysis.41  Factors important to 
standardize between treatment periods include time of day for the recording , quality 
of the previous night ' s  sleep, and type and scheduling of meals.41 Subjects must be 
isolated from sensory stimulation and intermittent disturbances during EEG 
recordings.41  Some studies have been carried out in sound-attenuated electrically­
shielded room with the recording equipment isolated from the subject. 69 Subjects 
have worn headphones to exclude external noise . 70 In general , experiments should 
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be designed to avoid spontaneous fluctuations in vigilance. Wong recommended that 
quantitative EEG measurements be obtained in a quiet, dark environment. 71 The 
subject should be instructed to remain relaxed and alert. This setting fosters 
decreased vigilance, and may be inappropriate for studying sedative drugs or 
potentially useful for studying stimulants.41 The guidelines suggested by the expert 
group of the Federal Health Office of the Institute for Drugs state that factors that 
should be controlled include room temperature, humidity , sound level and light 
intensity, intermittent disturbing events , organization of the measurement setting, 
position of the subject, amount and nature of sensory stimulation , degree of 
interaction with staff, adaptation to the situation, level of vigilance, time of recording, 
and ti ming and type of meals. 68 
Familiarization sessions are necessary to acclimate subjects to the testing 
environment and the study procedures prior to administering study treatments. Irwin 
and Fink report that less EEG changes and a more stable level of alertness occurred 
during the first session in pharmaco-EEG studies than on subsequent days. IS They 
postulate that this increased alertness is due to unfamiliarity with the testing situation . 
Herrmann notes that an single blind adaptation day is necessary because subjects are 
often restless and anxious on the first day in a study.  67 
Vigilance is a term used to describe the behavior of watching for and 
responding to irregular critical signals .72 It encompasses the concepts of attention , 
attentiveness, and arousal . Vigilance is the primary factor affecting the resting 
EEG.41 Alpha amplitude is attenuated when subjects reported a subjective feeling of 
decreased vigilance.49 Some studies have included both a vigilance-controlled and a 
resting EEG recording at each measurement time.73 During the vigilance-controlled 
EEG the technician tries to keep the subject alert by arousing the subject when signs 
of drowsiness appear on the EEG. Pooling data across subjects whose alert EEG 
patterns are intrinsically different can result in loss of information .70 Subjects may 
also be requested to perform a simple auditory continuous performance task to 
stabilize the level of vigilance. 74 Another method proposed to aid in the 
maintenance of vigilance is to have subjects continuously press a button.75 If they 
release the button , a tone sounds to arouse them. Changes in vigilance are easier to 
detect in subjects with high background alpha activity.74 Some investigators have 
given snacks every few hours rather than heavy meals at usual meal times during 
pharmaco-EEG studies to reduce the effects of heavy meals on vigilance.73 
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I t  is important to accurately select artifact-free epochs for quantitative EEG 
analysis . 76 Artifacts can occur due to eye movement, muscle activity ,  respiratory 
motion, glossal and pharyngeal movement, sweating, poor electrode contact, and 
ambient electrical fields. n Some artifacts unique to quantitative EEG also occur, 
such as leakage and smearing. 35 Leakage results in increased frequency values across 
the whole spectrum and occurs when data with a nonzero initial and final value is 
used for a frequency transformation. Smearing is the artifactual broadening of peaks 
in the frequency domain resulting from the use of certain filters designed to reduce 
leakage. Detection of artifacts is not an easy task. Automated artifact rejection may 
be helpful, but the detection rates are not sufficiently high at this point to replace a 
detailed review of the EEG record for artifacts by the electroencephalographer. 35.78 
Artifact monitoring electrodes can be used to measure vertical and horizontal eye 
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movements to aid i n  the artifact rejection process. Artifacts are most prominent in 
the delta and theta frequency ranges.17 Editing of the EEG record to remove artifacts 
should be conducted by an individual blinded to the treatment that the subject received 
to ensure that marking of artifacts is not drug-specific.67 
Choice of reference electrodes also presents a problem . 3S Many different 
reference sites have been suggested, including linked clavicles, linked mandibles, 
chin ,  linked ears, nose, vertex , an average of an electrodes closest neighboring 
electrodes, and an average of all other electrodes. Any of these reference sites can 
become contaminated with EEG or other electrical activity, which obscures the 
interpretation of the EEG . There is no convincing evidence that one referencing 
scheme is preferable to another for quantitative EEG.69 In pharmaco-EEG, where the 
methodology is highly standardized , the choice of reference may be unimportant as 
long as the reference is not active.69 Most investigators use linked ears as the 
reference point for quantitative EEG studies . 17  Linked ears is an effective reference 
as long as the potentials are relatively low in amplitude and uncorrelated .79 If one 
or both of the ears is very active, the results can be very misleading. Unlike 
traditional EEG , quantitative EEG techniques often allow for the recording of several 
reference sites simultaneously .  Different references can then be examined during data 
analysis. 
The number of EEG channels recorded during pharmaco-EEG studies is also 
important. Different numbers of electrodes are applied to the scalp for quantitative 
EEG measurements by different investigators. Typically, 1 6  to 32 electrodes are 
used. Investigators have used as few as 2 and as many as 128.  There is no 
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consensus on the number or placement o f  electrodes for quantitative EEG beyond the 
traditional 10-20 system of 2 1  electrodes. 35 Spatial distribution of EEG effects may 
be important for assessing the effects of drugs, so a sufficient number of electrodes to 
permit examination of spatial distributions are necessary,'41 The number of electrodes 
is limited by the expense of amplification and filtering equipment, computer speed and 
storage capacity, and difficulty of attaching large numbers of electrodes quickly and 
accurately . TI 
The epoch length and duration of each recording also requires consideration . 
Quantitative EEG data is usually acquired and processed in very short segments of 
time termed epochs or frames. The typical length is several seconds, but can be as 
long as 30 seconds. Usually, successive epochs are acquired and analyzed , so that 
the entire recording last for several minutes. The epoch length needs to be short 
enough to allow for rejection of all artifact contaminated epochs without jeopardizing 
the entire recording, but long enough so that the frequency analysis can accurately 
determine the lowest frequency components. 35 The number of epochs recorded is also 
important. Stability or ergodicity of the EEG refers to changes in the EEG (such as 
change of state or vigiJance) during the recording or between recording sessions. The 
recording should be short enough to minimize changes in state during the recording, 
but long enough to gather sufficient artifact-free epochs for further analysis.35 BEG 
activity must be sampled over a period that is sufficiently long to insure that it is 
representative of the state of the subject.TI Herrmann reports that a 5 minute 
recording was long enough to ensure that means were not overly dependent on 
random variation and short enough to minimize the effects of fluctuating vigilance.67 
A variety of stimulation modalities have been incorporated in pharmaco-EEG 
studies. Under conditions of no stimulation, spontaneous EEG is measured during 
some level of alertness such as alert with eyes-open or eyes-closed, drowsy, or in 
other sleep states. In general , the level of vigilance maintained during spontaneous 
EEG recordings must be carefuUy controlled. The improved control of situational 
variability during sensory stimulation may result in improved sensitivity of evoked 
phenomena compared to quantitation of spontaneous EEG .41 
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The definition of the classic frequency bands is also an important consideration 
in quantitative EEG studies. The classic EEG frequency bands are often defined as 0-
4 Hz for delta, 5-7 Hz for theta, 8- 1 3  Hz for alpha, and 1 4  Hz or greater for beta.35 
In quantitative techniques however, different divisions between the bands are 
sometimes employed. For example, frequency ranges may be defined to allow for 
even breaks at 4 Hz intervals (4 , 8, and 1 2  Hz) . Band definitions are also chosen 
based on clinical experience or statistical methods such as factor analysis .77 There is 
quite a bit of variability between manufacturers and investigators in the definitions of 
the frequency bands, so it is important to know the delineation used in a particular 
investigation when evaluating results . 35 
A wide variety of EEG-derived parameters have been used as response variables 
in pharmaco-EEG studies. Several response variables from spectral analysis have be 
used for comparing treatments.77 Power, which is the square of the amplitude, 
emphasizes very active areas, while amplitudes provide good resolution of mid- and 
low-range activity . Relative power or amplitude (which is calculated by dividing the 
total power or amplitude in the given frequency band by the total power or amplitude 
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across all frequency bands) controls for absolute differences in magnitude between the 
measures, thus facilitating a direct qualitative comparison between subjects. Spectral 
edge, or the frequency below which 95 % of the total EEG power is located, have 
been used to quantitate the effects of benzodiazepines and anesthetics. Several 
parameters from aperiodic analysis have also been used for this purpose. 54 Irwin65 
proposed a measure called the spectral difference index which is a measure of the 
difference between two relative power spectra. This index was found to be a 
sensitive EEG discriminator between drug and placebo sessions for a variety of drugs. 
A similar parameter, the spectral dynamics measure has also been proposed. 80 
Response variables may differ in their sensitivities among subjects, and results of 
studies may differ depending on the response measure under consideration .65 For 
general anesthetics for example, different response measures have been useful for 
each class of drugs. 54 There is no ideal measure of drug response based on the EEG 
for all drugs. Measures should show within-individual baseline consistency and a 
minimal response to placebo. Appropriate measures for different classes of drugs and 
the clinical relevance of changes in these measures requires further investigation . 
Obtaining consistent, accurate results in pharmaco-EEG studies depends in large 
part on carefully controlling the conditions under which the investigation is conducted. 
Some of the factors that must be considered in designing, conducting and interpreting 
pharmaco-EEG studies are discussed above. In the next section , statistical issues 
important for interpreting the results in these studies are reviewed. 
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2 . 1 . 3 Statistical Problems in EEG Analysis 
Statistical difficulties arise in the analysis of pharmaco-EEG studies primarily 
due to the multiplicity of observations: A large number of EEG parameters are 
derived from at least several electrode sites at several points in time. 81 The studies 
are usually crossover in design , with placebo and several drugs or dose levels of a 
drug administered. Other measures such as psychometric tests and mood scales may 
also be coHected. Because of the sizable amount of data and multiple inferential 
statistical statements, classical methods of confmnatory statistics used in clinical trials 
cannot be applied directly. The large number of measurements inflates the likelihood 
of finding chance differences from placebo (alpha error) . In addition , data in EEG 
studies is usually gathered from a small number of subjects. Because of the small 
number of subjects, statistical generalizations are seldom possible. 
Several approaches have been proposed to address the issue of multiplicity of 
observations. To apply a confirmatory statistical analysis ,  a few response measures 
believed to have the must important clinical significance could be chosen for 
hypothesis testing prior to initiating the study. The p-value must then corrected for 
the multiple comparisons by methods such as the Bonferroni correction . 82 Another 
strategy is to reduce the total number of variables for hypothesis testing by pooling 
variables. This could involve summing across groups of electrodes or frequency 
bands, or performing techniques such as a principal components analysis. 82 Again, 
correction of the p-value for the number of comparisons being made is necessary . 
Yet another strategy, although impractical, would be to use a very large number of 
subjects in the study. 
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In many pharmaco-EEG studies, confirmatory statistical analyses are not 
feasible. It may not be possible to pre-select effect measures to examine before 
conducting the study, especially for new drugs. It may also be of interest to examine 
a large number of variables to generate new hypotheses. In these cases , statistical 
analysis is treated as exploratory in nature. Whenever large numbers of post-hoc 
analyses are performed in exploratory data analysis, replication of the results in 
comparable prospective controlled studies is necessary. When this type of validation , 
which is the most convincing, is not feasible, alternate approaches can be considered , 
several statistical validation schemes could be used . 78 These strategies involve 
reserving a portion of the data for testing the results obtained with the rest of the 
data. 
As an alternative to confirmatory and exploratory analysis, Abt has proposed a 
concept termed "Descriptive Data Analysis" for topographical EEG data. 83,&4 In 
this approach , expected differences between the treatments based on previously 
reported studies and patterns apparent from examining the data are evaluated 
statistically without adjustment of the level of significance. The results of these 
analyses are used to make descriptive inferential statements about the data, but not to 
reject null hypotheses. This approach takes into account the idea that greater 
confidence can be placed in statistical results if they have biological relevance (for 
example, if results are related to dose level , are consistent across subjects, or reflect 
the behavioral effects or pharmacokinetics of the drug) . 
Several solutions have been applied to the problem of multiplicity of 
observations in pharmaco-EEG studies. None of these approaches is entirely suitable 
however, and more work is necessary to address this problem . 
2.2 Dextroamphetamine 
Dextroamphetamine, a sympathomimetic amine with CNS stimulant properties, 
was chosen as a model compound to study the sensitivity of quantitative EEG as a 
pharmacodynamic measure. Amphetamines have been used clinically since 1935 to 
treat conditions such as obesity , narcolepsy, hypotension, and attention deficit 
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disorder. Currently, dextroamphetamine preparations are subject to control under the 
Federal Controlled Substances Act of 1 970 as Schedule II drugs. Characteristics of 
dextroamphetamine and its effects on the central and peripheral nervous system are 
described in the following sections. 
2.2.1 Chemical Slructure 
Dexlroamphetamine is the d isomer of amphetamine ({3-phenylisopropylamine) . 
The chemical structure is shown in Figure 2.1. Dextroamphetamine is a basic drug, 
with a pKa of 9.90.  Amphetamine was first synthesized in 1 887 . 17 
Figure 2. 1 The chemical structure of amphetamine 
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2 .2 .2  Pharmacology8S 
Amphetamine is an indirectly acting sympathomimetic drug with potent eNS 
stimulant properties. The d isomer, dextroamphetamine, is three to four times more 
potent as a eNS stimulant than the I isomer. The I isomer is slightly more potent in 
its effects on the cardiovascular system. Amphetamines affect the eNS , the 
cardiovascular system and smooth muscle. 
In the eNS , amphetamines stimulate the medullary respiratory center, the 
cerebral cortex and possibly the reticular activating system. The resulting 
psychological effects depend on the dose and the state and personality of the person 
taldng it. Amphetamines can cause changes in mood (Section 2 . 2 . 6) and in 
performance on various mental and motor tasks (Section 2 . 2 . 7) .  Usage for long 
periods of time or at high doses is usually followed by fatigue and depression . 
Amphetamines have also been reported to decrease appetite perhaps through action on 
the lateral hypothalamic feeding center. 
Amphetamine's action on the eNS appears to result from the release of biogenic 
amines from their storage sites in the nerve terminals of neurons in the eNS . Release 
of norepinephrine appears to be related to increased alertness, appetite suppression , 
and some aspects of motor stimulation. At higher doses, dopamine release appears to 
be responsible for other aspects of altered motor activity and stereotyped behavior. 
At even higher doses, release of 5-hydroxytryptamine (serotonin) may result in 
disturbances of perception. In addition , amphetamine is believed to exercise a direct 
agonistic effect on serotonin receptors. Release of these various neurotransmitters is 
associated with changes in the levels of peptide hormones of the anterior pituitary . 
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These changes are discussed in Section 2 .2 .5 .  
The effects of  amphetamine on  the cardiovascular system result from a 
combination of release of norepinephrine from peripheral nerve terminals and direct 
action on peripheral ex and f3 receptors. Administration of amphetamine results in 
increased systolic and diastolic blood pressure. Heart rate is increased or may be 
slowed by compensatory reflex.ive mechanisms. Effects on smooth muscle, as in the 
gastrointestinal tract, is variable, depending on the state of enteric activity. If activity 
is high , amphetamine may cause relaxation with slowing of movement of intestinal 
contents. On the other hand , if the gastrointestinal system is already relaxed, activity 
may be increased . 
Because amphetamines act on multiple receptors and neurotransmitters in the 
peripheral and central nervous systems, measures of response associated with several 
body systems can be used to assess amphetamine pharmacodynamics. Although the 
mechanisms are not well understood, some measures of CNS stimulation , such as 
mood scales and psychomotor performance tasks are more directly related to 
pharmacological action on specific neurotransmitters or areas of the CNS than others. 
For measures based on changes in the EEG after administration of amphetamine, the 
relationships are even less clear. Changes in the EEG following amphetamine 
administration are discussed in Section 2 .2 .4 .  
2 .2 .3  Pharmacoldnetics 
The pharmacoldnetics of amphetamine have been studied in normal and drug­
dependent volunteers since the 1 950s. The pharmacoldnetic literature for 
amphetamine was recently reviewed by Busto and colleagues . 86 A summary of 
pharmacokinetic parameters obtained from studies in normal volunteers is shown in 
Table 2 . 1 .  Data on the absorption, distribution and excretion of amphetamine is  
presented below. 
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Absorption. Information about the rate and extent of amphetamine absorption 
from the gastrointestinal tract is limited. Beckett and Rowland8? analyzed urinary 
excretion data by the Wagner-Nelson Method and determined that the absorption of 
amphetamine appears to be complete within 2 .5  hours of an oral dose of 10 mg d­
amphetamine ( I  subject) or 15 mg I-amphetamine (3 subjects) . Angrist and 
colleagues88 report that maximum concentrations following 0.25 mg/kg and 0.5 
mg/kg of amphetamine given orally occurred 2-3 and 3-4 hours after administration 
respectively. At I hr, the average plasma levels were lower for the high dose than 
for the low dose. The authors hypothesize that differences between the brands of 
tablets used to prepare the doses in the high and low dose study may account for this 
observation. Wan and colleagues report that concurrent administration of enteric­
coated ammonium chloride or sodium bicarbonate orally did not appear to affect the 
rate or extent of amphetamine absorption . 18 The presence of food does not appear to 
alter the absorption of amphetamine. 88 
Distribution . Protein binding of racemic ( ± ) ,  d- (+) ,  and /- (-) amphetamine 
was determined using an ultrafiltrate technique at plasma concentrations of 1 0  to 1 00  
ng/mL. Plasma protein binding was similar for the two isomers, about 1 6 % Y  
Cerebrospinal fluid concentrations are about 80 % of that observed i n  plasma, which 
reflects the extent of protein binding .89 The apparent volume of distribution after 
Table 2. 1 Summary of Amphetamine Pharmacokinetic Studies in Normal Volunteers 
Reference Isomer Dose/Route Urine pH C ... 
(ng/mL) 
Wan. + /- 1 0  mg PO alkalinized 
Matin & 
Azarnoff' 8 + /- 10 mg PO acidified 
+ 10 mg PO alkalinized 
- 10 mg PO alka! inized 
Beckett & + 1 5  mg PO acidified 
Rowland" 15 mg PO acidified -
+ 10 mg PO acidified 
+ 1 3  mg IV acidi fied 
Davis. + /- 5 . 8  nM IV acidi fied 
Kopin. 
Lemberger 
& alkalinized 
Axelrod90 
Beckett. + 15 mg PO uncontrolled 44 
Salmon & 
Mitchard91 acidified 49.5 
Angrist. + 0.25 mg/kg uncontrolled 39.6' 
Corwin. PO ( ±  2 . 8) 
Bartlik & 
Cooper" 3 5 . 3b 
( ±  3 .4) 
+ 0.5 mg/kg uncontrolled 67.� 
PO (± 5 .45) 
C... = maximum serum or plasma concentration observed 
T... = time at which C ... occurs 
CI = apparent total body clearance 
t ll2 = elimination half-life 
a = fasting 
b = non fasting 
T ... CI 
(hr) (m1/min) 
1 6- 1 1 5  
242-539 
2-3 
2-3 
3-4 
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tll2 
(hr) 
17 .0 ( + )  
23 . 7  (-) 
6 . 8  ( + )  
7 . 7  (-) 
1 5 . 6  ( + )  
25.0 (-) 
4.9 
5.6 
5 . 5  
4 .5  
8- 10 .5  
16-3 1 
oral amphetamine is approximately 250 L in normal healthy volunteers92 and similar 
between the enantiomers, indicating extensive distribution . 18 
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Excretion. Amphetamine is eliminated by excretion unchanged in the urine and 
by metabolism. In a study of amphetamine pharmacokinetics following 1 0  mg oral 
doses, Wan and associates found that plasma amphetamine levels decline 
monoexponentially following absorption and can be adequately described by a 1 -
compartment model . 1 8  Peak concentrations following administration of either isomer 
were proportional to dose. 
The excretion of amphetamine in urine is dependent on the urine pH and urine 
flow. When the urine is acidified , the excretion of unchanged amphetamine is 
approximately four times that of the deaminated metabolites (hippuric and benzoic 
acids) . When the urine is alkalinized, excretion of the deaminated metabolites is 
approximately equal to that of the unchanged drug.90 The elimination half-life under 
conditions of acidic urine production (PH < 6.0) is 8 to 10 .5 hours, while under 
alkaline conditions (PH > 7.5) ,  the half-life was prolonged to 1 6  to 3 1  hours.90 The 
renal clearance of amphetamine also depends on urine flow. When the pH is between 
5 and 6, renal clearance is about half as much if flow is less than 30 mLlhr than if 
flow is 30- 1 25 mLlhr. Diuresis, with flows greater than 1 25 mLlhr, further increases 
renal clearance of amphetamine.93 In a study by Beckett and Rowland87 however, 
the influence of urine flow rate on the urinary excretion rate of amphetamine appeared 
to be minimal .  The rate of urinary excretion of amphetamine is  directly proportional 
to amphetamine plasma concentrations when urine is maintained under acidic 
conditions. This does not hold true when urine pH is allowed to fluctuate.91 Under 
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uncontrolled conditions for urine pH, amphetamine renal clearance can be accounted 
for by glomerular filtration . Under acidic conditions however, the renal clearance is 
much higher than the glomerular filtration rate, indicating that other processes are 
contributing to the overall renal clearance. Beckett and associates hypothesize that the 
drug passes from blood to urine as the urine flows down the kidney tubules due to the 
high concentration gradient of un-ionized drug across the membrane.91 
After a 5 mg oral dose of [14C]amphetamine, 90 % of the 14C was excreted into 
the urine (PH not controlled) in 3 to 4 days, with about 60 - 65 % excreted on Day 
1 .94 On Day I ,  approximately 30 % of the 14C was excreted unchanged. Metabolites 
included 4-hydroxyamphetamine (3 %) ,  benzoic acid (2 1 % )  and hippuric acid ( 1 6 %) .  
Hydroxyamphetamine is pharmacologically active, but probably does not exert a 
clinically significant effect after a single dose of amphetamine. d-amphetamine has a 
shorter elimination half-life than I-amphetamine, because d-amphetamine is 
metabolized more rapidly. I S  This is more apparent under basic urine conditions, 
when metabolism is the major route of elimination . Metabolism of amphetamine by 
deamination is stereospecific94, and occurs more extensively for the d- isomer. The 
elimination half-life in chronic amphetamine abusers is significantly longer than in 
drug-naive control subjects. The difference was not apparent under acidic urine 
conditions,  but was noticeable under alkaline urine conditions.93 This may be due to 
increased tissue affinity for amphetamine in drug-dependent individuals. 
Amphetamine does not appear to undergo hepatic recycling , as none was found 
in the bile (free or conjugated) after the administration of 10 mg d-amphetamine 
sulfate of a cholecystectomy patient with a bile duct fistula.s7 
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2 .2 .4  EEG Changes after Amphetamine Administration 
EEG changes following amphetamine administration have been reported in 
normal volunteers after single doses in several studies. In an early study,  Pfeiffer and 
associates9S examined EEG changes in 20 male volunteers (2 1 -30 years of age) after 
receiving racemic amphetamine (0. 1 mg/kg) intravenously, dextroamphetamine ( 1 5  
mg) orally, or placebo intravenously and orally i n  a crossover fashion. EEG changes 
were quantitated using a measure termed cortical electrical energy. Activity from the 
left parietal area was integrated for the intravenous doses, and left occipital activity 
was integrated for oral doses. After intravenous dosing, the mean cortical electrical 
energy and its variability were significantly decreased (p < 0.05) 20-25 minutes after 
the infusion compared to control (before dosing). No difference was seen at 0-5 , lO­
I S ,  30-35 , or 40-55 minutes after the infusion . After oral dosing, mean cortical 
activity was significantly (p < 0.05) decreased at 60-70 minutes after dosing, and its 
variability was significantly decreased at 30-40, 60-70, and 90- 100 minutes after 
ingestion compared to control . No changes were observed 1 20- 1 30 minutes after 
dosing. Changes in cortical electrical energy appear to be short-lived following 1 5  
m g  oral doses of dextroamphetamine. 
In a later study by Fink and colleagues,2° single 10 mg doses of 
dextroamphetamine were administered to female normal volunteers and the EEG was 
recorded for 30 minutes before and four hours after dosing. To be included in the 
studies, subjects had to have at least 50% alpha in the occipital region. A bipolar 
montage with bifrontal and right occipital-vertex leads was used. The state of 
alertness was maintained using an auditory reaction time task.  Data were analyzed 
using a period analysis program which produced 19 EEG measures for each 60 sec 
epoch. Epochs with artifacts in greater than 20% of the sample were deleted. A 
mean and standard deviation was computed for each measurement time from the 
artifact-free epochs. These investigators report a significant first session effect. 
Decreased delta activity compared to baseline was observed soon after dosing and 
lasted throughout the testing period. Alpha activity increased and remained elevated 
through 3 hrs of testing. 
30 
In another study of the EEG effects of dextroamphetamine in normal volunteers, 
Hamilton and associatesl9 examined twelve healthy male and female subjects aged 20-
4 1  years. Subjects received placebo, dexamphetamine 5 mg and dexamphetamine 1 0  
mg orally. Eyes closed EEG was measured before dosing and at 2 . 5  and 5 . 75 hours 
after dosing. Significant increases compared to placebo were noted only in the alpha 
(7 .5  to 1 3 . 5  Hz) and beta ( 1 3 .5  to 26 Hz) frequency bands following the 1 0  mg dose 
at 2 .5  hr. The EEG was only examined twice after dosing, so the duration of the 
effect is difficult to assess . No significant effect at any time was observed however 
after the 5 mg dose of dextroamphetamine. 
Matejcek72 studied the EEG effects of dextroamphetamine in six healthy male 
volunteers in a placebo-controlled, randomized , double-blind, crossover study. 
Subjects were screened for well-defined alpha rhythm in the parietal and occipital 
regions on a resting EEG with eyes closed to obtain a homogeneous group with 
respect to EEG characteristics. Subjects underwent a familiarization procedure where 
they received a placebo and completed all tests as if on a study day prior to 
randomization to treatments. Subjects received single oral doses of 5 and 1 0  mg 
dextroamphetamine and placebo at intervals of one week during the study. Twenty 
minutes of resting EEG with eyes closed was recorded from leads �-c" O)-C" P4-
C" and P)-C, at 0, 2 ,  4, 6, and 8 hr after drug administration . These investigators 
found a dose-dependent decrease in the proportion of delta and theta activity and an 
increase in that of alpha activity, particularly at the 2 hr measurement. There was a 
trend toward an increased percentage of beta activity, but it was not statistically 
significant.  They conclude that dextroamphetamine possesses vigilance-promoting 
properties and that the observed EEG changes correlate with this effect. 
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In a recent double-blind, placebo-controlled crossover pharmacodynamic study 
utilizing EEG measures, conducted by Saletu and colleagues,96 single 20 mg doses of 
dextroamphetamine and placebo were administered orally to 1 8  healthy male and 
female volunteers. EEGs were recorded before dosing at 2, 4, 6 and 8 hours after 
dosing. Administration of dextroamphetamine resulted in increased total power, 
decreased delta and theta power, and increased alpha and beta power on the EEG and 
the changes were observed from 2 to 8 hours after dosing. The peak amphetamine 
plasma concentrations were approximately 50 ng/mL and occurred about 2 hours after 
dosing. When the level of vigilance was controlled during the EEG recording, no 
differences between dextroamphetamine and placebo were observed. 
These studies demonstrate that EEG changes occur following doses of at least 
1 5  mg of dextroamphetamine in normal volunteers and they can be followed over 
time. The duration of effect is unclear however. Increases in fast activity and 
decreases in slow activity on the EEG are most frequently reported . In his review of 
drug effects on the EEG, Glaze97 notes that amphetamines primarily increase beta 
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and alpha activity , but this is difficult to detect upon visual analysis of the EEG 
record. Computerized drug profiling studies·3 indicate that the increase in alpha 
activity after dextroamphetamine administration occurs over the parietal and occipital 
areas. Correlation of these changes with changes in mood, performance, or serum 
concentration are not well-described. Studies by Lukas and associates98 indicate that 
EEG alpha activity is significantly increased during periods of drug-induced euphoria 
following intravenous administration of amphetamine. They note that it appears that a 
threshold level and a relatively rapid rate of increase in plasma drug concentrations is 
necessary for this euphoria to occur. They also report that it is difficult to study the 
relationships between mood changes and brain electrical activity without introducing 
artifacts into the EEG recording. Further work in this area is warranted . 
2 .2 .5  Neuroendocrine Changes after Amphetamine Administration 
A wide variety of drugs are known to influence anterior pituitary hormone 
secretion . Changes in hormone secretion are another potential source of 
pharmacodynamic response measures. Evidence suggests that drugs with different 
pharmacological actions have different effects on the secretion of anterior pituitary 
hormones and that secretion patterns can be used to discern a drug's  effects on the 
CNS .99 Amphetamines alter secretion of a number of these hormones, including 
Adrenocorticotrophic hormone (ACTH), prolactin ,  thyroid stimulating hormone 
(TSH) , follicle stimulating hormone (FSH), luteinizing hormone (LH) , and growth 
hormone. 100 Prolactin response was chosen as a representative neuroendocrine 
measure for dextroamphetamine effects in this study because prolactin levels have 
been measured after amphetamine administration in a number of studies and the 
Clinical Research Center Core Laboratory has considerable experience analyzing 
serum and plasma prolactin following pharmacologic challenge. 
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An understanding of the factors influencing the secretion of prolactin are 
important for interpreting the neuroendocrine response to amphetamine. Many of 
these factors are reviewed by Kuret and Murad. 1ol The synthesis and storage of 
prolactin takes place primarily in the pituitary lactotrophs. Placental tissue can also 
synthesize prolactin .  Normal plasma concentrations of prolactin range from 5 to 1 0  
ng/mL, with concentrations i n  males lower than those i n  females. A number of 
physiological factors can increase the secretion of prolactin including sleep, stress, 
hypoglycemia; fluctuations in estrogen concentrations, and exercise. Secretion of 
prolactin shows a circadian rhythm, with peak concentrations occurring during sleep. 
In addition , minute to minute fluctuations are also observed due to the pulsatile nature 
of prolactin secretion . Prolactin ' s  half-life in plasma is approximately 1 5  to 20 
minutes. Prolactin secretion from the pituitary is primarily under negative control by 
the hypothalamus. Secretion is inhibited by release of prolactin release-inhibiting 
hormone (PRlH) from the hypothalamus. Some evidence suggests that prolactin 
secretion is controlled by dopaminergic neurons and that PRlH is actually dopamine. 
Prolactin secretion is then predominately inhibited by dopamine. Serotonin however 
stimulates the secretion of prolactin .  99 
Dextroamphetamine has been reported to cause both increases and decreases in 
the secretion of prolactin. Results from several studies are summarized in Table 2 .2 .  
The effect on  secretion may depend on  the dose and route of  administration . 
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Dextroamphetamine is believed to affect dopamine release at lower doses and 
serotonin release at higher doses, and thus may cause opposing effects on prolactin 
secretion. In a study by Nurnberger and associates,31 normal volunteers were given 
intravenous doses of amphetamine after pretreatment with haloperidol and 
amphetamine without pretreatment in a crossover study. No change in prolactin 
compared to baseline was observed following amphetamine alone, but a large increase 
was observed when amphetamine was preceded by haloperidol . This increase was 
much larger than that observed after haloperidol alone in a previous study. 
Haloperidol blocks dopamine (D:J receptors, and therefore would be expected to 
increase prolactin levels. It was hypothesized that the significant rise in prolactin 
observed after amphetamine plus haloperidol was due to the unopposed effects of 
serotonin on prolactin secretion . Amphetamine effects through doparninergic 
mechanisms, which should decrease prolactin secretion , would be blocked by the 
haloperidol , and only the stimulatory effects of serotonin would remain .  A second 
possible mechanism was also proposed : amphetamines may release endogenous 
opiates that may stimulate prolactin secretion. None of these studies have examined 
the dose-response relationship between dextroamphetamine dose and prolactin 
secretion over a dosage range including low and high doses. Further work 
characterizing this relationship is needed . 
Table 2 .2  
Dose 
20 mg 
30 mg 
0.3 mg/kg 
0. 10  mg/kg 
0. 1 5  mg/kg 
20 mg 
10  mg 
20 mg 
Summary of Studies Reporting the Effect of Dextroamphetamine on 
Prolactin Secretion in Normal Volunteers 
Route Subjects Change in Serum 
Prolactin 
Oral 24 (male) Statistically 
significant increase 
compared to placebo 
Oral 1 0  (male No difference from 
and placebo 
female) 
IV 8 (male Increase compared 
and to baseline, but not 
female) significant 
IV 1 2  (male) No difference from 
basel ine 
IV 12 (male) Statisticall y 
significant increase 
compared to 
baseline 
Oral 1 8  (male No difference from 
and baseline 
female) 
Oral 9 (male) Statisticall y 
significant decrease 
compared to 
baseline 
Oral 9 (male) Statistically 
significant decrease 
compared to 
baseline 
Reference 
Jacobs, 
Silverstone & 
Reesloo 
Dommisse, 
Schulz, 
Narasimhachari , 
et al 1<12 
Nurnberger, 
Simmons-Alling, 
Kessler, et al31 
Halbreich , Sachar, 
Asnis, et al 103 
Halbreich , Sachar, 
Asnis, et al 103 
Saletu , 
Grunberger, 
Anderer, et al96 
Wells, Silverstone 
& Reesl� 
Wells, S ilverstone 
& Reesl� 
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2 . 2 . 6  Mood Changes after Amphetamine Administration 
Amphetamines have been noted to produce alterations in mood in a number of 
clinical studies. lOS The primary effect on mood is euphoria or feelings of well-
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being. About 20% of individuals however, experience dysphoria. IOl The subjective 
effects produced by amphetamine depend on the user, the environment, the dose, and 
the route of administration. 106 The euphoriant activity of amphetamine is believed 
to be mediated by dopaminergic mechanisms in the CNS .IOS A summary of selected 
studies of the effects of oral amphetamines on mood in man are presented in Table 
2 . 3 .  These studies suggest that the predominate effect of oral amphetamine on mood 
is euphoria. The effect is greater at higher doses ( 1 5  - 30 mg), but can be measured 
in doses as low as 5 mg. The I -mg dose did not elicit a measurable response on 
mood . The maximum effect on mood appears to occur 1 - 3 hrs after dosing and may 
last longer than 6 hr. The higher the dose, the longer the effect. 
Several scales have been used to measure mood changes following amphetamine 
administration . Both self-rated and observer-rated scales have been utilized . In 
choosing such a measurement tool for use in a pharmacodynamic study of stimulant 
response, the validity, reliability and suitability for repeated measures must be 
considered . Visual analog scales have been used in a number of studies to measure 
euphoria. Visual analog scales are easy for the subject to complete, easy for the 
investigator to score, do not require a great deal of motivation from the subject, and 
the rater is not restricted by demarcations on the scale in how fine a discrimination 
can be made. lU7 Visual analog scales can be valid and reliable for measuring the 
effects of drugs acting on the CNS , and can be used to measure effects repeatedly 
Table 2 .3  
Dose 
30 mg 
10 and 
20 mg 
5 mg 
1 and 
10 mg 
5 and 
1 0  mg 
1 5  mg 
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Summary of Selected Studies Reporting the Effects of Oral 
Amphetamine on Mood in Healthy Volunteers 
Subjects Mood Scales Results 
1 0  (male Hopkins Mood Statistically significant 
and Scale & The increase in well-being 
female) Amphetamine compared to placebo 
Interview Rating 
Scale 
9 (male) Visual Analog Scale Dose-related increase 
(Miserable--Happy) in subjective rating of 
mood lasting from 1 -3 
hr ( l Omg) and 1 - > 4hr 
(20mg) 
3 1  (male Profile of Mood Increased scores for 
and States - modified vigor, friendliness, 
female) elation, arousal and 
positive mood 
compared to placebo, 
maximum at 3hr and 
continuing 
> 6hr in some 
9 Visual Analog Scale No effect with 1 mg; 
(female) ( depressed--elated) 10 mg produced 
elevation of mood 
maximum at 1 . 5 hr 
and lasting up to 2 . 5  
hr but not statistically 
significant 
1 2  Visual Analog Scale Increased alertness, 
(males excitation, interest, 
and elation compared to 
females) placebo ( 1 0  > 5) at 2 
hr, with effects 
persisting on some 
measures > 5 hr 
9 Visual Analog Scale Increased alertness, 
(males) & Symptom extroversion, euphoria 
Oriented Preference and stimulation 
Scale compared to placebo 
Reference 
Dommisse, 
Schulz, 
Narasimha-
chari , et al102 
S ilverstone 
Wells & 
Trenchard24 
Johanson & 
Uhlenhuth108 
Jain,  
Kyriakides, 
Silverstone, 
et al109 
Hamilton, 
Smith & 
peckl9 
Taeuber, 
Zapf, Rupp, 
et al30 
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after drug administration . Scores on visual analog scales of euphoria have been used 
to distinguish doses of amphetamine (See Table 2 . 3) .  
Other scales, such as the Profile o f  M ood  States (POMS)1 l0, the NIMH Self­
rating Scale22 and the Addiction Research Center Inventory (ARCI) 1 1 l  scales have 
been used to measure euphoria. These scales usually take longer to complete and 
require more subject motivation . A modification of the ARCI has been studied by 
Martin and colleagues21 to measure euphoria in studies of amphetamine. They 
administered questions from the PCAG (sedation), MBG (euphoria) , LSD (dysphoria 
and psychoses) and BG (an empiric amphetamine scale) subscales of the ARCI to 
male prisoners before and after dosing with amphetamine. Based on the results of 
this study, they constructed an I I -item amphetamine scale (A) that included those 
items on the ARCI that showed a significant linear regression of response against dose 
for 3 doses of amphetamine (7 . 5 ,  1 5  and 30 mg/70 kg) . The BG (amphetamine) 
sub scale of the ARCI has also been used by other investigators studying amphetamine 
response.2J The ARCI has been shown to reliably distinguish between amphetamine 
effects. I I I  In our studies, we used the MBG subscale of the ARCI and the A scale 
developed by Martin ,  modified to measure amphetamine responses over a five-point 
range. 
2 . 2 . 7  Changes in Performance after Amphetamine Administration 
A large number of studies have investigated the effects of amphetamine on 
psychomotor and perceptual performance using laboratory based performance tests 
such as finger tapping, reaction time, critical flicker fusion, digit symbol substitution, 
tracking tasks , and mental arithmetic. 105 The reported effects of amphetamine on 
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psychomotor, perceptual , and intellectual function are conflicting. Some studies 
report no changes while others report changes on some tasks. A summary of selected 
studies on the effects of oral amphetamine on performance in normal volunteers is 
presented in Table 2.4 .  
Several factors impact on the usefulness of psychometric test results in 
describing pharmacodynamic effects of CNS active drugs.4 Motivational factors can 
influence the response to many psychometric tests. Expectations of the subjects, level 
of payment, intentions of the volunteers and expectations of the investigator can all 
influence experimental results. The effects of practice, learning and memory on 
performance must also be considered . Many components, besides the effect of the 
drug, involving factors such as personality ,  motivation and expectations determine 
performance on a psychometric test. These factors should be controlled for as much 
as possible in the design and conduct of the study to improve the usefulness of 
psychometric tests. Experiments should be double-blind and placebo-controlled . 
Subjects must be carefully screened and those administering the tests well-trained . 
Adequate practice sessions are essential. 
For our studies, two tasks were chosen to measure the response to 
dextroamphetamine. The first was an attentional task (continuous performance task 
(CPT» and the second was a motor task (finger tapping) . Similar tasks have been 
used by other investigators to measure the effects of amphetamine on performance. 
Computerized versions of these tasks were chosen to allow for improved 
standardization of procedures, accurate measurement and recording of responses, and 
ease of use. 1 1 2  A major disadvantage to these tasks however, is  that reliability and 
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Table 2 .4  Summary of  Selected Studies on  the Effects of  Oral Amphetamine on 
Psychomotor Performance in Healthy Volunteers 
Dose Subjects Tests Results Reference 
1 5  mg 9 (males) Choice reaction time, simple Significant increase only in Taeuber, 
reaction time, mental CFF and correct solutions Zapf, Rupp, 
arithmetic, critical flicker on mental arithmetic et al)() 
fusion (CFF) compared to placebo 
5 and 1 2  Auditory vigilance test, For both doses, significant Hamilton, 
1 0  mg (males Auditory reaction time, increase in percent correct Smith & 
and tapping test on auditory vigilance test, Peckl9 
females) decreased reaction time, no 
difference in tapping 
0 . 25 1 6-low Motor activity test, skin Increased performance on Rapoport, 
and dose, 1 5- conductance reaction time, CPT (high dose), decreased Buchsbaum, 
0 .5  high dose visual continuous reaction time (low dose), Weingartneret 
mg/kg (males) performance task , learning beneficial effects on the aP I)  
task learning task (both doses) 
5 mg 8 (males) Symbol-Digit Substitution No significant differences Schmedtje, 
Task (DSST), Simple from placebo Oman, Letz, 
Reaction Time, Pattern et al26 
recognition, Digit Span, 
Pattern Memory 
10 mg 1 1  CFF, Discriminant Reaction No significant differences Berchou & 
(males Time from placebo Blockl l'  
and 
females) 
1 0  mg 6 (males) Tremor, Precision Hole No significant differences Domino, 
Steadiness, Tracking from placebo except in the Albers, 
compensatory tracking task Potvin, et al21 
which requires sustained 
concentration and motor 
coordination 
5 ,  10,  12  Wobble Board , Pursuit Dose-related improvement Evans, 
and 1 5  (males) Meter, Delayed Auditory in stability (eyes closed) on Martz, 
mg Feedback the Wobble Board, and on Lemberger et 
rapid response on the 8129 
Pursuit Meter only 
4 1  
validity for these particular versions has not been established. If some of the subjects 
are unfamiliar with computers, learning time may be increased. Studies of validity 
(i.e. , is the task truly measuring attention?) are necessary before claims concerning 
the drugs effects on performance can be made. 
2 .2 . 8 Cardiovascular Changes after Amphetamine Administration 
Amphetamines affect the cardiovascular system through direct and indirect 
actions on a and f3 receptors. Systolic and diastolic blood pressure have been 
reported to increase following administration of amphetamines. Heart rate may 
increase or decrease. Gaut, Pocelinko, Abrams and Daltonl lS studied thirteen obese 
subjects in a double-blind , randomized , crossover design where subjects received 20 
mg of dextroamphetamine and placebo. Blood pressure and heart rate were measured 
before dosing and at I and 3 hr after dosing . They found an increase in systolic 
blood pressure compared to placebo of 2 1 . 8 %  ( ± 7.4%) and 14 .0% ( ±4 . 5 % )  at I and 
3 hr following amphetamine dosing respectively. Diastolic blood pressure increased 
20. 6% ( ± 6. 1 %)  at I hr and 1 5 . 2 %  ( ± 4.9%) at 3 hr after amphetamine 
administration compared to placebo. Heart rate increased less dramatically, with a 
change compared to placebo of 0. 8 %  (±3 .4%)  at 1 hr and 12 .4% ( ±  1 . 9%)  at 3 hr 
after amphetamine dosing . All of these changes were statistically significant (p < 
0.05) except for heart rate at 1 hr (not significant) . Hamilton and associates19 report a 
rise in heart rate and diastolic blood pressure, but not of diastolic blood pressure after 
I O  mg of dextroamphetamine compared to placebo. 
Studies of the effects of amphetamine on blood pressure and heart rate in 
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animals suggest that tonic and reflex (baroreceptor) neural activity obscure the pressor 
and tachycardic effects of amphetamine on peripheral nerves. Simpsonl l6 reported 
that blood pressure and heart rate increases after amphetamine administration to male 
Wistar rats and that this increase is larger and more sustained in animals pretreated 
with chlorisondamine. Chlorisondamine is a ganglionic blocker which eliminates 
tonic and reflex neural activity. This suggests that the conflicting results of the effect 
of amphetamine on the cardiovascular system , especially heart rate, may be mediated 
by baroreceptor reflexes or CNS influences on the peripheral responses. In 
chlorisondamine-pretreated animals, there was a positive relationship between the 
amount of drug administered and the magnitude of the cardiovascular responses. 
CHAPTER 3 
Part I - Reproducibility of Control Responses 
3 . 1 Specific Aims 
The purpose of this study was to investigate the inter- and intra-individual variability 
associated with a series of potential CNS pharmacodynamic response measures under 
baseline (no drug) conditions. These measures included quantitative EEG , automated 
psychometric tests, and self-rated mood scales. Within day and between day 
reproducibility was evaluated . Responses for each measure were examined for 
evidence of circadian changes and learning effects. Results from this study were used 
to design subsequent studies of quantitative EEG as a pharmacodynamic measure for 
CNS stimulation .  
3 .2  Methods 
3 .2 . 1 Clinical Study of Control Responses 
The clinical portions of this study were conducted at the Clinical Research 
Center at Virginia Commonwealth University . The Committee on the Conduct of 
Human Research at Virginia Commonwealth University reviewed and approved the 
study protocol and the informed consent form before the study began . The study 
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protocol and consent form are in Appendix A .  
This study was an open-labeled pilot study i n  which healthy volunteers 
underwent a series of tests (electroencephalography ,  automated psychometric tests, 
and self-rated scales of mood) on three occasions one week apart. On each of the 
three study days, the series of tests were repeated eight times over a 1 2  hour period. 
Subjects undertook the study in groups of one or two. 
Subjects. Eight healthy volunteers participated in this study.  Subjects were 
recruited from within the hospital and schools at Virginia Commonwealth University. 
Volunteers were considered for inclusion in the study if they were nonsmokers 
between the ages of 1 8  and 35 ,  and determined to be in good health based on the 
results of a medical history, physical examination, laboratory tests (including a 
SMAC-20, CBC , and urinalysis) , 1 2-lead electrocardiogram, and vital signs. 
Volunteers were excluded from the study if they 1) had a history of drug addiction , 
alcohol abuse, or psychological dependence on drugs, 2) had a first degree relative 
(mother, father, or siblings) with a history of mental illness or alcohol/drug abuse, 3) 
took any medications chronically or had taken any prescription or investigational 
drugs in the four weeks prior to starting the study,  or 4) had a normal daily caffeine 
intake greater than two cups of coffee. Before entering the study, each subject signed 
an informed consent form attesting that his participation was voluntary and that the 
study procedures were explained. 
Procedure. During each of the three study periods, the following procedure was 
observed: 
Beginning 72 hours before each study day, subjects avoided caffeine, alcohol , 
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and all medications, including over-the-counter medications. Subjects entered the 
study facility at 7:00 a .m.  on the study day and were released after completion of the 
1 2  hr test battery on the same day. Subjects fasted from midnight on the evening 
before the study day until after the 4 hr test battery. Lunch was served after the 4 hr 
test battery and dinner at 10 hr after the baseline test battery. The menu was similar 
during each study period. 
Five-minute segments of 28 channel EEG were recorded for each subject using 
a NeuroScience Brain Imager (San Diego, CA) with eyes closed at 0, 1 ,  2, 3, 4, 6, 8,  
and 1 2  hrs. Subjects reclined in a hospital bed with the lights off during the 
recordings. They were asked to count back from 500 by 3s to maintain vigilance. 
The electrodes were placed using an Electro-cap according to the 1 0/20 International 
System with 8 additional electrodes located 50% between the standard 1 0/20 
placement. Omni-Prep «D.O. Weaver & Co. ,Aurora, CO) was used to prepare the 
scalp and Electro-Gel (Electro-Cap International , Inc. , Dallas, TX) was used as the 
conducting gel . Linked ears were used as a reference. Four additional electrodes 
were placed to monitor for vertical and lateral eye movements and electromyographic 
activity. Electrodes in the cap, ear clips, and eye movement monitors were made of 
tin .  Electrode impedances were checked before each recording, and maintained at 
less than 5 . 6  kohms and similar between electrodes. Disturbances in the room or 
subject movement during the EEG was recorded. The Brain Imager filters were set 
as follows: Low filter - 0.30 Hz, High filter - 40 Hz, Notch filter - off. The raw 
EEG was stored on optical disks. The system integrity of the Brain Imager was 
checked weekJy throughout the study to ensure stability of channel calibration and 
proper filter functioning. EEG recordings on Study Day 1 for Subject 1 (TM) were 
made simultaneously on the Brain Imager and a standard EEG machine (Grass 
Instruments Model 8- 1 80, Quincy, MA) . The electro-cap was connected to both 
input boards by an adapter. The pen recordings from the standard EEG machine 
were reviewed by a board certified electroencephalographer who determined that 
recordings from the electro-cap were acceptable. 
Each subject completed a computerized visual CPT (NeuroScan, Inc . )  at 0, 1 ,  
2 ,  3 ,  4 ,  6 ,  8 and 1 2  hr. In this task, the digits 0 through 9 briefly appear on the 
screen .  The subject presses the left button of the mouse when a 0 appears and the 
right button for all other digits. The interstimulus interval varied from 0. 8 to 1 .2 
seconds. A total of 120 stimuli were presented during each testing session. Two 
practice sessions were completed before beginning the 0 hr test battery. 
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Subjects completed a computerized motor task, finger tapping (NeuroScan, Inc.)  
at 0,  1 ,  2 ,  3 ,  4 ,  6 ,  8 and 1 2  hr.  During this task, subjects tap the mouse button as 
fast as possible for 10 seconds, first with their right hand and then with their left. A 
total of three trials with each hand were completed during each testing session . Two 
practice sessions were completed before beginning the 0 hr test battery. 
A self-rated scale (Appendix B) based on the MBG (a measure of euphoria) and 
the A (a measure of amphetamine effects) subscales of the Addiction Research Center 
Inventory Scales described by Martin et al .2 1  was completed by each subject at 0, 1 ,  
2 ,  3 ,  4 ,  6 ,  8 and 1 2  hr. The scale consisted of 23 questions which the subject 
responded to on a scale of 1 to 5 .  At the same times, a 100 m m  visual analog mood 
scale (Appendix C) was completed. 
The test battery was conducted in the following sequence: 1 )  EEG, 2) visual 
CPT, 3) rating scales, and 4) finger tapping. 
3 .2 .2  Data Analysis 
The measures of response that were examined for the test battery described 
above are listed in Table 3 . 1 .  
Table 3 . 1 Response Measures Evaluated in Part I - Reproducibility of Control 
Responses 
EEG Variables 
TP Total Power - all frequencies (p. Y� 
TPD Total Power - Delta band (p. y2) 
TPT Total Power - Theta band (p. y2) 
TPA Total Power - Alpha band (p.y2) 
TPBI Total Power - Beta I band (p. y2) 
TPBII Total Power - Beta II band (p. Y� 
Psychometric test 
RPD Relative Power - Delta band 
RPT Relative Power - Theta band 
RPA Relative Power - Alpha band 
RPBI Relative Power - Beta I band 
RPBII Relative Power - Beta II band 
FfLT Finger Tapping with Left Hand (taps/sec) 
FfRT Finger Tapping with Right Hand (taps/sec) 
CPTPC Percent Correct on Continuous Performance Task (%)  
CPTAL Average Latency on Continuous Performance Task (sec) 
Mood Scales 
RS Total Score on Self-Rated Mood Scale 
Y AS Score on Visual Analog Mood Scale 
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EEG Analysis. As each EEG was recorded, the signal was processed by a Fast 
Fourier Transform procedure, to determine the amplitude of the EEG in five 
frequency bands (Delta: 0 .39 - 3 .9 Hz, Theta: 4 .3  - 7 .8  Hz, Alpha: 8 .2  - 1 1 . 7  Hz, 
Beta I: 12 . 1 - 16 .0  Hz, and Beta II: 16 .4 - 30.0 Hz) at each electrode. Each of the 
five-minute recordings was reviewed and edited to remove each 2 .5  second epoch 
(frame) that contained artifacts (eye movements, muscle movement,  electrode 
artifacts, or disturbances noted during the recording) . 1 I7· 1 1 8.3S The remaining 
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frames were averaged using the EEG statistical operations package on the Brain 
Imager to form an average topographical map representing the five minute recording. 
Recordings with fewer than 24 artifact-free frames were not processed further and 
were listed as " missing " .  To compute the average map, the Brain Imager first forms 
sub-averages from consecutive groups of eight frames each . 1 19 The voltage value 
measured at each of the 28 electrodes for the first eight frames are added together and 
then divided by 8, the number of frames. This process is then repeated for the next 
group of 8 frames and so on . The overall average is then formed by averaging the 
sub-averages. The overall average ftle contains the average amplitude in each of the 
5 frequency bands at each of the 28 electrodes. This ftle was then transferred from 
the Brain Imager to an IBM compatible 80386 personal computer. ISTAT 
(NeuroScience, Inc . )  a statistical package for EEG processing was used to prepare 
ASCII files of the average files. These files were then imported into the Quattro Pro 
spreadsheet software (Borland International , Scotts Valley, CA) for further 
processing. 
Power was determined for each average recording by squaring the amplitude 
values at each electrode in each frequency band.  Total amplitude and total power in 
each frequency band was calculated by summing the amplitude or power at each of 
the electrodes for a given frequency band. Total amplitude and total power across all 
frequency bands was calculated by adding together the total amplitude or total power 
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in each of the frequency bands. Relative power in each frequency band was 
calculated by dividing the total power in the given frequency band by the total power 
across all frequency bands. 
Approximately 6 months after the first EEG editing process, EEGs from one 
period for three subjects were re-edited by the same investigator to examine the 
reliability of the EEG editing process over time. These edited EEGs were averaged 
and transferred as described above, and total power in each frequency band was 
calculated. These EEGs are referred to as the reliability sample. 
Psychometric test analysis. For the computerized visual CPT, latency of 
response was determined for each trial during the session . The average latency of 
response and the percent of correct responses for each test session was determined. 
For the finger tapping task,  the average rate (taps/sec) of finger tapping for each hand 
was calculated for each session by averaging the results of the three trials conducted 
during each session . The effect of learning on test performance was evaluated by 
examining plots of the test score versus the cumulative test battery number during the 
entire study. A total of 30 test batteries were attempted during the study (10 on each 
of the 3 study days) . 
Rating scales. A total score on the self-rated mood scale was determined for 
each test session by summing the scores obtained for each of the 23 items on the 
scale. A score between 0 and 100 was obtained for the visual analog mood scale for 
each test session by measuring the number of millimeters between the left end of the 
scale and the mark placed by the subject. 
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3 .2 .3  Statistical Methods 
Within-day, between-day and inter-subject variability was examined for each 
response variable. Within-day variability for each response measure was determined 
by calculating the mean , standard deviation , and relative standard deviation of the 
response at each time point for each study day for each subject. Relative standard 
deviation, also termed coefficient of variation , is defined as the standard deviation 
divided by the mean and expressed as a percentage. Between-day variability for each 
response was determined by calculating the mean , standard deviation , and relative 
standard deviation of the mean response for each study day for each subject. Inter­
subject variability was determined by calculating the mean , standard deviation, and 
relative standard deviation of the response on all study days at all time points for each 
subject. 
To look at the effect of study day and time of day on the response measures, a 
repeated measures analysis of variance with study day, time of day, and subject as 
factors and the response as the dependent variable was performed using the PROC 
GLM procedurel20 in SAS. The residuals were tested for normality using PROC 
UNIVARIATE120• This procedure computes the Shapiro-Wilk statistic, W, for the 
null hypothesis that the residuals are normally distributed. When the probability of a 
smaller value of W was less than or equal to 0. 1 ,  the null hypothesis of normality was 
rejected. The hypothesis of normally distributed residuals was rejected for most of 
the variables tested in this study, so a rank transform was performed on the values for 
the response measures. The ranks for each response measure for each study day were 
compared using repeated measures analysis of variance with study day, time of day, 
5 1  
and subject as factors and each rank transformed response as the dependent variable. 
To examine the reliability of the EEG editing process over time, Pearson 
product moment coefficients were calculated between the total power and power in 
each frequency band obtained during the first and second editing of the reliability 
sample. The multivariate procedure PROC CANCORR120 in SAS was used for this 
computation . The correlation coefficients obtained between the first and second 
editing are termed stability coefficients. 12 1 
3 .3  Results 
Nine male volunteers were entered into the study. Demographic and physical 
characteristics of the subjects are shown in Table 3 .2 .  All of the subjects were 
judged to be healthy based on the results of a physical examination , a medical history, 
and clinical laboratory tests before entering the study. Eight subjects completed the 
study. Subject 4 (BR) dropped out after the first period for personal reasons. None 
of the subjects reported adverse events related to the study procedures. 
Within-day variability for each of the response measures is presented in Figures 
3 . 1 and 3 .2 .  These figures show the average (M) and range (H - L) of the relative 
standard deviation of each response at each time point for each study day for each 
subject. Within-day variability ranged from 0 to 80 percent for the response measures 
investigated . The highest variability was associated with total EEG power in the delta 
frequency band and other EEG-derived parameters and the lowest variability was 
noted for the computerized psychometric tests. 
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Table 3.2 Demographic and Physical Characteristics of Participants in Part I -
Reproducibility of Control Responses 
Subject Initials Age (years) Weight (kg) Race 
Number 
TM 24 9 l . 8  Black 
2 MP 39 83 .6 White 
3 SW 36 78. 2  White 
4 BR 23 63 .0 Black 
5 MM 20 69. 1 White 
6 AT 25 90.9 White 
7 JC 34 63. 2  Hispanic 
8 ML 33 90.9  Black 
9 SW 26 70.5 White 
Between-day variability for each response measure is presented in Figures 3 .3  
and 3 .4 .  These figures show the average (M) and range (H-L) of  the relative 
standard deviation of the mean response for each study day for each subject. 
Between-day variability was in general lower than within-day variability and ranged 
from 2 to 48 percent. The average within-day variability was less than 20% for all of 
the measures. Again, the highest variability was associated with parameters derived 
from the EEG . 
Intersubject variability for each response measure is presented in Figures 3 .5  
and 3 .6 . These figures show the average (M) and range (H-L) of  the relative 
standard deviation of the mean response for all study days for each subject. 
Intersubject variability ranged from 2 to 87 percent, with the highest variability again 
observed for the EEG measures. The lowest intersubject variability was noted for the 
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computerized performance tests. Intersubject variability was greater than both within­
day and between-day variability. 
Learning effects were observed for the finger tapping and CPT. Figures 3 .7  
and 3 . 8  show representative plots of  scores on  these tests versus test battery number. 
Each task was administered a total of 30 times to each subject during the entire study. 
Similar plots for all subject are presented in Appendix D.  These plots show that 
performance on the visual CPT and finger tapping continues to improve after the first 
2 to 6 test sessions for most subjects, when a relatively stable level of performance is 
achieved . Each study day, the number of test sessions necessary to reach a stable 
level of performance is decreased. 
Results from the analysis of variance showed that the main effect of time of day 
is statistically significant (p < 0.05) for several of the response measures, including 
the visual analog mood scale, finger tapping, average latency on the CPT, and EEG 
power in the Theta and Beta II  frequency bands. Examples from representative 
subjects illustrating these effects are shown in Figures 3.9 and 3 . 1 0. In a comparison 
of the results on Study Day 1 with those on Study Days 2 and 3 for the self-rated 
mood scale, finger tapping with the right hand, percent correct on the CPT and EEG 
total power in the delta frequency band showed statistically significant (p < 0.05) 
differences. Scores on these measures attained on the first day of testing are different 
than those achieved on subsequent days. Examples demonstrating this effect are 
shown in Figures 3 . 1 1  and 3 . 12 .  
Missing data was problematic for several of  the measures studied. Self-rated 
scales of mood show few if any missing values because they can be completed rapidly 
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Figure 3 . 8  Example of the learning effect on the finger tapping task (Data from 
Subject 3) 
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Figure 3 .9  Example of the effect of time of day on the continuous performance task 
average latency (Data from Subject 6) 
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Figure 3 . 1 1  Example of the first day effect on the self-rated mood scale (Data from 
Subject 8) 
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band (Data from Subject 2) 
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and do not require any equipment that is subject to mechanical problems. The 
computerized psychometric tests showed a higher number of missing data points due 
primarily to breakdowns of the computerized system, such as failure of the computer 
hard disk drive for example. Approximately 5 % of the CPT and fmger tapping tests 
were lost. Approximately 5 % of the measurements were missing for the EEG as 
well . These measurements were lost primarily due to excessive artifacts present 
during the recordings. 
Results from the reliability of the EEG editing process over time show high 
correlation (correlation coefficient > 0 .90) for all of the EEG-derived measures 
evaluated. Results from the canonical correlation between the first and second editing 
are presented in Table 3 . 3 .  
Table 3 .3  Correlations Between the Results of  the First and Second EEG Editing 
Procedure 
EEG Measure Correlation Coefficient 
Total Power - Delta 0 .9 12  
Total Power - Theta 0.93 1 
Total Power - Alpha 0.938 
Total Power - Beta I 0 .992 
Total Power - Beta II 0.997 
Total Power 0 .970 
3 .4  Discussion 
This study was designed to evaluate the variability associated with a series of 
potential response measures of CNS stimulation and to provide information needed for 
planning future studies of quantitative EEG as a pharmacodynamic tool. Response 
measures evaluated included self-rated assessments of mood, computerized 
psychometric tests and electroencephalography.  
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Intersubject variability was greater than intrasubject variability for these 
response measures, indicating that a crossover design should be considered for future 
studies. In a crossover design , the comparison of treatments is based on within­
subject or intrasubject variability. 122 Because intrasubject variability is less than 
intersubject variability the crossover design would be more powerful than a parallel 
group design for examining treatment differences. 
Two potential disadvantages to the crossover design must also be considered. 
The first is the possibility of a differential carryover effect and the second is the 
impact of missing data. Carryover effect can be minimized by incorporating a 
sufficientl y long washout period between each leg of the study. Determining the 
duration of the washout period so that it is long enough to ensure that no measurable 
drug levels remain in the system when the next period begins is relatively simple. 
Psychological carryover may be more difficult to control. For example, a subject's 
response on a rating scale may be influenced by previous treatments because the 
frame of reference changes. Later treatments are compared with the earlier ones. 
This phenomenon has been observed in studies of psychoactive drugs. 122 Missing data 
may be a more significant problem . Missing data complicates the statistical analysis 
and the design loses efficiency. There is an increased opportunity for data to be lost 
to the analysis in a crossover design ,  since each subject must provide data on more 
than one occasion . Loss of computerized psychometric test data could be minimized 
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by keeping a backup personal computer available to run the STIM program. Loss of 
EEG data is more difficult to control . Pre-screening subjects and excluding those 
with excessive eye movement artifacts is one approach that may decrease missing 
data. Also controlling the testing environment for noise level and temperature may 
reduce data loss. Excessive noise may increase eye movements and high temperatures 
may result in poor electrode performance due to sweating of the scalp .123 Having 
the subject hold cotton gauze lightly against the closed eyelids may also decrease eye 
movement artifacts. Despite these limitations, a crossover design was chosen over a 
parallel design for future studies due to the efficiency of the design when intersubject 
variability is greater than intrasubject variability and the resulting need for a smaller 
number of subjects . 
Based on the results of this study, incorporation of a placebo period into the 
crossover design is also desirable. The analysis of variance showed statistically 
significant effect of time of day for several of the response measures studied , 
indicating circadian variability in the response under baseline (no drug) conditions. 
Circadian periodicity in the wakeful EEG has been reported by other 
investigators . 124,61 For measures with circadian variability , the availability of a 
placebo period for comparison with drug treatments is preferable to using the baseline 
(0 hr) as the only control . 
EEG and some psychometric test responses may be different on the first day of 
testing than on subsequent days for some subjects, as indicated by the statistical 
comparison of responses on Study Day 1 versus those on Days 2 and 3 .  These first 
session effects have been previously reported for EEG studies of drug effects. I S  
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These authors hypothesize that the during the first session, subjects maintain arousal 
because of unfamiliarity with the testing environment and study procedures. They 
suggest the incorporation of a familiarization session in EEG studies prior to study 
initiation to overcome this limitation . Differences in relative power in the alpha band 
between EEGS recorded one week apart under no drug conditions has been reported 
by Sebban and associates. 125 They hypothesize that this variability is l inked to an 
habituation to the testing environment with time. Our results and those of other 
authors indicate that familiarization sessions are necessary for pharmacodynamic 
studies using quantitative EEG . 
Learning effects were also observed for the psychometric tests. Response 
measures that show learning effects are more difficult to use in pharmacodynamic 
studies, because the learning effect can confound the drug effect under study. To 
ensure that subjects are performing at a relatively stable level before receiving the 
treatments, practice sessions are necessary . Between 4 and 6 testing sessions were 
needed on the first study day for the majority of subjects in this study .  These 
practices could be incorporated into the familiarization session . In addition , at least 2 
practices are needed each study day based on the performance observed in this study. 
This study also demonstrates that it is feasible to conduct a study where subjects 
undergo testing as often as every hour without unreasonable stress on the study 
schedule or fatigue for the subjects. A test session could be completed in 
approximately 15 minutes. Subjects tolerated the procedures well ,  including wearing 
the electro-cap continuously for longer than 12 hours. Subjects reported that the 
informed consent form adequately described the study procedures . 
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By incorporating a crossover design with a placebo period, practice sessions for 
the computerized psychometric tests and a familiarization session before the study, 
these response measures should be suitable for future studies. A verage between-day 
variability for all of the response measures was less than 20 % ,  which is relatively 
low compared to expected potential drug effects. The greatest variability was 
associated with the EEG measures studied when the data is collected in the clinical 
setting . This may mean that the EEG measures will be the least sensitive of the 
measures for distinguishing drug effects. The sensitivity of the EEG as a 
pharmacodynamic measure requires further investigation . 
3.5 Conclusions 
Based on the results of this study, subsequent studies for the purpose of 
evaluating quantitative EEG as a pharmacodynamic tool should incorporate a placebo­
controlled, crossover design. A familiarization session to acquaint the subjects with 
the study setting and procedures is necessary to reduce first-session effects. Practice 
sessions are needed for the psychometric tests to minimize the effects of learning on 
the comparison of treatments. The testing sessions can feasibly be conducted at least 
hourly, and subjects can tolerate the procedures for as long as 1 2  hours. The 
response measures studied are suitable for future studies to evaluate quantitative EEG 
as a pharmacodynamic tool for measuring CNS stimulation. 
Chapter 4 
Part II - Comparison of Quantitative Electroencephalography to Behavioral , 
Psychological and Neuroendocrine Measures of Response to Dextroamphetamine 
4. 1 Specific Aims 
The purpose of this study was to evaluate the usefulness of quantitative EEG as 
a measure of CNS response to stimulants. The study was designed to examine the 
relationship between EEG changes after administration of dextroamphetamine and 1 )  
performance o n  automated psychometric tests, 2)  serum prolactin levels,  3)  subjective 
response as assessed by self-rated mood scales, and 4) serum concentration of 
dextroamphetamine. The sensitivity of EEG parameters to dextroamphetamine 
concentration in serum was compared with that of more subjective measures. 
4.2 Methods 
4.2 . 1 Clinical Study of Response to Dextroamphetamine 
The clinical portions of this study were conducted at the Clinical Research 
Center at Virginia Commonwealth University . The Committee on the Conduct of 
Human Research at Virginia Commonwealth University reviewed and approved the 
study protocol and the informed consent form before the study began. The protocol 
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and consent form for this study are in Appendix A .  
This study was a double-blind, placebo-controlled four-period crossover study 
with healthy, male volunteers assigned to randomly ordered treatment sequences. 
Subjects undertook the study in groups of two. The start of each study period was 
separated by a washout period of at least one week. Subjects received one of four 
treatments during each study period: dextroamphetamine 20 mg, dextroamphetamine 
10 mg, dextroamphetamine 5 mg or placebo as a single oral dose according to the 
randomization schedule (Appendix E) . Eight volunteers were scheduled to be 
enrolled in the study. The number of subjects included was the minimum that would 
ensure that at least two subjects were assigned to each treatment sequence. 
Subjects. The volunteers were considered for inclusion in the study if they were 
nonsmokers determined to be in good health based on the results of their medical 
history, physical examination , and electrocardiography and had no clinically 
significant deviation from the normal range of values determined in laboratory tests 
consisting of complete blood count, urinalysis, and clinical chemistry. Volunteers 
were excluded from the study if they 1 )  had a history of drug addiction, alcohol 
abuse, or psychological dependence on drugs, 2) had a first degree relative (mother, 
father or siblings) with a history of mental illness or alcohol/drug abuse, 3) took any 
medications chronically or had taken any prescription or investigational drugs in the 
four weeks prior to starting the study or 4) had a normal daily caffeine intake of 
greater than two cups of coffee. Before enrolling in the study, all subjects underwent 
an EEG and psychometric testing familiarization period lasting for at least 4 hours. 
Subjects with a high number of artifacts on the EEG or who could not tolerate 
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wearing the electro-cap for extended periods of time were excluded. Before entering 
the study,  each subject signed an informed consent form attesting that his participation 
was voluntary and the study procedures were explained. The physical examination, 
electrocardiography,  and laboratory tests were repeated within one week of the 
conclusion of the subject's participation in the study. 
Procedure. During each of the four study periods, the following procedure was 
followed: 
Beginning 72 hours before each study day, subjects avoided caffeine, alcohol , 
and all medications, including over-the-counter medications. Subjects also began a 
low monoamine diet that was maintained throughout the study period. Tyramine­
containing foods such as liver, fermented or dried sausage, canned or dried fish, 
sauerkraut, fava beans, fermented beverages, and cheese were restricted. The low 
tyramine diet was instituted as a safety measure, because tyramine can displace 
norepinephrine from storage sites and indirectly cause a rise in blood pressure. Much 
of the dietary tyramine is metabolically inactivated presystemically, but the degree to 
which this occurs may be genetically determined . 126 The degree of influence of 
tyramine in combination with dextroamphetamine on blood pressure may vary 
between individuals, so dietary tyramine was maintained at a low level for all 
subjects. Imposing a very similar diet for all subjects may also serve to make the 
response to dextroamphetamine more uniform across subjects. 
Subjects entered the study facility on the evening of the day preceding each day 
of dextroamphetamine or placebo dosing and were not released until after the 
collection of the last blood sample of the study period. Subjects were required to 
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have a negative urine drug screen and breath alcohol test during each study period 
before receiving dextroamphetamine or placebo. Subjects fasted from midnight on the 
evening before dosing until after the 4 hr blood sample was drawn. Water was 
permitted during the fasting period. Lunch was served after the 4 hr blood sample 
and dinner at 10 hours after dosing. All meals were low in tyramine content and 
large quantities of foods potentially promoting alkalinization of the urine (such as 
milk, nuts, vegetables and fruits) were avoided. The same menu was served on 
corresponding days of each study period. Subjects began a period of bed rest one 
hour before dextroamphetamine or placebo administration that continued until after 
the 6 hr test battery . 
Repeated 2 gram oral doses of ammonium chloride (4 x 500 mg enteric-coated 
tablets, Rugby Laboratories Inc. , West Hempstead , NY) were given to acidify the 
urine and enhance the excretion of dextroamphetamine at the following times: - 12 ,  -8, 
-2, 2 ,  6, 10 ,  14, and 18 hr after dextroamphetamine or placebo dosing as described 
by Wan et alY Subjects received a light snack prior to the - 1 2  and -8 hr ammonium 
chloride dosing to minimize potential gastrointestinal distress. 
Subjects received one of the four treatments: dextroamphetamine 20 mg, 
dextroamphetamine 10 mg, dextroamphetamine 5 mg, or placebo orally. Both the 
subjects and the investigator were blinded to treatment. Doses were prepared by the 
MCV Hospitals Department of Pharmacy and dispensed by the MCV Hospitals 
Investigational Pharmacy. Dexedrine tablets (SKF Laboratories, Philadelphia, PA) 
containing 5 mg dextroamphetamine sulfate were used to prepare the doses. The 
tablets were placed in opaque gelatin capsules to maintain blinding. Sufficient lactose 
was added to the capsules to make all doses the same weight. Placebo capsules 
contained lactose only. Each dose was administered as two capsules. 
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Prior to dosing, a heparin containing catheter was inserted into a forearm vein 
for access to blood sampling. Seven-mL samples for determination of 
dextroamphetamine concentration were collected in red-top tubes with no additives at 
the following times: pre-dose, 1 ,  1 .33,  2,  2 .33,  3 ,  3 . 33 , 4,  6, 8 ,  12 ,  1 8 ,  and 24 hr 
after dextroamphetamine or placebo dosing. Blood samples were allowed to clot, 
centrifuged (within 1 hour of venipuncture) for 10 minutes, serum harvested, and 
stored at -20 degrees Celsius until analysis. Five-mL samples for the determination 
of prolactin concentration were collected in red-top tubes with no additives at the 
following times: pre-dose, I ,  2, 3, 4 ,  5 and 6 hr after dextroamphetamine or placebo 
dosing. Blood samples were allowed to clot, centrifuged (within 1 hour of 
venipuncture) for 1 0  minutes , serum harvested , and stored at -20 degrees Celsius until 
analysis. 
Subjects completely emptied their bladders just before dextroamphetamine or 
placebo dosing and the urine pH was determined using a pH meter (Corning) 
immediately at room temperature after gently shaking the specimen. Two 25 mL 
aliquots of the urine were retained and frozen until analysis. Urine was then collected 
over the following intervals after dextroamphetamine or placebo dosing: 0-2 hr, 2-4 
hr, 4-8 hr, 8- 12  hr, 12- 1 8  hr, 1 8-24 hr. The pH of the urine voided at the end of 
each collection interval was determined and the total volume of urine collected during 
the interval was measured. A 25 mL aliquot of the urine was retained and frozen 
until analysis for dextroamphetamine concentration. Subjects were required to drink 
at least 1 20 mL of water every hour beginning one hour before dextroamphetamine 
dosing and continuing through the four hours after dosing. 
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Five-minute segments of 28 channel EEG were recorded for each subject using 
a NeuroScience Brain Imager (San Diego, CA) with eyes closed at 0, 1 ,  2, 3, 4, 6, 8 ,  
and 12  hrs . Subjects reclined in a hospital bed with the lights off during the 
recordings. They were asked to count back from 500 by 3s to maintain vigilance. 
The electrodes were placed using an Electro-cap according to the 10/20 International 
System with 8 additional electrodes located 50% between the standard 10/20 
placement. Omni-Prep «D.O. Weaver & Co. ,Aurora, CO) was used to prepare the 
scalp and Electro-Gel (Electro-Cap International , Inc. , Dallas, TX) was used as the 
conducting gel . Linked ears were used as a reference. Four additional electrodes 
were placed to monitor for vertical and lateral eye movements and electromyographic 
activity . Electrodes in the cap, ear clips, and eye movement monitors were made of 
tin .  Electrode impedances were checked before each recording, and maintained at 
less than 5 . 6  kohms and similar between electrodes. Disturbances in the room or 
subject movement during the EEG was recorded. The Brain Imager filters were set 
as follows: Low filter - 0.30 Hz, High filter - 40 Hz, Notch filter - off. The raw 
EEG was stored on optical disks . System integrity of the Brain Imager was checked 
weekly throughout the study to ensure stability of channel calibration and proper filter 
functioning. 
Each subject completed a computerized visual CPT (NeuroScan , Inc . )  at 0, 1 ,  
2,  3 ,  4 ,  6, 8 and 1 2  hr. In this task, the digits 0 through 9 briefly appear on the 
screen. The subject presses the left button of the mouse when a 0 appears and the 
right button for all other digits. The interstimulus interval varied from 0.8 to 1 .2 
seconds. A total of 120 stimuli were presented during each testing session. Two 
practice sessions were completed before beginning the 0 hr test battery. 
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Subjects completed a computerized motor task, finger tapping (NeuroScan, Inc. )  
at 0 ,  1 ,  2 ,  3 ,  4 ,  6,  8 and 1 2  hr. During this task, subjects tap the mouse button as 
fast as possible for 10  seconds, first with their right hand and then with their left. A 
total of three trials with each hand were completed during each testing session. Two 
practice sessions were completed before beginning the 0 hr test battery. 
A self-rated scale (Appendix B) based on the MBG (a measure of euphoria) and 
the A (a measure of amphetamine effects) sub scales of the Addiction Research Center 
Inventory Scales described by Martin et al .21 was completed by each subject at 0, 1 ,  
2,  3 ,  4 ,  6,  8 and 12  hr. The scale consisted of 23 questions which the subject 
responded to on a scale of 1 to 5 .  At the same times, a 100 mm visual analog mood 
scale (Appendix C) was completed . 
Blood pressure (sitting) and heart rate were measured at the following times: 
predose and 1 ,  2, 3, 4, 6, 8, 12 ,  and 24 hr after dextroamphetamine or placebo 
dosing using a Dynamap (Critikon, Tampa, FL) . 
When above measurements were scheduled at the same time, they were 
conducted in the following sequence: 1 )  urine collection , 2) blood samples, 3) EEG, 
4) CPT, 5) rating scales, 6) finger tapping and 7) vital signs with the blood sample 
being collected at exactly the scheduled time. 
All subjects were observed for symptoms and signs of clinical intolerance to the 
drugs or procedures and asked to report any adverse effects. These were evaluated 
by the physician monitor for their clinical significance and potential need for 
treatment. 
At the conclusion of his participation in the study, each subject was asked to 
identify which treatment he believed he had received during each period. 
4.2.2 Sample analysis 
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Assays for amphetamine in serum were performed by the author at the School 
of Pharmacy. Method development was conducted with the guidance of Clark March 
in the Biopharmaceutical Analysis Laboratory and is described in section 4 .2 .2a. The 
final method is described in section 4.2 .2b.  Validation of the method is described in 
section 4 .2 .2c. Description of the analysis of the subject samples from the clinical 
study is in section 4 .2 .2d. Amphetamine in urine was analyzed by a GC-MS method 
in the MCVH Toxicology Laboratory under the direction of Dr. Alphonse Poklis. 
The method is described in section 4 .2 .2e. Urine samples for subjects 1 ,  2, 4, 6,  8, 
9 and 10 were analyzed for amphetamine concentration. Assays for prolactin in 
serum were performed using an RIA method by Linda Lawrence, M.S .  in the Clinical 
Research Center Core Laboratory at MCV. Description of the method is found in 
section 4 .2 . 2f. 
4 .2 .2a Analytical Method Development for Amphetamine in Serum 
Analytical method development for amphetamine in serum began in September 
of 199 1 ,  after the completion of the clinical study. Requirements set forth to guide 
initial method selection included 1) ability to quantitate serum concentrations in the 
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range of 1 ng/mL (expected concentrations at 24 hours after 5 mg dose) to 60 ng/mL 
(expected peak concentration after 20 mg dose), 2) 1 mL or smaller serum sample 
needed for each extraction, and 3) necessary equipment and expertise available within 
the School of Pharmacy and supplies reasonable in cost. To achieve quantitation at 
serum levels in the low ng/mL range, gas chromatographic (GC) methods with 
detection of derivatized drug by mass spectrometry (MS), electron-capture detection 
(BCD), flame-ionization detection (FID), or nitrogen-phosphorus detection (NPD) are 
most likely to be useful . 127.17 Of these methods, GC-MS is the most sensitive. 
Equipment to perform the analysis by GC-MS was not readily available however, so 
alternatives were considered. A GC equipped with an ECD and an NPD was 
available, so a method for amphetamine in plasma, urine, and cerebral spinal fluid 
using GC_NPDI28. 129. 130 developed by Dr. Narasimhachari at VCU was chosen 
as the initial method to investigate. 
In Dr. Narasimhachari 's  method , the internal standard l3-methylphenethylamine 
is added to l -mL aliquots of plasma containing amphetamine. The sample is 
alkalinized by the addition of 0.5 mL of 2 N NaOH, salinized with 1 gram of NaCI 
and extracted twice with 5 mL of ethyl acetate. The organic layer is separated, 
pooled, and then back extracted with 0.5 mL of 0.5 N HCI and the organic layer 
discarded . The acid extract is alkalinized with 0.5 mL of 2N NaOH and extracted 
into 5 mL of ethyl acetate. The organic layer is  separated and mixed with 0.5 mL 
CS2 and set aside for 2 hours. The sample is then washed with 0.5 mL of 0.5 N 
HCI, the organic layer is evaporated to dryness, and then reconstituted in 1 00  JLL of 
ethyl acetate and injected onto the GC column. A Hewlett Packard 5840 GC with a 
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nitrogen-specific detector was used. Three columns were used: I )  a 1 . 3-m glass 
column packed with 2 %  OV- l O I  on Chromosorb WHP, 2) a 1 . 3-m glass column 
packed with 3 %  SP-2250 on Supelcoport 100-200 mesh and 3) a 0.65-m glass column 
with 3 %  OV-225 on Chromosorb WHP. The oven temperature was 140"C or 145°C, 
the injector temperature was 250"C and the detector temperature was 3000c. This 
method provided retention times of less than 3 minutes for both the analyte and 
internal standard. 
Dr. Narasimhachari 's  method required modification for use in our laboratory 
because of equipment differences. The method was adapted for use with a 5890 
Series II GC with nitrogen-phosphorus detector, 7673 Autosampler and controller, 
3396 Series II integrator, and capillary column fittings (Hewlett Packard Co. , 
Avondale, PA) as follows: 
A 15-m DB5 capillary column with internal diameter of 0.32 mm and fIlm 
thickness of 0.25 microns (J&W Scientific, Folsom, CA) was used with injections 
made in the splitless mode. Helium was used as the carrier gas, with a column flow 
of 1 . 2 mLimin at an injector temperature of 2000C,  detector temperature of 250"C 
and column temperature of l 000C.  To l -mL samples containing amphetamine and {3-
methylphenethylamine in water was added 0.5 mL I N  NaOH and 5 mL ethyl acetate. 
The organic layer was separated and retained , and 0. 1 mL CS2 was added. After 1 
hour, the samples were evaporated to dryness and reconstituted with 50 ILL ethyl 
acetate. 1 ILL was injected onto the column. 
These initial conditions did not provide adequate sensitivity for amphetamine. 
In addition , an interfering peak at the retention time of the internal standard was 
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present. The following factors were modified in an attempt to improve sensitivity and 
chromatography:  1 )  integrator attenuation (-2, - 1 ,  0, 1 or 2), 2) injection volume ( 1 , 2 
or 3 �L), 3) purge valve reset time (0.5 ,  0.75 ,  1 ,  or 1 .5 �L), 3) injection port 
temperature (90, 100, or 1 1 0"C), 4) oven temperature program (rate = 2 ,  5 ,  10 or 
15°C/min), 5) injection port liner type (untapered or dual-tapered),  6) reconstitution 
solvent (ethyl acetate, toluene, toluene:methanol [96:4] , dodecane or isooctane), 7) 
volume of C� added (25 ,  50, 75, 100, 125 or 150 �L) , 8) volume of ethyl acetate 
for extraction (2 , 3 ,  4 ,  5 or 6 mL), and 9) choice of internal standard (j3-
methylphenethylamine or a-phenethylamine. Modifications to these factors improved 
the sensitivity somewhat , but the interfering peak remained . 
Samples of amphetamine and ,s-methylphenethylamine in serum were prepared 
and extracted . Many interfering peaks were present, so a three-step extraction 
procedure similar to that described by Narasimhachari (discussed above) was tried. 
To each sample, 0 .5 mL of I N NaOH and 5 mL ethyl acetate were added. The 
organic layer was separated and 0.5 mL of 0.5 N HCl was added. The organic layer 
was separated and discarded . To the aqueous layer, 0.5 mL or 1 N NaOH and 5 mL 
of ethyl acetate was added . The organic layer was separated and 50 �L of C� was 
added. After 1 hour, the samples were evaporated to dryness, reconstituted with 20 
�L of ethyl acetate, and 2 �L were injected. The three-step extraction resulted in 
fewer interfering peaks, but did not eliminate them. In an attempt to remove or 
reduce the interfering peaks, the following factors were modified : 1 )  source of 
reagents, 2) preparation and storage of reagents, 3) pipet tips and extraction tubes 
used, and 4) type of extraction solvent (toluene or ethyl acetate) . Despite these 
modifications, problems with sensitivity and selectivity remained . Selectivity 
problems may have eventually been solved because the reagents appeared to be 
responsible, but concentrations in serum of less than 5 - 10 ng/mL were not 
quantifiable, so sensitivity was the major limiting problem. 
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Derivatization in gas chromatography can be used to improve chromatography,  
as with the isothiocyanate derivative of amphetamine'28, or  to enhance the detectability 
of a compound by introducing detector-oriented labels onto it. 131 The latter 
approach has been particularly successful with derivatives that enhance detection by 
ECD.  A number of  halogenated reagents have been used to derivatize primary 
arnines for subsequent analysis by GC-ECD. 132 The decision was made to switch to 
ECD and investigate alternative derivatizing reagents in an attempt to improve 
sensitivity and perhaps selectivity. 
The next experiments employed the same GC and column with the addition of 
an ECD to replace the NPD. Helium (grade 5) flow through the column was 1 .25 
mLimin with an injection port temperature of 200"C, detector temperature of 300"C 
and column temperature programmed at 1 10"C for 1 .5 min , increase at 10°C/min to 
1 60°C and hold for 10 min. 5 %  methane in argon was used as the make-up gas 
flowing at 65 mllmin. Splitless injection was used with a dual tapered liner and 
purge valve reset time of 0.75 min. 
The first derivatizing reagent investigated was trifluoroacetic anhydride (TFAA). 
Samples of amphetamine and is-methylphenethylamine were extracted using three 
different extraction solvents: ethyl acetate, toluene, and ethyl ether/hexane (8 :2). 
The derivatizing reagent was added to the organic extract and the mixture was heated 
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in a water bath at 50"C for 20 min. Samples were evaporated to dryness, reconstituted 
with ethyl acetate and 2 I'L were injected into the GC. No analyte peaks could be 
detected. Poole & Poolel33 reported the relative response of the ECD to 
haloalkylacyl derivatives of amphetamine. Responses relative to monochloroacetyl 
derivatives are as follows: trichloroacetyl 540, trifluoroacetyl < 0. 1 ,  
pentafluoropropionyl 40, heptafluorobutyryl 90, perfluorooctonyl 230, and 
pentafluorobenwyl 770. Based on these responses, trifluoroacetyl derivatives are 
least detectable, making TF AA a poor choice for derivatizing reagent. Subsequent 
experiments were conducted with trichloroacetyl chloride (rCA) and 
pentafluorobenzoyl chloride (PFB) as derivatizing reagents. 
When TCA and PFB were compared directly at the same concentration using 
toluene as the extraction solvent that the derivatization reaction was carried out in,  
peak height was less than half with TCA than with PFB. The peak shape however, 
was improved with the TCA derivative. To achieve quantitation as low as 1 ng/mL 
of amphetamine in serum,  it was decided to continue with the PFB derivative which 
provided greater detector response. The following factors were examined to improve 
sensitivity and selectivity using the PFB derivative: 1) concentration of PFB chloride 
(0.001 , 0.0 1 , 0. 1 ,  1 ,  10 or 100%),  2) addition of pyridine as an acid receptor to 
facilitate the derivatization reaction , 13I 3) concentration of pyridine added (0.01 , 0. 1 ,  
1 or 10%) , 4) volume of serum sample needed (0.5 or 1 mL), 5) storage of diluted 
derivatizing reagent (store in refrigerator, room temperature or dilute just prior to 
use) , 6) volume and concentration of NaOH and HCI solutions for extraction to 
determine the minimum acid and base that could be used while still maintaining 
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adequate pH at each step for effective extraction, 7) source of solvents (Fisher or 
Burdick & Jackson) ,  8) source of derivatizing reagent (Aldrich or Regis) , 9) removal 
of trace amounts of water prior to derivatization step, 10) method for washing 
glassware (with and without a final rinse in toluene) , 1 1 ) column type (DB- 1 7  or DB-
5) and 12)  type of extraction and centrifuge tubes (pyrex or borosilicate glass). After 
adjusting these factors, it appeared that the lowest level of quantitation that could be 
achieved was 2 ng of amphetamine per mL of serum,  which represents a peak height 
that was eight time the biological noise at the retention time for amphetamine. The 
retention times of amphetamine and ,s-methylphenethylamine were 14 .3  and 14 .6  min 
respectively . 
4 .2 .2b Description of the Analytical Method for Amphetamine in Serum 
The final method that was validated (section 4 .2 .2c) and used to analyze 
samples from the clinical study is described below. The reagents and supplies used 
for the assay are listed in Table 4. 1 .  
Sample preparation . Add 1 mL of serum, 25 J.LL of internal standard solution (2 
J.Lg/mL) ,and 0.5 mL of 0 .5  N NaOH to a culture tube. Vortex briefly. Add 5 mL 
ethyl acetate to the culture tube and vortex intermittently for 30 sec. Centrifuge for 
10  min at 1500 rpm. Transfer the ethyl acetate layer to a clean culture tube. Add 5 
mL of 0.001 N HCl . Vortex for 30 sec. Centrifuge for 10  min at 1 500 rpm. 
Aspirate the ethyl acetate layer to waste. Add 0.5 mL of 0.5N NaOH and vortex 
briefly.  Add 1 mL toluene and vortex for 30 sec. Centrifuge for 10  min at 1500 
rpm. Transfer toluene layer to centrifuge tube previously rinsed in toluene. Add 5 
Table 4. 1 Reagents and Supplies Used for Assay of Amphetamine in Serum 
1 .  d-Amphetamine, 1 mg/mL in methanol (All tech Associates, Deerfield, IL) 
2 .  ,s-Methylphenethylamine, 99  % (Aldrich Chemical Co. , Milwaukee, WI) 
3 .  Pyridine, silylation grade (pierce, Rockford, IL) 
4 .  Pentafluorobenzoyl chloride (Regis Chemical Company ,  Morton Grove, IL) 
5 .  Sodium hydroxide, ASC (Fisher Scientific, Fair Lawn, NJ) 
6. Hydrochloric acid, ASC (Fisher Scientific) 
7. Methanol , HPLC grade (Fisher Scientific) 
8 .  Toluene, High Purity (Baxter Healthcare Corp . ,  Burdick & Jackson Division, 
Muskegon , MI) 
9 .  Ethyl Acetate, High Purity (Baxter Healthcare Corp. , Burdick & Jackson 
Division) 
10.  Distilled , deionized water 
1 1 .  Helium, grade 5 .0  (AIRCO Medical Gases, Ashland, VA) 
12 .  5% Methane in  argon (AIRCO Medical Gases) 
1 3 .  Nitrogen , Medical grade (AIRCO Medical Gases) 
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14 .  Borosilicate glass screw cap culture tubes , 16  X 125mm, with teflon-lined caps 
(Baxter Diagnostics, Inc. , Scientific Products Division, McGaw Park, IL) 
15 .  Borosilicate glass screw cap centrifuge tubes, 10 mL, with teflon-lined caps 
(Scientific Products) 
1 6. Borosilicate glass transfer pipets, 5 3/4 inches (Scientific Products) 
17 .  Autosampler vial inserts, flat bottom, 200 JLL (Sun Brokers,  Wilmington , NC) 
1 8 .  Autosampler vial caps, teflon-lined rubber septum (Sun Brokers) 
19 .  Glass syringes, model 701 ,  (Hamilton Co. , Reno, NY) 
20. Injection port liner, dual tapered, 4mm 10, 800 JLL volume (Hewlett Packard, 
Avondale, PA) 
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ilL of 1 % pyridine and 5 ilL of 1 % pentafluorobenzoyl chloride. Vortex briefly. 
Place centrifuge tube in water bath at 50"C for 30 min. Evaporate toluene mixture to 
dryness under a flow of nitrogen in a Turbo-Vap LV evaporator (Zymark Corp. , 
Hopkington, MA) . Reconstitute the residue with 100 ilL of ethyl acetate and vortex 
briefly. Transfer the sample to an autosampler vial with insert and cap. Inject 1 ilL 
into the GC. 
Chromato�raphic Conditions. A 5890 Series IT gas chromatograph with nickel 
63 electron-capture detector, 7673 autosampler and controller and 3396 Series II 
integrator (Hewlett Packard Co. ,Avondale, PA) was used for the analyses. The 
column was a 15 m capillary DB-5 column with internal diameter of 0 .32 mm and 
film thickness of 0 .25 Ilm (J & W Scientific, Folsom, CA). The following gas flow 
rates were used : column - 1 .4 mLimin at 80"C (helium) , column head pressure - 5 
psi (helium), septum purge - 50 mLimin (helium), split - 3 mL/min (helium), make­
up gas - 65 mLimin at 300"C and pressure 50 psi (5 % methane in argon). 
Temperatures for the system were: injector - 200"C, detector - 300"C, oven program -
80°C for 1 . 5 min then 1000C/min to 2500C then 2500c for 1 min. The purge valve 
reset time was 0.75 min and the splitless injection mode was used. 
Data Evaluation. The amphetamine concentration of the prepared standards (50 
ng/mL, 20 ng/mL, 10 ng/mL, 5 ng/mL, 3 ng/mL, and 2 ng/mL) was regressed 
against the peak area ratio of amphetamine to internal standard to obtain calibration 
curves. The data was better described by a power function than a linear function , 
because the power function minimized the difference between back-calculated values 
and actual values for the highest standards. The following regression equation was 
8 1  
used: 
y = axb 
where x = concentration of amphetamine standard, y = peak area ratio, and a and b .  
are constants. The constants a and b were calculated with the linear regression 
function of Quattro Pro (Borland International , Inc. , Scotts Valley, CA) using a log 
transform of the data. An example calibration curve is shown in Figure 4 . 1 .  
4 .2 .2c Analytical Method Validation for Amphetamine in Serum 
The method was evaluated with respect to specificity, limit of quantitation , 
linearity , precision within a run, precision and accuracy between runs, extraction 
recovery , and stability of prepared samples. Analysis of spiked samples whose 
concentrations were unknown to the analyst were performed to further assess the 
accuracy of the method. The effects of freezing, thawing, and storage of the samples 
prior to analysis was also evaluated . 
Specificity. Serum collected during the placebo period of the clinical study 
from nine study volunteers and serum harvested from two additional donors was 
examined for the presence of potential interferences with amphetamine or the internal 
standard . I -mL samples were extracted, derivatized and injected on the GC. These 
chromatograms were inspected for the presence of interfering peaks at the retention 
times of amphetamine and the internal standard . Two of the samples had small peaks 
that interfered with amphetamine that were 1 2  % and 17  % of the peak height of the 2 
ng/mL standard. These were not considered to be significant interferences for this 
analysis. Chromatograms from the samples collected from the study volunteers are 
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Figure 4. 1 An example calibration curve for assay of amphetamine in serum 
presented in Appendix F. Serum from these sources was then used to prepare 
standards and controls for use during the method validation and subject sample 
analyses. 
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Limit of Quantitation. The lowest standard concentration of amphetamine for 
this analysis was established at 2 ng/mL of serum.  At this concentration, the peak 
height of amphetamine was eight times the noise of a amphetamine-free biological 
sample at the retention time of amphetamine. The mean back calculated concentration 
for the 2 ng/mL standard obtained during the analytical validation runs (average of 1 2  
analyses) was 2 .0  ng/mL with a relative standard deviation, expressed as a percent (%  
RSD) , of 7 .91  % .  
Linearit)'. Amphetamine serum concentrations over the range from 2 to 50 
ng/mL were evaluated for the calibration curve. Peak concentrations for subject 
samples following the 20 mg dose of amphetamine were expected to be approximately 
50 ng/mL. The standards and controls used for this evaluation were made using 
pooled serum from two of the sources evaluated for possible interferences. 
Calibration curves from six analytical runs, with duplicates of each standard 
concentration in each run , were examined. A blank serum sample was also analyzed 
with each run . Example chromatograms of each standard and control from one run 
are presented in Appendix G.  The constants (a and b) and the correlation coefficients 
of the calibration curves are presented in Table 4.2 .  As an additional measure of the 
appropriateness of the curve modeling , the calculated concentrations of the standards 
(back-calculated from the regression line) were examined . The back-calculated 
concentrations are presented in Table 4 .3 .  The RSD (%)  indicates the variability in 
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Table 4 .2  Regression Statistics for Serum Calibration Curves 
Date Run Number a b Correlation 
Coefficient 
1 /27/92 0.0275 0 .84 1 4  0.9979 
1 /28/92 2 0 .028 1 0 .84 1 6  0.9959 
1 /30/92 3 0.0287 0. 8490 0.9992 
2/8/92 4 0.0298 0. 8422 0.9988 
2/ 15/92 5 0. 0323 0 .825 1 0.9967 
2/1 8/92 6 0.03 1 3  0. 8069 0.9975 
Mean 0.0296 0. 8344 0. 9977 
SD 0.0019 0 .0142 0.001 1 
RSD ( % )  6 .41  1 .  7 1  0. 1 2  
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Table 4 . 3  Concentrations of Standards Back-calculated from the Regression 
Equations 
Amphetamine Concentration (ng/mL) 
Run No. 50 20 10  5 3 2 
54 . 35 19 .75 10 .41  4 .78 2 . 84 2 . 1 3  
53 .00 17 .35 9 . 8 1  4 .72 2 . 88 2.28 
2 5 1 .66 19 .95 1 1 . 57 5 . 65 3 . 2 1  1 . 89 
43 . 74 1 8 . 87 9 .97 5 . 68 2 . 85 1 . 66 
3 . 47.75 19 .59 10. 17  5 .03 2 . 88 1 .94 
5 1 . 2 1  2 1 .26 9 .73 5 . 17  2 . 82 2 . 1 8  
4 50.49 20.26 10. 8 1  5 .06 3 .03 2 .04 
50. 1 7  19 .94 9 .5 1 4 .30 3 . 1 1  2 .05 
5 5 1 .56 20. 83 10 .80 4 . 86 3. 19  1 . 86 
4 1 .25 22.22 1 1 . 1 3 4 .66 2 .68 2 . 1 1  
6 48.40 1 8 .47 9 .54 4 .63 3 .08 1 .96 
47.67 24 . 23 10.92 4 .79 3 .24 1 . 93 
Mean 49. 27 20.23 10 .36 4 .94 2.98 2.00 
SD 3 . 62 1 .72 0 .65 0.39 0. 17  0. 1 6  
RSD( %)  7 . 35 8 .49 6.26 7 .86 5 . 85 7 .91  
DFA(%) - 1 .46 1 . 1 3 3 .64 - 1 . 1 2 -0.53 0. 1 2  
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the calibration curves and the difference from actual , expressed as a percent (OF A %)  
shows the accuracy of  the calibration curves. DFA (%)  is calculated as: DFA(%) = 
[(mean - actual)/actual] x 100. These results indicate that the range of the calibration 
curve (2 ng/mL to 50 ng/mL) for amphetamine is appropriate and the variability is 
acceptable. 
Precision within a run. To evaluate precision within a run , six replicates of 
control samples (prepared by spiking blank serum with amphetamine at 35, 7 .54,  and 
3 .5  ng/mL) were analyzed in a single run .  The results of these analyses are presented 
in Table 4 .4 .  The variability, expressed as RSD (%) ,  is acceptable for the purposes 
of this analytical method. 
Precision and accuracy between runs. To evaluate precision and accuracy 
between runs, control samples (prepared by spiking blank serum with amphetamine at 
35 , 7 .5  and 3 . 5  ng/mL) were analyzed in six analytical runs. The results are shown 
in Table 4 .5 .  Precision was assessed by examining the RSD (%)  of each control 
across the 6 runs. Accuracy is reflected in the DFA (%) for each control across the 6 
runs. The precision and accuracy between runs for this method was acceptable. 
Extraction recovery. Extraction recovery was assessed by comparing results 
from serum samples spiked with amphetamine and carried through the extraction and 
derivatization step to results from blank serum samples carried through the extraction 
and then spiked with amphetamine just prior to derivatization . This process examines 
extraction recovery, but does not assess the efficiency of the derivatization reaction . 
To perform the recovery study, blank serum was spiked to amphetamine 
concentrations of 50, 5 and 2 ng/mL (3 samples at each concentration). These 
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Table 4.4 Data for Within-Run Precision 
Amphetamine Concentration (ng/mL) 
Replicate No. 35 7 .5  3 .5  
1 34. 60  8.03 3 . 25 
2 30. 88 7 .63 3 .26 
3 33.02 7.99 3 .05 
4 34 . 67 7 .66 3 . 10 
5 33 .80 7 .74 3 . 4 1  
6 33. 1 6  8 .09 3 . 2 1  
Mean 33 . 36 7 .86 3 . 2 1  
SD 1 .27 0. 19  0. 1 2  
RSD ( % )  3 . 82 2 .36 3 .63 
Table 4 .5  Data for Precision and Accuracy Between Runs 
Amphetamine Concentration (ng/mL) 
Run No. 35 7 .5  3 .5  
30. 87 7 .85 3 .49 
2 33.22 7 .72 3 . 1 6  
3 32.79 7 .4 1  3 .45 
4 34 . 60 8 .03 3 . 25 
5 29 .56 7 .29 3 .30 
6 32 .00 6 .90 3 .62 
Mean 32. 17  7.53 3.38 
SD 1 . 78 0 .4 1  0. 17  
RSD ( % )  5 .53 5 .44 5 .03 
DFA ( % )  -8.09 0.40 -3.43 
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samples and nine blank serum samples were extracted using the procedure described 
in section 4 .2 .2b.  Just before the addition of the derivatizing agent, the blank serum 
extracts were spiked with amphetamine to 50, 5 and 2 ng/mL (3 samples at each 
concentration). All samples were then derivatized and injected into the GC. 
Recovery was calculated as the mean peak height of the unextracted samples divided 
by the mean peak height of the extracted samples, expressed as a percent. The results 
are presented in Table 4 . 6. The extraction recovery of amphetamine was 53 .6 % ,  
42 . 5 %  and 47. 4 %  at 2 ,  5 and 50 ng/mL respectively. The extraction recovery of the 
internal standard was 49.5 % .  Spiking the amphetamine into toluene alone, rather 
than the toluene-serum extract was attempted initially,  but this resulted in greater peak 
heights for the extracted samples than the unextracted samples. This indicates the 
presence of a matrix effect in the derivatization or detection of amphetamine. 
Stability of prepared samples. To examine the stability of prepared samples, 
four standard curves were extracted and then exposed to various conditions. The first 
set of standards were carried through the entire procedure and injected into the GC 
immediately.  The second set of standards were carried through the entire procedure 
and allowed to sit on the autosampler tray (at room temperature) for 24 hours before 
they were injected. The third set of standards was carried through the extraction, 
derivatization and dry-down steps. Prior to reconstitution , the samples were stored in  
a freezer at -20°C for 24 hours. The samples were then brought to room temperature, 
reconstituted and injected into the GC. The fourth set of standards was carried 
through the entire process until they were ready to inject. They were then stored at -
20°C for 24 hours. They were then brought to room temperature and injected. The 
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results of these experiments are given in Table 4.7.  These results indicate that the 
samples can be processed and stored under any of these conditions without loss of the 
ability to detect amphetamine concentrations in the sample. 
Analysis of blinded Spiked samples. Ten blank serum samples were spiked with 
amphetamine at concentrations within the calibration curve range of the assay. The 
concentrations of amphetamine in these samples were unknown to the analyst at the 
time of the analyses. These results were used to further evaluate the accuracy of the 
method. The average DFA (%)  for the ten samples was 7.62 % .  The results are 
shown in Table 4 .8 .  These results provide further evidence that the accuracy of the 
method is adequate its intended use. 
Effects of freezing and thawing. A set of controls (35 ,  7.5 and 3 .5  ng/mL) was 
prepared and frozen. The controls were thawed 2 days later and a I -mL aliquot was 
analyzed for amphetamine concentration. The remainder of the sample was re-frozen. 
The controls were thawed again 8 days later, a I -mL aliquot was analyzed for 
amphetamine concentration, and the remainder of the sample was re-frozen . The 
freeze/thaw cycle was repeated 2 days later and then 20 days later (a total of four 
times) to test the stability of amphetamine in serum to repeated freezing and thawing. 
The results are presented in Table 4.9.  Repeated freezing and thawing did not 
significantly affect the concentrations of amphetamine in the controls. 
Stability of amphetamine in serum samples under storage conditions. This 
experiment was conducted to study the stability of serum samples containing 
amphetamine under the same storage conditions as the samples from the clinical study 
were stored . The first serum samples from the clinical study were collected in May, 
Table 4 .6  Extraction Recovery of  Amphetamine and �-methylphenethylamine 
from Serum 
Compound Concentration Mean Mean Recovery 
(ng/mL) Extracted Unextracted (%)  
Peak Height Peak Height 
Amphetamine 2 569 1 062 53.6 
Amphetamine 5 799 1 879 42.5 
Amphetamine 50 1 6 1 54 34080 47.4  
�-methyl- 50 59619  1 20506 49.5 
pheneth y lamine 
Table 4 .7 Results of Stability Study of Prepared Samples 
Amphetamine Peak Area Ratio to Internal Standard 
Standard 50 20 10  5 3 2 
Set 
0 .601  0. 2 1 8  0. 157 0. 109 0.074 0.046 
2 0. 670 0. 344 0. 1 38 0.087 0.06 1  0.044 
3 0. 754 0. 305 0. 1 39 0. 107 0.064 0.053 
4 0.687 0.270 * 0.087 0.061  0.034 
Mean 0.678 0.284 0. 145 0.098 0.065 0.044 
SO 0.063 0.054 0.01 1 0 .012  0.006 0.008 
RSO ( %)  9 .29 19 .01  7.59 12 .24 9 .54 17 .73 
* Sample lost due to autosampler failure 
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Table 4 . 8  Results of Analysis of Blinded Spiked Samples 
Amphetamine Added Amphetamine Found Percent Difference From 
(ng/mL) (ng/mL) Actual (DFA %)  
38 .5  39.57 2 .78 
0 BLQ 0 
6 .0 6.78 1 3 .00 
6.0 6 .03 0.50 
38.5 37.05 -3.77 
3 .5  4 .24 2 1 . 14 
0 BLQ 0 
3 .5  3 . 84 9 .7 1  
24.4 22. 12  -9. 34 
24. 4  20.5 1  - 15 .94 
Mean 7 .62 
BLQ = Below limit of quantitatlOn 
Table 4 .9  Effect of Repeated Freezing and Thawing on the Stability of 
Amphetamine in Serum 
Amphetamine Concentration (ng/mL) 
Cycle No. 35 7.5 3.5 
29. 17  7 .35 3 .05 
2 32.69 8 .22 3.42 
3 37.54 7.29 4 . 1 7  
4 28 .22 7 .65 3.5 1 
Mean 32 .07 7.63 3 .54 
SD 4.04 0.43 0.47 
RSD (%)  1 2 . 60 5 . 64 1 3 .28 
DFA (%)  -8.37 1 . 73 1 . 14 
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1 99 1  and were stored at -20"C in polypropylene culture tubes. Stability samples were 
prepared at this time by spiking blank serum with amphetamine to 10  and 40 ng/mL. 
The stability samples were stored in polypropylene culture tubes and frozen at -20"C 
in the same freezer as the study samples until March 1992, when analysis of the study 
samples was complete. At this time they were thawed for analysis. The 
concentrations determined for the 10 ng/mL and 40 ng/mL samples were 9. 10  and 
4 l .03 ng/mL, respectively. This indicates that amphetamine was stable in serum 
stored for 10 months at -20"C under the same storage conditions as the study samples. 
4.2 .2d Analysis of Subject Serum Samples for Amphetamine 
Samples were analyzed in batches made up of two standard curves (one at the 
beginning and one at the end of the run), two of each of three controls (35 , 7.5,  3 .5 
ng/mL), with a control run after each group of 7 study samples, a blank serum 
sample, and study samples from one subject (39 samples) . The following study 
samples were diluted before analysis by adding 0.5 mL blank serum to 0.5 mL study 
sample: 20 mg dose - 1 ,  1 . 33,  2, 2 .33,  3, 3 .33,  and 4 hr and 10 mg dose - 1 ,  1 .33, 
and 2 hr. A 35 ng/mL control was similarly diluted and analyzed with each run . 
Each batch contained a total of 59 samples. 
Results from both standard curves were used to determine the regression 
equation for each batch. In one batch (run on 3/4/92) , the first and second halfs of 
the run were different from one another. The peak height of the internal standard 
was higher during the second half of the run, so the two sets of standards could not 
be used to make a single standard curve. The regression of the curve from the first 
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set of standards was used to calculate concentrations for the first half of the samples 
and the regression of the curve from the second set of standards was used to calculate 
concentrations for the second half of the samples. All quality control samples were 
acceptable using this procedure, and repeat analysis of a portion of the samples from 
both the first and second half gave similar results to the first analysis. Regression 
statistics for the standard curves are presented in Table 4 . 10.  Concentrations for the 
standards back-calculated from the regression equations are shown in Table 4 . 1 1 . 
Concentrations for the quality control samples for each batch back-calculated from the 
regression equations are presented in Table 4 . 12 .  When the control samples that fell 
outside of the precision limits (outside ±2.58 X SO of the mean obtained for all of 
the runs) or accuracy limits (more than ±25 % of the mean obtained for all of the 
runs) are excluded , the RSO ( % )  for the 35 ng/mL (diluted), the 35 ng/mL 
(undiluted) ,  the 7.5 ng/mL and the 3 .5  ng/mL control were 17 .0% , 9 .4 % , 9 .8% , and 
1 2 . 1 % respectively .  
Samples with values less than 2 .0  ng/mL were considered to be below the limit 
of quantitation and were designated BLQ. Study sample analyses were repeated for 
the following reasons: 1) the concentration determined was greater than highest 
standard (50 ng/mL) , 2) poor chromatography, 3) the back calculated value for the 
control run before or after the study sample was either more than ± 25 % of the mean 
obtained for all of the runs (outside of accuracy limits) or outside ±2.58 X SO of the 
mean obtained for all of the runs (outside of precision l imits) , or 4) the value for the 
study sample appeared to be an outlier on a plot of concentration versus time. The 
original results were considered to be confirmed if the repeat value is within ± 20 %  
Table 4 . 10  Regression Statistics for Standard Curves from Analysis of Subject 
Samples 
Date a b Correlation 
Coefficient 
2/25/92 0.0234 0. 8628 0.9933 
2/29/92 0.0248 0. 8489 0.9942 
3/2/92 0.0235 0. 8455 0.9942 
3/4/921 0.0267 0 .8 124 0.99 1 3  
0 .0190 0. 8406 0.9975 
3/8/92 0.024 1 0. 8285 0.9865 
3/ 10/92 0.0233 0 .8783 0.9932 
31 1 1 /92 0.0 183 0.9 133 0.9989 
3/ 15/92 0.02 1 9  0.91 10  0.996 1 
31 17/92 0 .0190 0.9 1 84 0.9828 
Mean 0.0224 0. 8660 0.9930 
SD 0.0028 0.0360 0.0050 
RSD(%)  12 .48 4. 13  0.46 
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a =  Concentrations for samples from first half of batch calculated from regression 
of first standard curve and the for the second half from the second standard 
curve. 
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Table 4 . 1 1  Back-Calculated Concentrations for Standards from Analysis of Subject 
Samples 
Date 50 ng/mL 20 ng/mL 10 ng/mL 5 ng/mL 3 ng/mL 2 ng/mL 
Standard Standard Standard Standard Standard Standard 
2/25/92 56.25 22.28 10.74 5 .9 1  2 .76 2 .25 
44 . 87 19 .08 7 .64 5 . 5 1  2.59 1 .95 
2/29/92 55 .24 20.99 10 .91  5 .62 3 . 38 2 .26 
52.92 1 6.33 8 .23 4 .64 2 .59 1 .95 
3/2/92 50.49 22. 39 10 .66 5 . 87 3 .30 2 . 1 7  
54.99 1 6 .77 8 .40 4 .09 2.90 1 .94 
3/4/92 58 .40 17 .30 8 .05 5 . 8 1  3 .35 1 . 89 
50. 4 1  19 .20 1 1 .28 4 .39 2 .95 2 . 1 2  
3/8/92 59.08 a 7.79 6. 17  3 .77 2 .43 
55 .63 15 .08 10.40 4 .26 2 . 80 1 . 68 
3/ 10/92 43.94 2 1 . 1 4 1 1 .46 4 .90 2 . 88 2 .46 
48. 7 1  22 . 85 8 . 78 5 . 76 2 .7 1  1 .59 
31 1 1192 52 . 39 20.79 9.02 5 . 12 2 . 85 2. 1 8  
50. 83 19 . 1 3  9.99 5 .0 1  2 . 83 2.09 
3/15/92 49. 80 19 .05 10 .90 5 . 14 3 .71  2 .09 
52.39 20. 4 1  8 .49 5 .04 2 .56 1 . 87 
311 7/92 3 1 .33 2 1 . 27 9.00 4 .68 2.76 1 . 86 
78 . 7 1  19 .27 10. 1 1  6 .01  3 .54 1 .9 1  
Mean 52.58 19 .6 1  9.55 5 .22 3 .0 1  2.04 
SD 8 . 87 2 . 17  1 .26 0 .62 0 .38 0.23 
RSD ( %)  1 6 . 86 1 1 .08 1 3 . 19  1 1 .97 1 2 .59 1 1 . 14 
DFA -5 . 1 5 1 .96 4.53 -4 .37 -0.43 - 1 .92 
a = Standard rejected due to poor chromatography 
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Table 4 . 12  Back-Calculated Concentrations for Quality Control Samples from 
Analysis of Subject Samples 
Date 35 ng/mL 35 ng/mL 7.5 ng/mL 3 .5  ng/mL 
control control control control 
(diluted) 
2/25/92 30. 85 42.62" 8.40 3 . 35 
30.82 6. 8 1  3 .55 
2/29/92 36.69 33.05 7 .8 1  4 . 1 5  
26.87 5 .67 2 . 59 
3/2/92 46. 16" 33 .85 8 .42 3 . 60  
32 . 7 1  7.00 3 . 1 6  
3/4/92 40.29 36.42 7.56 2 .92 
28.38 7.79 3 . 30 
3/8/92 34 .03 35 . 22 6.52 2.93 
32 . 1 9 6 .88 2 .98 
3/ 10/92 26.24 36.28 7.25 3 .72 
27.66 7 .3 1  5 .05" 
31 1 1 /92 26.26 30.04 6.46 3 . 29 
27 .79 6.76 3 . 27 
31 15/92 3 1 . 85 33.23 8 . 17 3 .24 
34.09 7.55 3 .20 
3/ 1 7/92 25 .53 30. 60 8 . 1 1  2 .65 
30.78 7 .33 3 .66 
Mean 33. 10  32 . 37 7 .32 3 . 37 
SD 6 .61  3 .76 0.72 0.55 
RSD 19 .98 1 1 . 6 1  9 .80 1 6.43 
( % )  
DFA 5 . 43 7.52 2 . 37 3 .79 
a = Outside accuracy and precision limits 
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of the original value. If there was a discrepancy between the original and the repeat 
value, a third assay was performed. If the third assay agreed with the original, then 
the two values were averaged and reported. If the third assay agreed with the second, 
then the two were averaged and reported. If the third assay agreed with both the 
original and the second assay, then the mean of all three values was reported. Seven 
study samples were repeated due to controls falling outside the accuracy and precision 
limits, one was repeated because the assayed value was greater than 50 ng/mL, six 
were repeated due to poor chromatography, and 14 were repeated based on the plot of 
concentration versus time. 
4 .2 .2e Analytical Method for Amphetamine in Urine 
This method was developed in the MCVH Toxicology Laboratory under the 
direction of Dr. Alphonese Poklis. The extraction and derivatization is based on the 
method of Meeker and Reynolds. l34 Briefly, urine samples containing amphetamine 
were spiked with internal standard , made basic, and then extracted with chlorobutane. 
The analytes in chlorobutane were derivatized with pentafluoropropionic anhydride. 
The chlorobutane was evaporated, the residue reconstituted in ethyl acetate, and a 
portion injected into the gas chromatograph with mass selective detector. 
Standards and controls. A reference standard at 1 .0 mg/mL d-amphetamine in 
methanol (Radian Corporation, Austin ,  TX) was used to prepare working standards by 
spiking drug-free urine with d-amphetamine to 0.2,  0.5 , 1 .0, 2 .0,  4.0,  6.0 and 8.0 
ILg/mL. The internal standard was ds-amphetamine (Radian Corporation) with 0. 1 mL 
of a 10 ILg/mL solution added to each specimen prior to analysis. Controls were 
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prepared by spiking drug-free urine to 1 and 4 ILg/mL with d-amphetamine. 
Apparatus and procedures. Analyses were performed using an HP model 5890 
gas chromatograph coupled to an HP model 5971 A  mass selective detector (Hewlett­
Packard, Avondale, CA). Data processing was performed with a HP Chemstation 
with Version 3 .0  software. A 12m x 0.2mm glass capillary HP- 1 column was used. 
The injector temperature was 25O"C and the oven temperature was programmed with 
initial temperature of 1 80"C held for 2 minutes and then increased 1 0"C/min to a flnal 
temperature of 250"C. The retention time of d-amphetamine under these conditions 
was 3 .95 minutes. The mass selective detector was operated in the SIM mode, with 
d-amphetamine monitored at ions 9 1 , 1 1 8  and 190 m/z and the deuterated internal 
standard at 96, 123 and 194 ml z. 
Sample preparation . Briefly,  2-mL samples of urine were spiked with internal 
standard , made alkaline by the addition of ammonium hydroxide, then extracted with 
4 mL of chlorobutane. Three mL of the chlorobutane layer was removed and 
evaporated to 2 mL at room temperature under nitrogen . 100 ILL of 
pentafluoropropionic anhydride (Regis Chemical Co. , Morton Grove, IL) was added 
to the chlorobutane extract, the mixture was capped and heated in a dry heat block at 
70°C for 1 5  min . The mixture was allowed to cool and was evaporated to dryness 
under nitrogen at room temperature. The residue was reconstituted with 50 ILL of 
ethyl acetate and injected into the GC/MS . 
Subject Samples. Samples were analyzed for all three active treatments for 
Subjects 1 ,  4 ,  6,  8 ,  9 and 10.  Only the 5 mg and 20 mg doses were analyzed for 
Subject 2 .  Samples were not analyzed for Subjects 3 ,  5 and 7. 
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4 .2 .2f Analytical Method for Prolactin in Serum 
The analysis for prolactin concentration in serum was performed in the Clinical 
Research Center Core Laboratory by Linda Lawrence, M.S .  using a 
radioimmunoassay (RIA) (Amersham Corp. , Arlington Heights, IL). The analyses 
were performed in January and February, 1992 . Prolactin is stable in serum over the 
9 month period that the samples were stored when frozen at -20"C. \35 
In this method, a known amount of radiolabeled prolactin (prolactinJ251) is added 
to prolactin in the serum sample and competes for a limited number of binding sites 
on a prolactin specific antibody. The proportion of the prolactinJ25I that binds to the 
antibody is inversely related to the concentration of prolactin in the serum sample. 
The prolactin bound to the antibody is reacted with a second antibody, and the 
precipitated double antibody complex is separated by centrifugation . The supernatant 
containing unbound prolactin is discarded, and the proportion of prolactinJ251 in the 
precipitate is measured by a gamma scintillation counter. The concentration of 
prolactin in the sample is determined by interpolation from a serum concentration­
response curve established using serum reference standards. 
Details of the procedure are described by the manufacturer (prolactin RIA Kit 
instructions, Code 1M. 1 06 1  , Amersham Corporation, June 1989) . Assays were 
performed using the long protocol .  Standard curves were constructed using 0, 5 ,  15 ,  
50,  100 and 200 ng/mL prolactin standards. According to the manufacturer's 
specifications, controls were also run with the study samples (RIA Control Serum, Set 
3, Cat. No. 07 1 66 1 20, ICN Biomedicals Inc .) .  If controls fell outside of the 
laboratory quality controls limits, then the assays were repeated. 
100 
Sensitivity, defined as the smallest amount of prolactin that can be  distinguished 
from zero using this kit, is reported by the manufacturer to be approximately 1 .5 
ng/mL. This value is the prolactin concentration that causes a decrease in count of 
two times the standard deviation from the zero prolactin standard using standard 
counting procedures. Values below 1 .5 ng/mL were considered to be below the limit 
of quantitation (BLQ) . 
Reproducibility of the Prolactin RIA Kit was evaluated by the manufacturer 
using freeze-dried control sera. The within assay coefficient of variation was 4 .3 % ,  
3 .5 % ,  and 2 . 4 %  for the low, medium , and high controls respectively. The between 
assay coefficient of variation was 5 . 7 % ,  4 .6% and 5 . 8 %  for the low, medium and 
high controls respectively. Cross-reactivity of the antiserum with other pituitary and 
placental hormones was less than 0.2 % .  
4 .2 . 3  Pharmacokinetic Data Analysis 
Pharmacokinetic analysis based on serum data was performed using both 
noncompartmental and compartmental approaches. Methods used for the analysis of 
the serum data are discussed in section 4 .2 .3a. Pharmacokinetic analysis methods 
based on urine data is presented in section 4 .2 .3b. Statistical methods used to 
compare the pharmacokinetic data obtained for the three doses of amphetamine are 
described in  section 4 .2 .3c.  
4 .2 .3a Serum Data Analysis 
The pharmacokinetic variables estimated from the serum data for this study 
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were drug concentrations in serum at each sampling time, the maximum drug 
concentration (C.,..J, the time from dosing to Cmu: (T.,..J ,  the terminal (elimination) 
rate constant (k), areas under the drug concentration-time curve extrapolated to 
infinity (AUCoo), the apparent total body clearance normalized for bioavailability, F 
(CIfF), the mean residence time (MRT) and the absorption rate constant (ka). 
Determination of these variables is discussed by Gibaldi and Perrier. l36 Plots of 
amphetamine concentrations in serum versus time, In amphetamine concentration 
versus time, and amphetamine concentration divided by dose versus time were 
constructed. Cmu: was defined as the maximum serum concentration observed in the 
24 hr following dosing. T mu: is the time (relative to dosing) that Cmu: occurred. The 
elimination rate constant, k, was calculated by log-linear regression as the slope of the 
final linear portion of the In serum drug concentration versus time curve. At least 
three concentration-time points were used to determine k. 
AUCoo,  CIfF and MRT were calculate by noncompartmental methods using the 
Quattro Pro (Borland International, Scotts Valley, CA) spreadsheet 
NONCOMP.WK I ,  Version 2 . 1 developed by Dr. Jurgen Venitz, Department of 
Pharmacy and Pharmaceutics, VCU. AUCoo was calculated by first determining the 
A UC from 0 hr to the time (twJ of the last measured concentration (CwJ by the l inear 
trapezoidal rule and then extrapolating the area to time 00 by adding the last observed 
concentration divided by the terminal rate constant (AUCoo = AUCO-wt + Cw/k) . 
Cl/F was calculated by dividing the dose administered by AUCoo'  MRT was 
calculated by dividing AUMCoo by AUCoo'  AUMC"" was calculated by determining 
area under the moment curve (AUMC) from 0 hr to Cla,t using the linear trapezoidal 
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rule by summing individual areas calculated by 
and then extrapolating the area to time 00 by adding «fwtCIu/k) + C..j�) .  
The "goodness" of  the estimates of  AUC", were evaluated by  examining the 
ratio of the extrapolated portion of AUC to AUC", ([C..jk]/AUC",). The ratio 
(expressed as a percent) ranged from 1 1  to 4 1  % for the 5 mg dose, 7 to 23 % for the 
10  mg dose, and 9 to 17% for the 20 mg dose. For the 5 mg dose, the ratio was 
greater than 20 % for 3 of the subjects (8, 9, and 10). Less than 20 % of the total area 
was extrapolated for all subjects after the 10 and 20 mg doses. Similarly, estimates 
of AUMC", were evaluated by examining the ratio of the extrapolated portion of 
AUMC to AUMC",.  The ratio, expressed as a percent, ranged from 3 1  to 73 % for 
the 5 mg dose, 25 to 58%  for the 10  mg dose, and 28 to 47 % for the 20 mg dose. 
The estimates of AUC", were better than the estimates of AUMC"" because the 
contribution of the extrapolated portion of the area to the total AUC was smaller. 
Because T mu appeared to increase as the dose increased for a majority of the 
subjects, absorption rate of amphetamine at different doses was examined using 
compartmental pharmacokinetic methods. Pharmacokinetic compartmental models 
were fit to the serum amphetamine concentration versus time data using the nonlinear 
regression program PCNONLIN, Version 3 .0  (SCI Software, Lexington, KY). 
Several models,  including one-compartment with first order input and first order 
output with and without a lag time and two-compartment with first order input and 
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first order output from the central compartment with and without a lag time, and 
several weighting schemes, including 1 ,  l /y and l /y2, were evaluated. The Gauss­
Newton algorithm with the Levenberg modification was used as the estimation 
method. Initial values were obtained using the curve stripping program RSTRIP 
(Micromath, Salt Lake City, UT). The model which best fit the data was chosen 
based on the following criteria: 1 )  minimize the estimated standard error of the 
parameter estimates for k and ka, 2) random distribution of positive and negative 
deviations of the calculated function values, 3) minimize AIC (Akaike criteria) which 
is defined as the sum of squares corrected for the number of variables, and 4) random 
scatter in the plots of weighted residuals versus calculated values and weighted 
residuals versus the independent variable based on visual inspection of the plots , and 
5) minimize the condition number of the matrix of partial derivatives. 
Based on these criteria, the one compartment model with first order input and 
first order output without a lag time was the most appropriate model to describe the 
data for all subjects and all doses. For most subjects, using a weight of l /Y2 resulted 
in the best fit. Data from subjects 3 ( 10  and 20 mg dose) , 5 (5 mg dose) , 6 (20 mg 
dose) , 7 (5 and 10 mg dose) , and 8 ( 10  mg dose) were best modeled using a weight 
of 1 .  ka from the most appropriate model and weighting was used to compare 
treatments. 
Values for each of the pharmacokinetic variables were transferred to the V AX 
computer system (Digital Equipment Corporation) in VCU Health Sciences 
Computing Services for statistical analysis. 
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4.2 .3b Urine Data Analysis 
The pharmacokinetic variables estimated from the urine data for this study were 
the urinary excretion rate at the midpoint of the each urine collection interval , the 
elimination rate constant (1<:), and the renal clearance (Cl,.) . The dependency of Clr on 
urine pH and flow was examined. The natural log of the urinary excretion rate (the 
amount of drug excreted during the collection interval divided by the collection time) 
was plotted against time at the midpoint of the urine collection interval . The 
elimination rate constant (1<:) is equal to the negative of the slope of this line. To 
calculate Clf> the urinary excretion rate was plotted against serum concentration at the 
midpoint of the urine collection interval . If the serum concentration was not 
measured at this time, it was calculated by log-linear interpolation from the 
measurements made before and after the midpoint. Clr was determined from the slope 
of this plot. The first collection interval was excluded when evaluating Cl,. because 
the serum concentration at the midpoint of this interval was not representative of the 
entire interval due to the variability in the drug absorption process. The effect of 
urine flow and urine pH on Clr were examined by plotting Cl,. at each collection 
interval versus urine pH and urine flow at each collection interval in SAS . A 
smoothing function was used to smooth the response surface. 
4 .2 .3c Statistical Methods 
Descriptive statistics (mean, standard deviation and relative standard deviation) 
were calculated for each pharmacokinetic variable. Dose-dependency of the 
calculated pharmacokinetic parameters was evaluated by fitting the data for each 
pharmacokinetic parameter to a crossover model using a univariate mixed effects 
analysis of variance (model with both fixed and random effects) of the form 
Y ijk = JL + OJ + Tj + tk(i) + fjjk 
1 = 1 ,2 ,3 ,4  
j = 1 ,2 ,3  
k = 1 ,2 ,  . . .  , 8  
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where Yjjk is the response for the kth subject in the ith sequence in the jth 
period , JL is the overall mean , OJ is the effect of the ith sequence, Tj is the effect 
of the jth period , and tk(i) is the effect of the kth subject within the ith sequence, 
and fjjk is the random error associated with Yjjk• The fjjk are assumed to be 
normally distributed random variables with mean of 0 and common variance u,2. 
It is also assumed that the nested effects for subject are random and 
independently distributed with mean of 0 and common variance u/ , and 
independent of fjjk ' 
Model fitting was performed using PROC MIXED in SAS . J37 PROC MIXED 
allows modelling of the mean of y, as in the standard linear model , and also the 
variance of y .  The estimation method used for the covariance parameters was 
restricted maximum likelihood (REML) . The variance of y is modelled by choosing 
the form of the variance structure matrices. Simple (random effect) , unstructured, 
and time series (autoregressive) structures were evaluated. The autoregressive 
structure resulted in improved model fitting based on maximization of the Akaike's  
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Information Criterion for most variables. The autoregressive structure indicates that 
the correlation between measurements is less if they are made further apart in time. 
For pharmacokinetic parameters where the analysis with autoregressive variance 
structure did not converge, the simple structure was used. 
For pharmacokinetic parameters where the effect of treatment was significant (p 
< 0.05),  multiple comparisons of the treatments were performed using the 
ESTIMA TE procedure. 
The residuals were tested for normality using PROC UNIV ARIA TE120. This 
procedure computes the Shapiro-Wilk statistic, W, for the null hypothesis that the 
residuals are normally distributed . When the probability of a smaller value of W was 
less than or equal to 0. 1 ,  the null hypothesis of normality was rejected . The residuals 
were normally distributed for all of the pharmacokinetic variables examined . 
4 .2 .4  Pharmacodynamic Data Analysis 
The measures of response that were examined for each of the tests assessing 
pharmacodynamic effect are listed in Table 4 . 1 3 .  
4 .2 .4a EEG Analysis 
As each EEG was recorded , the signal was processed by a Fast Fourier 
Transform procedure, to determine the amplitude of the EEG in five frequency bands 
(Delta: 0.39 - 3 .9  Hz, Theta: 4 . 3  - 7 . 8  Hz, Alpha: 8 .2  - 1 1 .7 Hz, Beta I: 12 . 1 - 16.0 
Hz, and Beta II: 1 6.4  - 30.0 Hz) at each electrode. Each of the five-minute 
recordings was reviewed and edited to remove each 2 .5  second epoch (frame) that 
Table 4. 1 3  
EEG Variables 
Response Measures Evaluated in Part II - Comparison of Quantitative EEG for 
Assessment of CNS Stimulant Response 
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Total Amplitude - all frequencies (p.V) 
Total Amplitude - Delta band (p.V) 
Total Amplitude - Theta band (p.V) 
Total Amplitude - Alpha band (p.V) 
Total Amplitude - Beta I band (p.V) 
Total Amplitude - Beta II band (p.V) 
Total Power - all frequencies (p.Vl) 
Total Power - Delta band (p.V2) 
Total Amplitude (Central electrodes) - all frequencies (p.V) 
Total Amplitude (Central electrodes) - Delta band (p.V) 
Total Amplitude (Central electrodes) - Theta band (p.V) 
Total Amplitude (Central electrodes) - Alpha band (p.V) 
Total Amplitude (Central electrodes) - Beta I band (p.V) 
Total Amplitude (Central electrodes) - Beta II band (p.V) 
Total Power (Central electrodes) - all frequencies (p.Vl) 
Total Power (Central electrodes) - Delta band (p.V2) 
Total Power - Theta band (p.Vl) Total Power (Central electrodes) - Theta band (p.Vl) 
Total Power - Alpha band (p.Vl) Total Power (Central electrodes) - Alpha band (p.Vl) 
Total Power - Beta I band (p.Vl) Total Power (Central electrodes) - Beta I band (p.Vl) 
Total Power - Beta II band (p.Vl) 
Relative Power - Delta band 
Total Power (Central electrodes) - Beta II band (p.Vl) 
Relative Power - Theta band 
Relative Power - Alpha band 
Relative Standard Deviation of Ampljtude - Delta Band (% )  
Relative Standard Deviation o f  Amplitude - Alpha Band ( % )  
Relative Power - Beta I band 
Relative Power - Beta II band 
Total Amplitude (Occipital electrodes) - all frequencies (p. V) 
Total Amplitude (Occipital electrodes) - Delta band (p.V) 
Total Amplitude (Occipital electrodes) - Theta band (p. V) 
Total Amplitude (Occipital electrodes) - Alpha band (p.V) 
Total Amplitude (Occipital electrodes) - Beta I band (p. V) 
Total Amplitude (Occipital electrodes) - Beta II band (p.V) 
Total Power (Occipital electrodes) - all frequencies (p. Vl) 
Total Power (Occipital electrodes) - Delta band (p.V2) 
Total Power (Occipital electrodes) - Theta band (p. Vl) 
Total Power (Occipi tal electrodes) - Alpha band (p. Vl) 
Total Power (Occipital electrodes) - Beta I band (p.Vl) 
Total Power (Occipital electrodes) - Beta II band (p. V2) 
Psychometric tests 
Percent Correct on Continuous Performance Task ( %) 
Average Latency on Continuous Performance Task (sec) 
Mood Scales 
Total Score on Self-Rated Mood Scale 
Neuroendocrine test 
Prolactin serum concentration 
Cardiovascular measures 
Heart Rate 
Diastolic Blood Pressure 
Systolic Blood Pressure 
Finger Tapping with Left Hand (taps/sec) 
Finger Tapping with Right Hand (taps/sec) 
Score on Visual Analog Mood Scale 
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contained artifacts (eye movements, muscle movement, electrode artifacts, or 
disturbances noted during the recording). 1 17, 1 1 8  The remaining frames were averaged 
using the EEG statistical operations package on the Brain Imager to form an average 
topographical map representing the five minute recording. Recordings with fewer 
than 24 artifact-free frames were not processed further and were listed as " missing" .  
To compute averages and standard deviations representing th e  5-minute recording, the 
Brain Imager first forms sub-averages and sub-standard deviations from consecutive 
groups of eight frames each , 1 19 The amplitude in each frequency band (determined by 
FFf) measured at each of the 28 electrodes for the first eight artifact-free frames are 
added together and then divided by 8 ,  to determine the SUb-average. The sub­
standard deviation is also calculated. This process is then repeated for the next group 
of 8 frames and so on . The overall average and standard deviation is then formed by 
averaging the sub-averages and calculating their standard deviation . The overall 
average file contains the average amplitude in each of the 5 frequency bands at each 
of the 28 electrodes. The overall standard deviation file contains the standard 
deviation of the amplitude in the 5 frequency bands at each of the 28 electrodes. 
These files were then transferred from the Brain Imager to an IBM compatible 80386 
personal computer. 1ST A T (NeuroScience , Inc.) a statistical package for EEG 
processing was used to prepare ASCII files of the average and standard deviation 
files. These files were then imported into the Quattro Pro spreadsheet software 
(Borland International , Scotts Valley, CA) for further processing. 
Power was determined for each average recording by squaring the amplitude 
values at each electrode in each frequency band. Total amplitude and total power in 
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each frequency band was calculated by summing the amplitude or power at each of 
the electrodes for a given frequency band. Total amplitude and total power across all 
frequency bands was calculated by adding together the total amplitude or total power . 
in each of the frequency bands. Relative power in each frequency band was 
calculated by dividing the total power in the given frequency band by the total power 
across all frequency bands. 
Relative standard deviation (RSO) for each average recording was determined 
by dividing the standard deviation in each frequency band for each electrode by the 
average for the same frequency band and electrode, expressed as a percentage. The 
mean RSO was then calculated by averaging the RSO for all electrodes for each 
frequency band. 
Total amplitude and power in the central and occipital areas for each frequency 
band were calculated by adding together the amplitude or power at the central 
electrodes (C3 ,  CZ, and C4) and the occipital electrodes (0 1 ,  OZ and 02) 
respectively,  for a given frequency band. Total amplitude and total power in the 
central and occipital areas across all frequency bands was calculated by adding 
together the total amplitude or total power in the central and occipital areas 
respectively across all frequency bands. Frontal alpha power was not examined 
because it is more likely to be contaminated by eye movement artifacts. 
Values for the response measures calculated were transferred to the relational 
database Paradox (Borland International , Scotts Valley, CA) for data management and 
further analysis. 
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4 .2 .4b Analysis of Other Response Measures 
For the computerized visual CPT, latency of response was determined for trial 
during the session . The average latency of response and the percent of correct 
responses for each test session was determined. For the finger tapping task, the 
average rate (taps/sec) of finger tapping for each hand was calculated for each session 
by averaging the results of the three trials conducted during each session. 
A total score on the self-rated mood scale was determined for each test session 
by summing the scores obtained for each of the 23 items on the scale. A score 
between 0 and 100 was obtained for the visual analog mood scale for each test session 
by measuring the number of millimeters between the left end of the scale and the 
mark placed by the subject. Values for heart rate, systolic blood pressure and 
diastolic blood pressure were transcribed from the Dynamap (Critikon , Tampa,FL) 
output. Serum prolactin concentrations were determined as outlined in section 4 .2 .2e.  
Values for the response measures were transferred to the relational database 
Paradox (Borland International , Scotts Valley, CA) for data management and further 
analysis. 
4 . 2 .4c Pharmacodynamic methods 
Response-time profiles for each response measure were tabulated and plotted for 
each subject during each treatment. Baseline response for each measure during each 
treatment was defined as the value obtained at 0 hr, before receiving the study 
medication . Maximum response for each measure (E"..J was determined as the 
highest response observed during the 12  hours after receiving the study medication. 
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Minimum response (E..wJ was the lowest observed effect during the 1 2  hours after 
dosing. If more than one value for the response measure was missing, the Em.x or 
E...m was assigned as " missing" .  Maximum response during the first 4 hours (G.,.,. -
( l st 4 hr» was the highest value observed during the first four hours after dosing for 
each response measure. Minimum response during the first 4 hours (E...m - ( l st 4 hr» 
was the lowest effect observed during the first 4 hours after dosing. The response 
during the first four hours was examined separately,  because the effect was expected 
to be greatest during this time period. If one or more values for the response measure 
were missing, the Em.x - ( l st 4 hr) or E...m - ( 1 st 4 hr) was assigned as " missing" . 
Based on previous studies and examination of the data, either the maximum response 
(for responses that increase with increasing dose) or the minimum response (for 
responses that decrease with increasing dose) was chosen to represent the drug effect 
for each response measure. 
An effect time (ET) for each response measure after each treatment was 
calculated by: 
ET = ( I  EI -� I * 1 ) + ( 1 �-� I  *2) + ( 1 E:J-� 1  *3) + ( I E4-� 1  *4) + ( 1 �-� I  *6) + 
( I  Eg-� I *8) + (  1 EI2-� 1  * 1 2) 
where � = response at 0 hr E4 = response at 4 hr 
EI = response at 1 hr � = response at 6 hr 
� = response at 2 hr Eg = response at 8 hr 
E:J = response at 3 hr EI2 = response at 12 hr 
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This value was used as an indicator of the length of time that the response measure 
could distinguish a drug effect, weighted toward the later times (and lower 
concentrations). If a value for the response measure was missing at any time point, 
the ET was assigned as " missing" .  
I n  addition, each subject was given a euphoria score ( l  for euphoria and - 1  for 
dysphoria) for each treatment based on the self-rated mood scale scores and the visual 
analog mood scale scores. If the scores increased after dosing, the subject was given 
a score of 1 for that treatment. If the scores decreased after dosing, the subject was 
given a score of - 1  for that treatment. During the placebo period a euphoria score of 
o was assigned . 
Values for E.nu, E.nu - ( 1 st 4 hr) , �, EDlin, Emm - ( l st 4 hr) , ET and the 
euphoria score were transferred to the V AX computer system (Digital Equipment 
Corporation) in VCU Health Sciences Computing Services for subsequent analysis. 
4 .2 .4d Statistical Methods 
Because there are many variables of interest in this statistical analysis, the 
multiplicity of desired inferential statements about the data becomes problematic. 
Adjusting the level of significance (a) for the multiple statistical comparisons being 
made as in traditional confirmatory analysis would result in extremely small a values 
and virtually no likelihood of detecting any statistically significant differences. Using 
the concept of Descriptive Data Analysis as described by Abt138•J39, expected 
differences between the treatments based on previously reported studies and patterns 
apparent from examining the data were evaluated statistically without adjustment of 
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the level of significance. The results of these analyses were used to make descriptive 
inferential statements about the data, but not to reject null hypotheses. 
Pharmacodynamic parameters that were evaluated using DDA included: decrease in 
serum prolactin , increase or decrease in mood scores for both rating scales, decreased 
average latency on the CPT, decreased percent correct on the CPT, increased rate of 
finger tapping, increase in heart rate and blood pressure, increase in EEG fast activity 
(total alpha and beta power) and decrease in EEG slow activity (total delta and theta 
power) . Statistical comparisons for other pharmacodynamic parameters were treated 
as exploratory data analysis. They were used to generate hypotheses rather than to 
form final conclusions based on the data. 
Descriptive statistics (mean, standard deviation and relative standard deviation) 
were calculated for each pharmacodynamic variable for each response measure. 
Pharmacodynamic variables obtained during each treatment for each response measure 
were compared by fitting the data for each pharmacodynamic variable to a crossover 
model using a univariate mixed effects analysis of covariance of the form 
Yjjk = p. + OJ + Tj + rk(� + fjjk + 'Ymj 
1 = 1 ,2 ,3 ,4 
j = 1 ,2 , 3,4 
k = 1 ,2 ,  . . .  ,8 
m = 1 ,2 , (3) 
where Yjjk is the response for the kth subject in the ith sequence in the jth 
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period, p. is the overall mean, OJ is the effect of the ith sequence, 'lrj is the effect 
of the jth period, �i(i) is the effect of the kth subject within the ith sequence, 'Ymj 
is the effect of the mth covariate in the jth period and Gjk is the random error 
associated with Y ijk. The fjjk are normally distributed random variables with 
mean of 0 and common variance (J/. It is also assumed that the nested effects 
for subject are random and independently distributed with mean of 0 and 
common variance (J/, and independent of fjjk . 
Model fitting was performed using PROC MIXED in SAS. 137 Because the 
number of subjects receiving each of the four treatment sequences was not equal, the 
design was unbalanced . PROC MIXED is particularly useful for analyzing 
unbalanced designs and data sets with missing values. PROC MIXED allows 
modelling of the mean of y, as in the standard linear model , and also the variance of 
y. The estimation method used for the covariance parameters was restricted 
maximum likelihood (REML). The variance of y is modelled by choosing the form 
of the variance structure matrices. Simple (random effect) , unstructured , and time 
series (autoregressive) structures were evaluated. The autoregressive structure 
resulted in improved model fitting based on maximization of the Akaike's Information 
Criterion for most variables. The autoregressive structure indicates that the 
correlation between measurements is less if they are made further apart in time. 
Analysis using the unstructured variance structure would not converge for this data 
set. For pharmacodynamic parameters where the analysis with autoregressive 
variance structure did not converge, the simple structure was used. 
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For pharmacodynamic parameters where the effect of treatment was significant 
(p < 0.05),  multiple comparisons of the treatments were performed using the 
ESTIMATE procedure. 
Two covariates, � and the treatment that the subject thought they had received 
during each period (fRT 1Ub) , were used in the analysis of ET scores and E...u (or 
E",;,J. An additional covariate, the euphoria score, was used in the analysis of E...u -
( 1 st 4 hr) or E.nm - ( 1 st 4 hr) . 
The residuals were tested for normality using PROC UNIV ARIA TEI2O. This 
procedure computes the Shapiro-Wilk statistic, W, for the null hypothesis that the 
residuals are normally distributed. When the probability of a smaller value of W was 
less than or equal to 0. 1 ,  the null hypothesis of normality was rejected. The residuals 
were normally distributed for the pharmacodynamic variables examined. 
To assess the discriminating ability of the statistical tests performed for selected 
response measures, statistical power was estimated. 140 Because the calculations of 
power for crossover models is quite complex , the power of the F test for analysis of 
variance (fixed effect model) was determined . This estimation of power does not take 
into account the crossover design of the study and therefore is a conservative 
estimate. The Pearson-Hartley charts of the power of the F test were used to 
determine power. 140 For this study, the number of degrees of freedom in the 
numerator of F (III) is the number of treatments minus one, or 3 .  The level of 
significance (0') was selected at 0.05 .  The number of degrees of freedom in the 
denominator of F (IIJ which is the number of subjects if not a crossover study (8 
subjects x 4 periods) minus the number of treatments (4) , or 28. "2 = 30 was used to 
estimate power from the Pearson-Hartley charts. The noncentrality parameter (¢), 
which is a measure of how unequal the treatment means for the response are, was 
calculated by: 
¢ =  
where n = the sample size at each factor level 
r = the number of factor levels 
(1 = the standard deviation (square root of the estimated residual 
variance) 
I'-j = mean for treatment i 
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Values for (1 were obtained from the model fitting information in the output of PROC 
MIXED in SAS, and values for I'-j were obtained using PROC MEANS in SAS. With 
a, v . .  and V2 and estimates of ¢,  power can be obtained from the Pearson-Hartley 
chart. 
Results of the statistical analysis for prolactin, the self-rated mood scales, the 
computerized psychometric tests and quantitative EEG were used to compare the 
sensitivity of these response measures. 
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4 .3  Clinical Results 
Ten male volunteers were entered into the study. Demographic and physical 
characteristics of the subjects are shown in Table 4 . 14.  All of the subjects were 
judged to be healthy based on the results of a physical examination , a medical history, 
and clinical laboratory tests before entering the study. Eight subjects completed the 
study. Subject 5 was removed from the study after completing the second study 
period. During the first period, he received 5 mg of dextroamphetamine, and 
experienced an intense dysphoric reaction. He became tearful ,  anxious and 
withdrawn for approximately two hours after dosing. His mood improved as the 
morning progressed , and he wished to continue the study. No treatment for the 
adverse reaction was administered and he fully recovered. He returned for a placebo 
period (Study Period 2), but did not receive higher doses of dextroamphetamine. 
Subject 3 was removed from the study after completing the second study period due 
to an non study-related injury sustained at work between Study Periods 2 and 3. He 
began taking anti-infective medications prophylactically after the injury, and therefore 
did not meet the criteria to continue in the study. 
Adverse experiences were reported by four of the subjects . Subject 7 reported 
mild diarrhea and Subject 9 experienced mild pain in the chest during several study 
periods. The chest pain was not associated with EKG abnormalities and was 
diagnosed as gastroesophageal reflux by the medical monitor. These adverse 
experiences were attributed to the administration of ammonium chloride, because they 
began before the administration of dextroamphetamine. These adverse effects did not 
require discontinuation of the ammonium chloride and the subjects received no 
1 1 8 
Table 4 . 1 4  Demographic and Physical Characteristics of Participants i n  Part I I  -
Comparison of Quantitative Electroencephalography to 
Behavioral ,Psychological and Neuroendocrine Measures of Response to 
Dextroamphetamine 
Subject Initials Age (years) Weight (kg) Race 
Number 
TM 25 90. 7  Black 
2 MM 20 72.0 White 
3 JM 32 7 1 . 3  White 
4 FD 24 77. 7  Asian 
5 DK 19  67. 3  White 
6 MC 23 85.5  White 
7 BB 2 1  83.0 White 
8 PS 23 105 . 5  White 
9 AW 27 103 .0  Asian 
10 DA 28 68.0 Black 
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treatment for these symptoms. Subject 3 complained of feeling restless and "jittery" 
for approximately 3 hours after receiving the 20 mg dose of dextroamphetamine. 
Subject 5 experienced an intensely dysphoric mood after 5 mg of dextroamphetamine 
and was dropped from the study as described above. Laboratory tests, physical exam 
and electrocardiogram performed at the completion of the study revealed no clinically 
significant abnormalities compared to tests performed before entering the study. 
After each subject completed the study, they were asked which treatment they 
believed they had received during each period. The results are presented in Table 
4 . 1 5 .  
Subjects remained blinded to the treatment throughout their participation i n  the 
study.  The principal investigator was blinded during the clinical portion of the study 
and the editing of the EEGs. The principal investigator was un blinded before the 
analysis of the serum samples and further data analysis. The medical monitor for the 
study was blinded during the clinical portion of the study, but the blind was broken to 
evaluate the adverse effects experienced by Subject 5 .  
4 . 4  Pharmacokinetic Evaluation 
4 .4 . 1 Results 
The amphetamine concentration in serum versus time and the log amphetamine 
concentration in serum versus time plots after dextroamphetamine doses of 5 ,  1 0  and 
20 mg for each subject are shown in Appendix H.  Plots for two representative 
subjects are shown in Figures 4 .2 - 4 .5 .  Amphetamine serum concentration versus 
time profiles for almost all subjects and doses show multiple peaks during the first 3 -
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Figure 4 .3  Log amphetamine serum concentration versus time profile for Subject 2 
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4 hours after dosing. After this point, all subjects show a smooth monoexponential 
decline in serum concentrations. Individual profiles have between one to four peaks 
in the serum concentration . With the exception of the multiple peaks, the serum data 
is adequately described by a one compartment pharmacokinetic model with first order 
input and first order output. 
Mean pharmacokinetic parameters determined by noncompartmental analysis of 
the serum concentration data are presented in Table 4 . 16 .  The average Cmu was 15 .4  
( ±  3 . 7) , 30 . 8  ( ±  5 . 3) and 54 . 8  ( ± 16 .3) ng/mL for the 5 , 10 and 20 mg doses 
respectively. The average AUC .. was 148 .8  (± 30.9) ,  274.9 ( ±  42.4) and 574.5 (± 
1 1 5 .2) ng/mL*hr for the 5 ,  10 and 20 mg doses respectively. The values for Cmax 
and AUC .. are proportional to the dose administered. The elimination rate constants 
are similar between the doses, and correspond to an elimination half-life of 6.5 to 7.5 
hours. Tmax increased from 2. 1 (± 0 .7) hr at the lowest dose to 2 . 8  (± 0 .7) hr at the 
highest dose, although this was not statistically significant. Values for ka determined 
by compartmental analysis of serum concentration data are presented in Table 4 . 1 7. 
The absorption rate seems to decrease and T mu appears to increase as the dose 
increases. 
Plots of amphetamine concentration in serum divided by dose versus time were 
used to determine whether amphetamine can be characterized by linear 
pharmacokinetics in the dose range studied. These plots are located in Appendix I .  
They demonstrate that amphetamine appears to follow linear pharmacokinetics over 
the dose range studied. To examine the dose dependency of the calculated 
pharmacokinetic parameters, the data for each pharmacokinetic parameter were fit to 
Table 4 . 1 5  Subjects' Ranking o f  Treatment Order versus Actual Treatment 
Sequence Received 
Subject Number 
2 
3 
4 
5 
6 
7 
8 
9 
l O  
Subject's Ranking 
o - 20 - ( l O) - (5) 
0 - l O  - 5 - 20 
*** 
o - ( l O) - (5) - 20 
*** 
5 - 20 - 0 - 10 
10 - 20 - 5 - 0 
20 - ( ) - ( ) - ( ) 
1 0  - 0 - 20 - 5 
o - ( ) - ( ) - 20 
* = Did not receive treatments 
*** = Did not provide a ranking of treatments 
( )  = Unsure of ranking 
Actual Treatment 
Sequence 
5 - 0 - 20 - lO  
0 - lO  - 5 - 20 
l O  - 20 - * - * 
20 - 5 - lO  - 0 
5 - 0 - * - *  
0 - 10 - 5 - 20 
lO - 20 - 0 - 5 
20 - 5 - l O  - 0 
5 - 0 - 20 - l O  
0 - l O  - 5 - 20 
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Table 4. 1 6  Mean (± SO) Pharmacokinetic Parameters for Amphetamine Based on 
Noncompartmental Analysis of the Serum Concentration Data" 
Dose 
Parameter 5 mg 1 0  mg 20 mg 
k ( l /hr) 0. l O7 ( ±  0.022) 0 .099 (± 0.02 1 )  0.094 ( ±  0 .012) 
CIDIX (ng/mL) 15 .4 (± 3 .7) 30. 8 ( ±  5 . 3) 54 . 8  (± 1 6. 3) 
T IDIX (hr) 2 . 1 (± 0 .7) 2 . 6  ( ±  0.7) 2 . 8  ( ±  0 .7) 
CliP (L/hr/kg) 0.42 (± 0.06) 0.45 ( ±  0.06) 0.43 ( ±  0.07) 
MRT (hr) lO .6  ( ±  l .9) 1 l . 3  (± l .9) 1 l . 8  (± l . 3) 
AUC"" 148 .8  ( ±  30.9) 274.9 (± 42 .4) 574.5  (± 1 15 .2) 
(ng/mL*hr) 
a = Includes available data from all 10 subjects. 
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a crossover model using a univariate mixed effects analysis of variance. The effect of 
treatment was not statistically significant for k, Tmu, ClIF, and MRT. Cmu, AVC", 
and lea showed a significant treatment effect (p < 0.05).  For Cmu and AVC"" all 
treatments were statistically different from one another, with the highest value 
associated with the highest dose and the lowest value associated with the lowest dose. 
For lea, the lowest dose was statistically different from the two higher doses. Values 
for lea plotted against dose are shown in Figure 4.6.  Values for lea increase as the 
dose decreases, indicating that absorption is slowed at higher doses of amphetamine. 
Plots of the excretion rate of amphetamine into urine versus time and log of the 
excretion rate of amphetamine into urine versus time are shown in Appendix J. Plots 
for two representative subjects are shown in Figures 4.7 - 4 . 10 .  Elimination rate 
constants based on the urine data are presented in Table 4 . 1 8 .  The elimination rate 
constants obtained from serum data are in general smaller than those obtained from 
urine data. 
Plots of excretion rate of amphetamine into urine versus serum concentration at 
the midpoint of the urine collection interval for each dose for each subject are 
presented in Appendix K.  In  a number of  these plots i t  i s  evident that the renal 
clearance is not constant throughout the study period. The influence of urine pH and 
urine flow on renal clearance of amphetamine were evaluated by examining a three­
dimensional plot of renal clearance versus urine pH versus urine flow (Figure 4. 1 1 ) .  
As urine pH decreases, renal clearance increases. As urine flow decreases, 
instantaneous renal clearance decreases. Fluctuations in urine pH were relatively 
small (Range: 4 .6  - 6.5).  Urine flow ranged from 0.008 to 0 .6 125 Llhr. Renal 
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Table 4 . 1 7  Values for ka ( l/hr) Determined b y  Compartmental Analysis o f  Serum 
Amphetamine Concentration Data 
SYQj�t � 
2.52 
2 1 . 79 
3 b 
4 1 .92 
5 0.38 
6 2 . 80 
7 8 .77 
8 1 . 55 
9 1 . 1 9 
1 0  1 . 22 
Mean 2 .46 
SD 2.47 
a = Includes available data for all 10 subjects 
b = Subject did not receive this dose 
Dose 
� 2Q..mg 
0.40 1 . 30 
0.43 0.52 
5 . 63 0.33 
0.98 0.53 
b b 
1 . 27 0 .41  
0. 1 7  0.72 
0 .32 0.78 
0 .37 1 .23 
1 .02 1 .0 1  
1 . 1 7 0.76 
1 .  7 1  0 .35 
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Table 4 . 1 8  Elimination Rate Constants (k) for Amphetamine Determined from 
Serum and Urine Data Analysis 
Urine Serum 
Dose � � � � � � 
Sl!Qi�t 
0. 080 0. 1 1 1  0.075 0.073 0.070 0.072 
2 0. 1 29 a 0. 1 30 0.093 0. 1 0 1  0.075 
4 0.089 0.084 0.095 0. 123 0. 1 1 6 0.096 
6 0. 1 23 0. 1 1 2 0.095 0. 1 09  0. 1 14 0 . 1 00  
8 0. 157 0. 1 78 0.088 0 .099 0.087 0. 103 
9 0. 1 3 1  0 . 140 0. 155 0. 140 0. 1 3 1  0. 1 00  
1 0  0. 1 24 0. 101  0. 1 25 0.079 0.075 0 .097 
Mean 0. 1 19 0. 1 2 1  0. 1 09 0. 1 02 0.099 0.092 
SD 0.026 0.033 0.028 0.024 0 .023 0 .0 13  
a = urine samples not analyzed 
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clearance values ranged from 0 to 55 Llhr. The urine flow rate appears to have less 
effect on renal clearance than urine pH does. 
4.4 .2 Discussion 
The pharmacokinetic characteristics of amphetamine observed in this study are 
consistent with those noted by other investigators (See Section 2 .2 . 3) .  Amphetamine 
pharmacokinetics are linear over the dose range studied , with Cmax and AUC"" 
proportional to dose. Acidification of the urine by administration of enteric-coated 
ammonium chloride results in a constantly enhanced excretion of amphetamine. With 
the exception of the multiple peaks present during the absorption phase, the serum 
concentration versus time profile is adequately described by a one compartment 
pharmacokinetic model with first order input and first order output. 
Multiple peaks are present in the serum concentration versus time profile for 
almost all doses for all subjects. Similar profiles have been obtained by other 
investigators, although their significance has not been addressed. Beckett and 
coUeagues91 show plasma data from one subject under conditions of acidic and 
uncontrolled urine pH. Under acidic conditions, two peaks are present in the first 3 
hours. Under uncontrolled urine pH, three peaks are present, with the third occurring 
9 hours after dosing. Possible explanations for these multiple peaks include analytical 
variability, enterohepatic recycling, 14 1 , 142 resorption of drug from the bladder,143 
delayed gastric emptying of part of the dose, I44, 145,146 different rates of 
absorption at different sites along the GI tract, 147,148 discontinuous 
absorption, 149,150 variable dissolution of the dosage form ,151  or accumulation in a 
1 3 1  
post-absorptive storage area (such as hepatic parenchymal tissue) followed by release 
and reabsorption. 142 
Analytical variability is not the likely cause of the multiple peaks observed in 
this study, because the analytical method was validated and repeat analysis of samples 
obtained during the period of multiple peaks for two subjects gave similar results to 
the first analysis. Analytical variability may contribute to the effect however, since 
the highest variability in quality control samples was obtained from the high control 
that had been diluted prior to analysis. Most of the serum samples obtained during 
the first three hours were higher in concentration and were diluted prior to analysis. 
Enterohepatic recycling is also not likely to be responsible for the double peaks. 
Beckett and Rowland87 found no amphetamine or its conjugates present in the bile of a 
cholecystectomy patient with a bile duct fistula at 2 ,  4, 8 and 24 hr after oral 
administration of 10  mg of dextroamphetamine. Also, peaks due to biliary excretion 
and reabsorption are often seen after meal times, when the gallbladder contracts, 
which was not the case in this study. The dosage form administered is probably not 
responsible for the multiple peaks either, since they have been observed after the 
administration of an oral solution .91 It also does not appear that fluctuations can be 
explained by transfer of drug from plasma to stomach contents with subsequent 
reabsorption in the intestine because after intravenous administration, less than 1 % of 
the administered dose could be measured in gastric contents during the first 40 
minutes after dosing.91 Based on the data obtained in our study, it is not possible to 
elucidate the mechanism behind the multiple peaks observed. Any of the remaining 
hypotheses may be contributing to the phenomenon . 
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In part because of the multiple peaks observed, relatively large differences in 
serum amphetamine concentrations are observed between the samples collected at the 
start of the pharmacodynamic measurements (on the hour) and those collected at the 
end of the pharmacodynamic measurements (at 20 minutes after the hour). To before 
pharmacokinetic-pharmacodynamic modeling of the response data, especially for the 
data collected during the first four hours, the serum concentration at the time the 
response was actually measured should be estimated. Since the pharmacodynamic 
endpoints were always collected in the same order and the time of the measurement 
was recorded, it would be possible to approximate the actual concentration at the time 
the measurement was made. 
The pharmacokinetic parameters calculated in this study are similar to those 
determined by other investigators. Under conditions of acidified urine, the half-life of 
amphetamine is approximately 5 to 8 hours. In this study,  the half-life of 
amphetamine was approximately 7 hours. ClfF was similar to that reported by 
Beckett & colleagues.91 Under conditions of acidified urine, they found that ClfF was 
242 - 539 mllmin.  In this study , ClfF was approximately 500 mlfmin. 
Although not statistically significant, T max appears to increase as the dose 
increased. This phenomenon was also observed in the study by Angrist and 
associates, 88 where two groups of subjects received either a high or a low dose of 
amphetamine. T max was longer for the group who received the higher dose (3-4 
hours) than those who received the lower dose (2-3 hours). The dosage forms 
administered in the Angrist study were tablets, but a different brand was used to 
prepare each blinded dose level , so differences between the dosage forms was cited as 
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a possible explanation for the differences in Tmax. To further examine this observation 
in our study, lea was estimated for each subject at each dose assuming first order 
absorption. The blood sampling scheme used in this study was not optimized to 
characterize the absorption process, so estimates for T max and lea must be interpreted 
cautiously. Values for lea decreased as the dose increased, indicating the absorption 
was slowed at the higher doses. Statistical analysis showed that lea was significantly 
larger at the 5 mg dose, but that there was no difference between the 10 and 20 mg 
doses. 
One possible explanation for the slowing of absorption with increasing 
amphetamine dose is that amphetamine's effects on the gastrointestinal tract influence 
its own absorPtion . Amphetamine can inhibit gastrointestinal smooth muscle activity, 
thus slowing the intestinal transit time and delaying gastric emptying.85.152 A 
slowing of gastric emptying should delay the absorption of a drug like 
amphetamine. 153 Amphetamine is basic drug with a pKa of 9.9.  In the acidic 
conditions of the stomach, amphetamine is ionized and is unlikely to be absorbed. It 
must arrive at the small intestine for significant absorption to take place. 
Amphetamine's  influence on its own absorption could be viewed as a 
pharmacodynamic response measure for effects on the gastrointestinal system. 
Another potential explanation for the observed decrease in absorption rate as the 
dose increases is that the apparent amphetamine absorption rate is a saturable process. 
Simulation studies performed by Couet and colleaguesl54 indicate that T max increases 
as the dose increases for a drug that undergoes saturable absorption. AUC remains 
proportional to dose when it assumed that there is no limitation on the time that the 
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drug is in contact with the absorption site. Similar effects on Tmax and AUe were 
observed in our study,  so saturable absorption may be possible. Further research is 
needed to confirm the observations noted in this study and to elucidate the mechanism 
behind the dose-dependent absorption of amphetamine. 
The elimination rate constants calculated based on the serum and urine data 
were dissimilar for some subjects. Possible explanations for this observation are 1 )  
that estimates of average excretion rate during each collection interval do not 
adequately represent the instantaneous excretion rate at the midpoint of the collection 
interval , since the collection interval was approximately equal to the half-life of the 
drug during later intervals, 2) an insufficient number of data points was available for 
the urine data to provide a reliable estimate of k,  and 3) concentrations of 
amphetamine were near the limit of quantitation of the urine assay during later 
collection intervals, and small errors at low concentrations are magnified when 
multiplied by large urine volumes. Estimates of k from serum data are more reliable 
in this study. 
To obtain a constant renal clearance and minimize the effects of 
pharmacokinetics on the pharmacodynamic effects observed, control of urine pH and 
flow rate are essential . In this study, pH was maintained within a fairly narrow range 
(4 .5  to 6.5) and the influence on renal clearance was still apparent. Urine flow also 
affected renal clearance in this study. Other investigators also observed this effect'l3 , 
while others did nor!? Urine flow was not controlled in this study. Subjects were 
required to maintain a high level of oral fluid intake (at least 1 20 mL per hour for the 
first four hours after dosing), but subjects were allowed additional water and the 
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actual intake was quite variable between subjects. In future studies, controlled intake 
of fluids would be more appropriate. 
4.4 .3  Conclusions 
Amphetamine is characterized by l inear pharmacokinetics within the dosage 
range of 5 to 20 mg. Control of urine pH by administration of oral ammonium 
chloride results in constantly enhanced excretion of amphetamine. Multiple peaks are 
present in the serum-concentration time proftle, indicating that some process of 
cyclical or discontinuous absorption is occurring. The absorption rate of 
amphetamine appears to be dependent on the dose. As the dose increases, absorption 
is slowed . Further studies are needed to determine the mechanisms behind the 
multiple peaks observed in the serum concentration-time proftle and the dose­
dependent rate of absorption of amphetamine. 
To examine whether amphetamine is affecting its own absorption through its 
pharmacological effect on gastrointestinal transit ,  a clinical study similar to that of 
Robertson and colleagues155 could be conducted. Each subject should receive 
placebo, several dose levels of dextroamphetamine given as an oral solution, and an 
intravenous dose of dextroamphetamine in a crossover design . Along with the 
amphetamine dose or placebo, subjects would receive a capsule filled with pellets 
labelled with 99MTc sodium pertechnetate as described by Coupe and colleagues. 156 
A gamma camera could then be used to image the pellets as they move through the 
gastrointestinal tract, to enable estimation of gastric emptying and small intestinal 
transit. Frequent blood samples should be obtained during the first three hours after 
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drug administration to better characterize the absorption process . . Values for lea could 
then be estimated by fitting the serum concentration data to a one compartment 
pharmacokinetic model and using the method of Wagner and Nelson. IS? Data from 
both intravenous and oral doses would permit the use of deconvolution techniques to 
study the absorption of amphetamine. ISS Values for the absorption rate constant 
could be compared to effects on gastrointestinal transit to provide information about 
potential mechanisms for amphetamines influence on its own absorption. 
4.5 Pharmacodynamic Evaluation 
The results of the pharmacodynamic evaluation are presented below. Results, 
discussion and conclusions for the central nervous system and cardiovascular response 
measures are in section 4 .5 . 1 and 4 .5 .2  respectively .  The sensitivity and 
reproducibility of the response measures will be compared in Chapter 5 .  
4 . 5 . 1 Central Nervous System Response Measures 
The results for quantitative EEG, serum prolactin ,  the rating scales, and the 
psychometric tests are presented and discussed in the following sections. Plots for 
Subject 3 are not presented because he did not receive a placebo. His data was 
included in the statistical analysis however. 
4 .5 . 1a  Quantitative Electroencephalography 
4 .5 . 1a( 1 )  Results 
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Plots of baseline and placebo corrected total EEG power across all electrodes in 
each of the five frequency bands versus time for each subject who completed the 
study are presented in Appendix L. The EEG response values plotted at each time 
point were obtained by subtracting the baseline (0 hr) value for each treatment from 
the values at later time points for that treatment. The baseline corrected placebo 
profile was then subtracted from the baseline corrected profiles for the active 
treatments. Data for Subject 9 are not included because insufficient EEG data was 
collected during the placebo period. A review of these plots and similar plots of 
relative EEG power does not reveal EEG patterns consistent with increasing 
dextroamphetamine dose for most of the subjects. Relative standard deviation in the 
alpha and delta frequency bands also do not appear to change consistently with dose. 
Based on the work of other investigators (Section 2 .2 .4),  increases in power in the 
alpha and beta frequency bands and decreases in power in the delta and theta 
frequency bands would be expected after amphetamine dosing. 
For two of the subjects (Subjects 4 and 6) , EEG changes are apparent with 
increasing dextroamphetamine dose. The effect becomes greater as the dose 
increases. Subject 4 showed an increase in total power across all frequency bands, an 
increase in alpha power, and an increase in beta I power. These changes are shown 
in Figures 4 . 1 2  - 4 . 14 .  The EEG effects appear to be longer in duration as the dose 
increases . The increase in alpha power lasted 6 to 8 hours after the 20 mg dose, 6 
hours after the 10 mg dose, and 4 to 6 hours after the 5 mg dose. The maximum 
effect was apparent at 4 hr for all doses. Subject 6 showed an increase in total 
power, a decrease in theta power, and an increase in alpha power. These changes are 
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Figure 4. 1 2  Baseline and placebo corrected total EEG power across all frequency 
bands versus time profile for Subject 4 
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Figure 4. 1 3  Baseline and placebo corrected total EEG power i n  the alpha frequency 
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Figure 4 . 1 4  Baseline and placebo corrected total EEG power in the beta I frequency 
band versus time profile for Subject 4 
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shown i n  Figures 4 . 1 5  - 4. 1 7. The maximum effect occurred at 1 h r  for all doses. 
These changes are more prominent when power from only the occipital electrodes is 
examined . Changes in alpha power from the occipital electrodes for Subject 6 is 
presented in Figure 4 . 1 8 . Examination of plots of power from the occipital and 
central electrodes for all subjects did not reveal EEG changes other than those seen in 
plots of power from all electrodes. Changes in alpha power were more pronounced in 
the occipital region however. 
Subjects 4 and 6 are distinguished from the other subjects who completed the 
study by their baseline EEG characteristics. Average baseline total and relative power 
across all electrodes for each subject is presented in Table 4 .  19 .  Subjects 4 ,  6 and 8 
have much higher total power across all electrodes and in the alpha frequency band. 
These subjects also show greater than 35 % of the total EEG power in the alpha 
frequency band. Each of these subjects show EEG changes after dextroamphetamine 
dosing compared to the other subjects, although for Subject 8, the greatest response is 
observed after the 10 mg dose. The EEG response in total power in the alpha 
frequency band for all subjects are shown in Figures 4 . 1 9  - 4 .25 to illustrate this 
point. The EEG changes do not appear to be related to the mood response of the 
subjects. Subjects 6 and 8 experienced euphoria, while Subject 4 experienced 
dysphoria in response to dextroamphetamine. 
Statistical comparison of the values for E..w. (or E..w,) , E..w. - ( 1 st 4 hr) (or E..w. -
( 1 st 4 hr)) and ET for each of the EEG response variables for all subjects did not 
show any significant differences between the treatments that are consistent with 
increasing dextroamphetamine dose. The residuals were normally distributed for 
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Figure 4 . 1 5  Baseline and placebo corrected total EEG power across all frequency 
bands versus time profile for Subject 6 
5000 
4000 
3000 
� 
( 2000 > 
.5-
� 1000 
:r l-
I 0 
a: w 
� ·1000 ... 
-" � 
0 I-
-3000 
o 2 4 6 
TIME (HR) 
1 ___ 5 MG -+- 10 MG � 20 MG 
8 10 12 
142 
Figure 4 . 1 6  Baseline and placebo corrected total EEG power in  the theta frequency 
band versus time profile for Subject 6 
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Figure 4. 1 7  Baseline and placebo corrected total EEG power in  the alpha frequency 
band versus time profIle for Subject 6 
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Figure 4 . 1 8  Baseline and placebo corrected total EEG power in  the alpha frequency 
band from the occipital electrodes versus time profIle for Subject 6. 
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Table 4 . 19  Mean (RSD%) Total (fP) and Relative (RP) EEG Power Across All 
Electrodes at Baseline (0 hr) for Each Subject 
S TP TP TP TP TP TP RP RP RP RP RP 
u (PV� Delta Theta AJpha Beta I Beta Delta Theta AJpha Beta I Beta II 
b (Pv� (PV') (PV� (Pv� II 
j (Pv� 
1 75 1 9  7023 878 1 340 236 455 0.608 0. 1 1 8  0. 1 85 0.03 1  0.059 
(20.7) (24.5) (2 1 . 1 ) (49.8) (54.7) (59.0) ( 1 7.2) ( 1 7.9) (54.2) (34.7) (40. 1 )  
2 6547 3913 1 1 07 850 275 403 0. 599 0. 1 69 0. 1 30 0 . 042 0.061 
(8.2) (8.7) ( 1 7.6) (20.6) (23.4) ( 1 4.3) (7.3) ( 1 2.4) ( 1 7.8) ( 1 5 .5) (7. 1 )  
4 1 6980 6076 2834 6869 465 736 0. 367 0. 1 68 0.396 0.027 0 . 043 
( 1 1 . 5 )  ( 1 9 . 3) ( 1 2 . 8) (39.6) (3 1 . 8) (24.2) (29.3) ( 1 3 .9) (30.0) (25 .8) ( 1 7.7) 
6 34545 9954 4609 1 89 1 9  5 00  563 0.287 0 . 1 34 0.549 0.014 0.016 
(50.0) (60. 1 )  (53.6) (48.0) (5 1 .6) (64 .8) (21 .2) (1 4.5) (8.5) (36.4) (75.6) 
7 9 1 06  4758 1 1 36 2658 1 92 362 0 . 5 1 9  0 . 128 0.295 0.02 1  0.037 
(22.8) (28.9) ( 1 2.3) (20.9) (37.9) (72.6) ( 1 0.7) (23.2) ( 1 6.4) (29 . 1 )  (49.5) 
8 1 7484 65 1 2  2760 7 1 59 424 630 0.398 0 . 1 66  0.374 0.026 0.037 
(38.9) (38.4) (32.4) (59.0) (26.5) (38 . 1 )  (38 . 8) (27.6) (4 1 .5) ( 1 9.5) (22.7) 
9 9993 4772 1 44 1  3059 302 4 1 9  0.487 0 . 1 44 0.298 0.030 0.041 
( 1 5 . 1 )  ( 1 4. 8) ( 1 5 . 1 )  (45 .5) ( 1 3 .7) (35.6) (24.8) ( 1 .5)  (37.0) (8.4) (25 . 8 )  
10 8467 4954 1 059 1 764 204 486 0.569 0 . 129 0.2 1 8  0.025 0.060 
(24.6) (42.5) ( 1 5 .2) (25.6) ( 1 8 .0) ( 1 7 . 4) ( 1 8 . 9) (20.0) (37.6) (30.0) (28.3) 
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Figure 4 _ 1 9  Baseline and placebo corrected total EEG power i n  the alpha frequency 
band versus time profile for Subject 1 
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Figure 4_20 Baseline and placebo corrected total EEG power in the alpha frequency 
band versus time profile for Subject 2 
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Figure 4 . 2 1  Baseline and placebo corrected total EEG power i n  the alpha frequency 
band versus time profile for Subject 4 
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Figure 4 .22 Baseline and placebo corrected total EEG power in the alpha frequency 
band versus time profile for Subject 6 
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Figure 4.23 Baseline and placebo corrected total EEG power in the alpha frequency 
band versus time profile for Subject 7 
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Figure 4.24 Baseline and placebo corrected total EEG power in the alpha frequency 
band versus time profile for Subject 8 
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Figure 4 . 25 Baseline and placebo corrected total EEG power in the alpha frequency 
band versus time profUe for Subject 10 
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these variables, so transformation of the data was not necessary. Estimates of the 
power of the statistical tests were low for many of the variables. Statistical power for 
tests of E....x (or E.ruJ for total and relative power ranged from 0.20 to 0.96. Power 
was lower for relative power than total power and lower in the alpha and beta 
frequency bands than the delta and theta bands. 
Baseline response �) was a significant covariate for the vast majority of the 
EEG response variables, indicating that baseline response accounted for a significant 
portion of the variability in E....x. The baseline response differed from week to week 
for all subjects. As can be seen in Table 4 . 19 ,  the RSD% of baseline values for the 
EEG response variables for each subject ranged from 2 to 75 % .  The greatest 
variability was observed in the alpha and beta frequency bands. There was no 
apparent relationship between study period and baseline EEG characteristics. 
Excessive artifacts were present in 1 8  of the EEGs collected , resulting in 6% of 
the EEGs being designated as missing. The baseline EEG was missing for Subject 5 
(5 mg dose) , Subject 7 (5 mg dose), and Subject 9 (placebo). 
4 .5 . l a(2) Discussion 
Changes in the EEG related to dextroamphetamine dose were observed in less 
than one-half of the subjects who completed the study. Those subjects who 
demonstrated dose-related changes had similar baseline EEG characteristics. Their 
percentage of baseline EEG in the alpha frequency band was greater than 35 % .  They 
also showed higher total EEG power at baseline than the other subjects. Screening of 
subjects for a high baseline level of alpha activity may be necessary to study the 
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pharmacodynamics of CNS stimulation. Since vigilance changes are easier to detect 
in subjects with high background alpha activity74, vigilance-promoting effects of CNS 
stimulants may only be apparent on the EEG for subjects with high baseline alpha 
activity. In the eyes closed condition, decreased arousal is accompanied by decreased 
alpha activity , especially in subjects with high background alpha activity . 159 
Because alpha power may vary with normal aging, the results obtained in this study 
may not be generalizable to very young or very old subjects. 160 
Another potential explanation for the variable effect on the EEG between 
subjects may be the vigilance control method used during the EEG recording. In a 
study reported after this investigation was completed, Saletu and colleagues reported 
that EEG changes were evident after 20 mg dextroamphetamine compared to placebo 
only when EEGs were recorded under resting (not vigilance-controlled) conditions.96 
Vigilance control reduced the magnitude of EEG effects and altered the time course of 
effects observed. In our study,  vigilance was controlled to a degree by instructing 
subjects to count backward from 500 by 3s during the recording. Compliance with 
these instructions could not be verified objectively. Other techniques, such as holding 
a button that alarms if the pressure is relaxed, ensure that vigilance is maintained. In 
our study, the level of vigilance maintained could have been different between 
subjects with subsequent differences in the magnitude of the response. Also, 
vigilance may not have been equally controlled for all of the study periods for an 
individual subject. The EEG editing process may also have resulted in a potential 
preferential selection of drowsy records over awake records due to lower artifacts in 
the drowsy records .  If  this in fact occurred, the results of the study may be biased 
towards the more drowsy, giving different results than if it were a sample of only 
awake records. 
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The differences i n  EEG response between subjects do not appear to be related to 
the type of mood response to dextroamphetamine experienced by the subject. Mood 
changes observed in this study are discussed in detail in Section 4 .5 . 1c.  Whether 
subjects felt euphoria or dysphoria did not seem to influence whether EEG changes 
were observed for an individual . Categorizing subjects as EEG responders or 
nonresponders does not result in the same grouping as categorizing subjects as 
euphoric or dysphoric. 
Baseline values for EEG variables also play an important role in interpreting the 
data. Baseline values were different between weeks in the study. Differences in 
baseline values between the fIrst study period and later periods were not evident, 
indicating that the familiarization session was suffIcient to accustom subjects to the 
study environment and procedures. It is necessary to take into account the baseline 
level when comparing treatments for an individual . Baseline values were also a 
signifIcant covariate in the statistical analysis. Differences in baseline values between 
weeks may be related to differences in the testing environment, level of stress 
perceived by the subject, or quality of the subject ' s  previous night's  sleep.4 1 An 
adequate determination of the baseline is essential for examining the EEG response to 
dextroamphetamine. Error in this measurement or loss of this measurement due to 
artifacts has the potential to greatly influence the outcome of the data analysis. 
Therefore, making more than one baseline EEG measurement before dosing may be 
worthwhile. 
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Examination of smaller groups of electrodes (occipital and central electrodes) 
did not contribute added discriminating ability over that provided by examining a sum 
of all of the electrodes. Because alpha activity is most prominent over the occipital 
region, the effects on alpha power were more evident there. EEG effects were not 
apparent in the occipital or central regions that were not evident across all of the 
electrodes. 
Statistical comparisons of the treatments revealed no significant differences 
between the doses for any of the EEG variables. Since only those subjects with high 
background alpha activity show EEG response to dextroamphetamine, pooling the data 
across all of the subjects in this study masks any differences in EEG effects between 
the treatments. The study sample was heterogenous with regard to background alpha 
activity, and the sample was too small to perform statistical analysis on subgroups of 
patients. Statistical power was relatively low to detect differences between 
treatments. An increased sample size or more homogenous subject group with respect 
to alpha activity is necessary for statistical analysis of treatment differences. Other 
investigators have noted that differences between the alert EEG patterns of individuals 
are important factors when attempting to elucidate subtle effects in the EEG indicative 
of vigilance changes. They suggest that pooling data across subjects results in loss of 
information . 159 
The number of EEG recordings containing excessive artifacts was similar to that 
observed in Part I of this study in which no drug was administered (Chapter 3) . The 
pharmacological action of dextroamphetamine and the drawing of blood samples does 
not appear to significantly increase the number of artifacts obtained on the EEG 
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recordings. The average variability between baseline EEG responses on each study 
day was also similar to that observed in Part I of the study. 
In conclusion, dose-related EEG changes after dextroamphetamine 
administration were observed only in a subgroup of patients who had high baseline 
alpha activity. For these subjects, the EEG response was higher in magnitude and 
longer in duration as the dose increased. Because the subject group was heterogenous 
with respect to baseline alpha activity, statistical analysis was not useful for examining 
differences in EEG response between the treatments. The baseline EEG measurement 
must also be taken into account when comparing treatments. Future studies 
attempting to use EEG to measure eNS stimulation should include a screening 
procedure to obtain a homogenous subject group with respect to background alpha 
activity and a more dependable determination of baseline values for EEG variables 
during each period. 
4.5 . l b  Prolactin Response 
4 .5 . 1b( l )  Results 
Plots of baseline and placebo corrected serum prolactin versus time for each 
subject are presented in Appendix M. The serum prolactin values plotted at each time 
point were obtained by subtracting the baseline (0 hr) value for each treatment from 
the values at later time points for that treatment. The baseline corrected placebo 
profile was then subtracted from the baseline corrected profiles for the active 
treatments. Representative plots from Subjects I and 6 are shown in Figures 4 .26 and 
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4 .27. Based on these plots, it appears that there is an inverse relationship between 
dose and effect on prolactin . Serum prolactin decreases after the administration of 
dextroamphetamine, with the maximum decrease occurring after the 5 mg dose. The 
duration of the effect is also longer after the 5 mg dose. 
The maximum effect on serum prolactin is observed between 1 and 4 hr. It 
occurs at the same time after each dose level for an individual . The onset of effect is 
apparent at 1 hr for the lower doses in most subjects, but is delayed until 2 hr at the 
higher dose in some subjects. The effects on serum prolactin are usually evident until 
at least 5 hr. Subject 10 shows little change in serum prolactin in response to dose. 
Prolactin response does not appear to be related to whether the subject experiences 
euphoria or dysphoria, since prolactin generally decreased for all subjects regardless 
of the direction of mood alterations. 
Statistical comparison of the maximum decrease in serum prolactin CEmm) for 
each treatment confirms this observation. The mean Ealin for the baseline and placebo 
corrected serum prolactin values were 8 .8  ng/mL, 8 .2  ng/mL, and 4.3  ng/mL for the 
5 ,  1 0  and 20 mg doses respectively.  The mixed effects analysis of covariance showed 
a statistically significant effect for treatment (p < 0.05) , with all treatments different 
from placebo. The power for this statistical test was estimated to be 0 .85 .  The 
statistical tests could not distinguish between the treatments however. 
Baseline serum prolactin values were not statistically significant covariates in the 
mixed effects analysis of covariance. There was, however, notable variation between 
the baseline values obtained during each period for many of the subjects. Baseline 
serum prolactin values for each subject are presented in Table 4 .20. There does not 
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Figure 4 _26 . Baseline and placebo corrected serum prolactin concentration versus time 
plot for Subject 1 
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Figure 4 _27 Baseline and placebo corrected serum prolactin concentration versus time 
plot for Subject 6 
appear to be a correlation between the serum prolactin level and the study period. 
The pattern of prolactin secretion obtained during the placebo period for the 
subjects who completed the study is presented in Figure 4.28.  For most subjects, 
prolactin levels remain within the normal range of approximately 5 to 1 0  ng/mL. 
Subject 2 shows unusually high levels of prolactin for a young healthy male. 
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When the baseline and placebo corrected serum prolactin concentrations for 
each subject at each dose level are plotted against the serum amphetamine 
concentrations obtained at the same time, hysteresis is observed in approximately 70% 
of the plots. One-half of these hysteresis loops are in the clockwise direction and 
one-half are in the counterclockwise direction . The direction is consistent within a 
subject. Representative plots are presented in Figure 4 .29 (clockwise hysteresis) , 
Figure 4 . 30 (counterclockwise hysteresis) , and Figure 4 .3 1  (no hysteresis) . The 
direction of the loop does not appear to be related to baseline prolactin levels ,  mood 
response, or absorption rate constant of dextroamphetamine observed for each subject. 
4 . 5 . 1b(2) Discussion 
Serum prolactin levels, like the EEG parameters, are a surrogate measure of the 
effect of dextroamphetamine on the central nervous system . Drugs that increase 
dopaminergic neurotransmission in the CNS reduce prolactin secretion and drugs 
which increase serotonergic neurotransmission in the CNS increase prolactin 
secretion. Dextroamphetamine is believed to affect dopamine release at lower doses 
and serotonin release at higher doses , and thus may cause opposing effects on 
prolactin secretion , ss Amphetamines may also exert direct agonist action at central 
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Figure 4.28 Serum prolactin concentration versus time plots for the placebo period 
for each subject 
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Figure 4 _29 Baseline and placebo corrected serum prolactin concentration versus 
serum amphetamine concentration for Subject 6 (5 mg dose) 
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Figure 4 _30 Baseline and placebo corrected serum prolactin concentration versus 
serum amphetamine concentration for Subject 2 (5 mg dose) 
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Figure 4 _ 3 1  Baseline and placebo corrected serum prolactin concentration versus 
serum amphetamine concentration for Subject 10  ( 10  mg dose) 
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Table 4 .20 Serum Prolactin Levels at Baseline (0 hr) for Each Subject 
Subject Period Period Period Period Mean RSD (%) 
1 2 3 4 (ng/mL) 
10 .2  5 .0 5 .9  8 .5  7 .4  32.2 
2 7 .6  9 .5 5 .4  12 .9  8 .9  35.9 
3 3 .0  2 .0  2 . 5  28 .3 
4 7 .8  1 1 .0 6.9 5 .7  7.9 28.9 
5 8 .2  2 .0  5 . 1 86.0  
6 4 .0 4 .3  10 .6  4 .0  5 .7  56 .8  
7 9 .0 5 . 7  3 . 0  7.4 6 .3  40.7 
8 4 .0  4 .0  3 .0  1 3 .0 6.0 78.0 
9 4 .9  5 . 1  3 . 5  1 5 . 0  7 . 1 74.4  
10  14 .0  8 . 3  8.0 1 1 .0 10 .3  27.2 
serotonin receptors. In this study, prolactin secretion diminished after 
dextroamphetamine administration, with the greatest decrease occurring after the 
lowest dose. One potential explanation for this observation is that at the 5 mg dose, 
dextroamphetamine primarily acts to release dopamine from storage sites in the nerve 
terminal . As the dose increases, serotonin is also released , which opposes the effect 
of dopamine on prolactin secretion . 
Previous studies have reported that dextroamphetamine causes both increases 
and decreases in the secretion of prolactin (see Section 2 .2 .5) The effect on secretion 
appears to depend on the dose administered . Most studies show no change or an 
increase in prolactin levels after oral dextroamphetamine doses of 20 - 30 mg. Few 
studies have reported the effects of lower doses on prolactin secretion. Wells and 
colleagues observed decreased prolactin levels after 10  and 20 mg oral doses of 
16 1  
dextroamphetamine, with the greatest decrease observed for the 20  mg dose.104 Our 
data suggests that a portion of the variability in prolactin response between studies 
may be due to the doses administered. Our findings have implications for research 
involving prolactin response to the administration of amphetamines in the study of 
psychiatric illnesses. Prolactin response in normal controls in these pharmacological 
challenge studies may depend on the dose administered. Further work is needed to 
determine whether psychiatric illness alters this dose effect relationship. 
Spontaneous fluctuations in prolactin secretion were observed during the placebo 
period for all subjects. Prolactin secretion shows a circadian rhythm.  Superimposed 
upon this are minute-to-minute fluctuations due to factors such as stress and exercise. 
To reduce differences in these fluctuations between periods, the subjects were 
required to remain reclining in bed beginning one hour before dosing until after the 6 
hr prolactin levels were drawn. The fluctuating nature of prolactin secretion in the 
absence of drug treatment emphasizes the necessity of including a placebo period to 
aid in the interpretation of potential drug effects. Pharmacodynamic models have 
been developed which include the fluctuation of the hormone secretion . 161 These 
models have improved predictive capability compared to those which consider the 
placebo response to be constant. 
Baseline serum prolactin levels during each period also showed differences from 
period to period for all of the subjects. These differences could be due to different 
levels of stress or other factors which can increase prolactin secretion. Higher 
baseline levels were not apparent during the first period, when higher levels of stress 
might be anticipated due to the subjects not being well-acquainted with the study 
environment. As with the EEG, it may useful in future studies to make more than 
one baseline determination of prolactin levels. 
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Hysteresis loops are observed in plots of serum prolactin concentration versus 
serum amphetamine concentration for 2/3 of the subjects. Because the direction of 
the hysteresis differs between subjects, it is difficult to postulate potential mechanisms 
contributing to the phenomenon. In fact, because it occurs equally in both directions, 
there may be no true hysteresis present. The fluctuating nature of the serum 
amphetamine concentrations noted during the first four hours after drug administration 
may also contribute to the discrepancy observed in the direction of the hysteresis. 
As with the EEG measures discussed in the previous section, serum prolactin 
response does not appear to be directly related to the clinical or therapeutic effects of 
dextroamphetamine. Alterations in EEG measures and serum prolactin levels were 
not associated with the direction or magnitude of the mood change experienced by the 
subjects. The effects of dextroamphetamine on mood in these subjects will be 
discussed in detail in the next section. 
4 . 5 . 1c  Mood Rating Scales 
4 .5 . 1c( 1 )  Results 
Plots of baseline and placebo corrected rating scale scores (self-rated mood scale 
and visual analog mood scale) versus time for each subject are presented in Appendix 
N. The rating scale scores plotted at each time point were obtained by subtracting the 
baseline (0 hr) value for each treatment from the values at later time points for that 
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treatment. The baseline corrected placebo profile was then subtracted from the 
baseline corrected profiles for the active treatments. Plots of the self-rated mood 
scale and the visual analog mood scale responses versus time for a subject who 
experienced euphoria after dextroamphetamine administration (Subject 2) are shown in 
Figures 4 . 32 and 4 . 33 .  Similar plots for a subject who experienced dysphoria after 
dextroamphetamine administration (Subject 4) are shown in Figures 4 . 34 and 4 . 35 .  
Dysphoria (based on the self-rated mood scale scores) was reported after 20% 
of the dextroamphetamine doses given. Subject 4 experienced dysphoria after all 3 
doses and Subject 8 became dysphoric only after the 20 mg dose. Subject 5 became 
intensely dysphoric after the 5 mg dose, and was consequently discharged from the 
study. At the 5 mg dose level , no change in mood occurred for 4 of the 9 subjects 
evaluated. At the 20 mg dose, only 1 subject did not experience a change in mood. 
When subjects experienced a change in mood (based on the self-rated mood 
scale scores) , it was generally apparent by the 1 hr measurement. The change in 
mood was typically greatest for the 20 mg dose, although Subjects 4 and 7 showed 
similar effects at all 3 dose levels .  The maximum effect occurred between 1 and 3 
hours for most subjects. The duration of the mood changes generally ranged from 3 
to 8 hr, with a longer duration noted after the highest dose. The subject who 
experienced the most intense euphoria following the 20 mg dose (Subject 2) still had 
elevated mood scale ratings when measurements were discontinued at 1 2  h .  
Statistical analysis of the Emu and ET values for the self-rated mood scale 
showed no significant differences between treatments. When differences between the 
treatments that the subjects believed they had received during each period were 
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Figure 4 .32 Baseline and placebo corrected self-rated mood scale score versus time 
plot for Subject 2 
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Figure 4 . 33 Baseline and placebo corrected visual analog mood scale score versus 
time plot for Subject 2 
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Figure 4 _34 Baseline and placebo corrected self-rated mood scale score versus time 
plot for Subject 4 
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Figure 4 .35 Baseline and placebo corrected visual analog mood scale score versus 
time plot for Subject 4 
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compared, statistically significant differences were found (p < 0.05). During the 
period when subjects believed that they had received the 20 mg dose, E....x was 
significantly greater than that obtained in the other periods. The other " treatments" 
were not statistically different. Statistical analysis of the E....x values for the visual 
analog mood scales showed no significant differences between actual treatments or the 
treatments the subjects believed they had received. Estimated power for these tests 
was less than 0 .3  however. In addition, no significant effect of sequence was noted 
for the mood ratings. 
The visual analog mood scale scores show less consistent change with dose than 
the self-rated mood scale. After 60% of the administered doses, scores were less than 
baseline at I hr. Subject 2,  who showed the highest euphoria based on the self-rated 
mood scale also has the highest response on the visual analog mood scale. Scores for 
Subjects I and 4 showed little change with dose. 
Baseline mood scale scores for both scales were not statistically significant 
covariates in the mixed effects analysis of covariance. Average baseline mood scale 
scores for each subject are presented in Table 4 .2 1 .  There does not appear to be a 
correlation between the baseline mood scale scores and the study period. 
4 .5 . l c(2) Discussion 
A bimodal distribution of mood response was observed in this study. Most 
subject-dose combinations resulted in euphoria, but some (20%)  resulted in dysphoria. 
The rate of dysphoria observed in this study is similar to that reported by other 
investigators. Almost 40 years ago, von Flesinger and associates l62 reported that 
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Table 4.2 1 Average Mood Rating Scale Scores at Baseline (0 hr) for Each Subject 
Subject Self-Rated Mood Scale Visual Analog Mood Scale 
Number Mean RSD %  Mean RSD %  
1 52.0 6. 8 48.3 8 .5 
2 59.3 8 .4 45 . 5  20.0 
4 66.5  3 .4  53 . 3  7 . 3  
5 60.0 25.9 52.0 2 1 . 8  
6 60.0 4.9 48.5 4.3 
7 70.0 1 . 7 59.0 23.0 
8 79 .0 1 . 7 56.5 17 .7 
9 69. 3  0 .7  50. 8 4 .4  
10  57. 8  2 . 2  4 1 . 3  20.4 
20% of normal subjects were dysphoric after receiving amphetamine. Their subjects 
also underwent psychological testing that showed more immature Rorschach scores 
for the dysphoric subjects compared to the euphoric subjects. Angrist and 
colleagues88 reported that 2 out of seven subjects showed decreased self-ratings of 
"happy" after 0.25 mg/kg of dextroamphetamine given orally. They also found that 
under fasting conditions, 4 subjects had increases in self-rating for "happy" ,  while 
with food , 6 subjects had increases in self-rating for "happy" .  Dommisse and 
associateslO2 also found a similar rate of dysphoria following 30 mg of oral 
dextroamphetamine. Psychological or personality differences between subjects may 
contribute to the heterogeneity in mood response observed in our study, but this 
cannot be examined because psychological testing was not performed . It may also be 
related to the study conditions, such as conducting testing while subjects are fasting 
and drawing blood samples. Subject 5 ,  who experienced intense dysphoria after the 5 
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mg dose, was the youngest participant in the study, had no experience with the 
hospital environment, and had never been a research subject before. Dose seems to 
play a role as well . Subject 8 became dysphoric only after the highest dose. These 
observations suggest that the mood response to dextroamphetamine results from a 
complex interaction between individual sensitivity , the study environment, and the 
dose administered. 
Because of the heterogeneity in the mood response to dextroamphetamine, 
statistical analysis did not show significant differences between the treatments. The 
study sample was too small to perform subgroup analysis. The maximum self-rated 
mood scale scores were statistically significantly higher during the period when 
subjects believed that they had received the 20 mg dose. The subjects expected to 
feel euphoric or at least better after receiving dextroamphetamine, perhaps because of 
previous knowledge about the drug or information provided in the informed consent. 
Consequently, they ranked the period during which they felt the best as the highest 
dose level . Subject 2, who experienced euphoria, ranked his treatments correctly. 
Subject 4 on the other hand, experienced dysphoria and ranked his doses in the 
inverse order. 
The visual analog mood scale showed less consistent responses with dose than 
the self-rated mood scale. The visual analog mood scale asked subjects to rank on a 
100 mm line how they felt between "the worst they had ever felt" and "the best they 
had ever felt" . This is a very broad range, and may have been less sensitive than the 
self-rated mood scale for examining euphoria. In addition, the subject's score on the 
visual analog scale may have been influenced by feelings other than those measured 
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by the self-rated mood scale. The self-rated mood scale is designed to measure 
euphoria, and very similar scales have been shown to discriminate between dose 
levels of amphetarnine in normal volunteers. The self-rated mood scale may be a 
more specific indicator of euphoria/dysphoria than the visual analog mood scale. 
There was no significant effect of sequence in the statistical analysis of the results 
from both mood scales. It might be expected that the subject's frame of reference for 
rating mood would change based on the experience of prior study periods, obscuring 
the interpretation of the mood scale results. In our study,  the ratings on the scales do 
not appear to be greatly influenced by the order in which the treatments were 
received. 
Baseline responses were less variable for the mood rating scales than for the 
EEG parameters and prolactin levels. They also were not significant covariates in the 
analysis of covariance. The variability was slightly higher for the visual analog scale 
than the self-rated mood scale. One measurement before dosing appears to be 
sufficient to characterize the baseline response during each period. No difference in 
baseline responses between the first period and subsequent periods was evident, 
indicating that the familiarization session was adequate for most subjects to feel 
familiar with the testing environment. Subject 5 is an exception to this generalization. 
His baseline mood response was quite different in Period 1 ,  when he received the 5 
mg dose, than in Period 2 ,  when he received the placebo treatment (a score of 49 
versus 7 1  for the self-rated scale, and 44 versus 60 for the visual analog scale) . 
Although he experienced intense dysphoria during Period 1 and was not aware that he 
was receiving a placebo in Period 2 ,  his baseline mood scores were much higher 
1 70 
during the second period. His anxiety about participating in the study may have 
influenced his mood response to dextroamphetamine. The familiarization session , 
which did not include blood sampling and drug administration , was not sufficient to 
acclimate the subject to the study environment. He was much more at ease prior to 
dosing during Period 2 than during Period 1 .  Administering two blinded placebo 
treatment periods, one prior receiving the drug under study and the second 
randomized in with the active treatments, would be useful to minimize this effect. 
4 .5 . 1d Computerized Psychometric Tests 
4 . 5 . 1d( l )  Results 
Plots of baseline and placebo corrected psychometric test scores (CPT average 
latency, CPT percent correct, and finger tapping rate for the right and left hand) 
versus time for each subject are presented in Appendix O. The psychometric test 
scores plotted at each time point were obtained by subtracting the baseline (0 hr) 
value for each treatment from the values at later time points for that treatment. The 
baseline corrected placebo profile was then subtracted from the baseline corrected 
profiles for the active treatments. Representative plots for these response measures 
from Subject 1 are presented in Figures 4 .36 - 4 .39 .  
A review of these plots for each subject reveals no obvious changes consistent 
with dextroamphetamine dose for either the CPT measures or the finger tapping task. 
Changes observed after dosing were small and fluctuated around the baseline for most 
subjects. The baseline and placebo-corrected, percent-correct on the CPT did not 
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Figure 4 .37 Baseline and placebo corrected percent correct on the continuous 
performance task for Subject 1 
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Figure 4.38 Baseline and placebo corrected finger tapping rate with the right hand for 
Subject 1 
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Figure 4 .39 Baseline and placebo corrected finger tapping rate with the left hand for 
Subject 1 
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increase or decrease by greater than 10% after any of the treatments for any of the 
subjects. The baseline and placebo corrected average rate of finger tapping did not 
increase or decrease by more than 3 taps per second for the right hand or 2 taps per 
second for the left hand for any of the subjects. Statistical analysis of the G...x or 
<Emm) and ET values for each response measure showed no significant differences 
between treatments at the alpha level of 0.05 .  Estimated power for these statistical 
tests was 0.45,  0.50, 0.45, and 0 .88 for the CPT average latency, the CPT percent 
correct, the finger tapping right hand, and the finger tapping left hand respectively. 
The baseline values were significant covariates in the analysis of covariance for 
the CPT average latency and the finger tapping (left hand). Average baseline values 
for the psychometric tests for each subject are presented in Table 4 .22 .  The 
variability in baseline values between periods was low compared to the other response 
measures. The CPT average latency was more variable at baseline than the percent 
correct. Finger tapping with the left hand was more variable than finger tapping with 
the right hand . Baseline values measured during Period I were not noticeably 
different from those measured during subsequent periods. 
4 . 5 . 1d(2) Discussion 
Based on visual inspection of the baseline and placebo corrected psychometric 
test response versus time plots and the statistical analysis of the G...x (or E.ruJ values 
for each treatment for each subject, it appears that performance on the psychometric 
tests was not influenced by the drug treatment administered. This is consistent with 
the results reported by other investigators (see Section 2 . 2.7) .  While some studies 
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Table 4 .22 Average Psychometric Test Scores at Baseline (0 hr) for Each Subject 
Subject Continuous Performance Task Finger Tapping Task 
A verage Latency Percent Right Hand Left Hand 
(sec) Correct (%)  (taps/sec) (taps/sec) 
Mean RSD% Mean RSD Mean RSD % Mean RSD % 
% 
0.407 1 9 . 8  99 .0  1 . 1  5 .03 1 . 9 4 . 38 3 .7  
2 0 .35 1 1  5 . 3  99 .4 0.4 5 . 7 1  3 .9  4 .94 2 .7  
4 0. 3704 6.5  99 .3  0 .6  6 .59 1 . 2  5 .32 2 . 8  
5 0. 3603 0.4 99.2  1 . 2 5 . 00  5 . 7  4 .40 8 .7  
6 0 . 3060 4. 1 98.3 1 .9 5 .08 1 . 5 4 .5  1 .6 
7 0.2372 7 .4  94. 2  4 . 3  6.61 10 .6 4 .62 5 .4 
8 0 .33 15  6 .5 99 .0 0 .8  4 .9 1  18 .6  4 .23 3 .9  
9 0. 3922 1 1 . 3  97. 5  3 . 1 4 .95 3 . 1 4.43 2 .2  
10  0 .3812  5 . 1 99. 6  0.5 4 .66 1 5 . 2  5 . 22 10 .3  
report changes in performance on some tests after subjects receive amphetamine, 
many others report no differences after drug administration . The computerized tests 
employed in our testing environment were not able to detect differences between the 
treatments. The power for the statistical tests for these response measures were 
relatively low. With a larger sample size, the small differences observed between 
treatments may have been statistically significant. 
Performance on the tasks did not appear to consistently increase or decrease 
during the dosing intervals. The responses measured as baseline at each period also 
showed no patterns of increasing or decreasing as the study progressed. This 
indicates that the practice tests during the familiarization session and prior to baseline 
measurements during each period were probably sufficient to minimize learning 
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effects on the test results. 
Variability between the baseline measurements for the psychometric tests at each 
period for each subject were less than those observed for the EEG measures, prolactin 
levels,  and mood scale scores. The average latency was more variable than the 
percent correct on the CPT. The task was not difficult, and subjects performed it 
with less than 10% errors after the first few practices leaving little room for 
improvement. The speed of response as measured by the average latency however is 
likely to be more variable. Baseline scores for finger tapping with the left hand was 
more variable than baseline scores for finger tapping with the right hand. All of the 
subjects in this study were right handed . This may explain why the baseline for the 
left hand is more variable than the baseline for the right. 
These psychometric tests did not prove to be useful for distinguishing the effects 
of dextroamphetamine on performance. Dextroamphetamine, at the doses studied , 
may in fact have no effect on elements of performance these tests are intended to 
measure. Alternatively ,  the observations may be affected by characteristics of the 
particular tests administered , the environment in which the tests were given , or 
characteristics of this subject sample. 
4 .5 . 1e  Conclusions 
A number of response measures were used in this study to assess CNS 
stimulation . Dose-related EEG changes were observed in only 3 of the subjects. The 
characteristic that distinguished these subjects from the nonresponders was the level of 
background alpha activity . Statistical analysis was not useful for comparing 
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treatments, because there were too few subjects to perform subgroup analysis based 
on background alpha activity. Future studies of CNS stimulation should exclude 
volunteers that show less than 35 % alpha activity on screening EEG recordings. 
Prolactin levels showed dose related changes in the majority of the subjects. In 
general , prolactin levels decreased after dextroamphetamine administration , with the 
greatest effect occurring at the lowest dose level . Statistical analysis showed 
significant differences between placebo and the treatments. The treatments could not 
be distinguished from each other however. Baseline serum prolactin levels were 
variable from period to period. Future studies should include more than one 
measurement of serum prolactin prior to drug administration. 
Mood scales also showed a heterogenous response, with some subjects showing 
euphoria and some showing dysphoria. Dysphoria occurred 20% of the time, which 
is similar to the rate reported by other investigators. The self-rated mood scale was 
more useful than the visual analog mood scale for distinguishing between dose levels. 
The effect on mood may be dependent on dose, since one subject experienced 
dysphoria only at the highest dose. Another subject experienced intense dysphoria, 
which may have been related to his anxiety about participating in a study for the first 
time. Future studies should include two blinded placebo periods, one as the first 
study period and the second randomized with the active treatments. 
The average latency and percent correct on the CPT and the rate of finger 
tapping with the right and left hand were not useful for distinguishing between the 
dextroamphetamine dose levels. This result may indicate that amphetamine does not 
affect attention and motor performance. Alternatively ,  it may indicate that these 
particular tasks administered in our study environment to our study population were 
not sensitive enough to measure the performance changes that occurred . 
The sensitivity, reproducibility, and suitability of each of these tests for 
pharmacodynamic studies of CNS stimulation will be compared and discussed in 
Chapter 5 .  
4 .5 .2  Cardiovascular Response Measures 
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The results for blood pressure and heart rate are presented and discussed in the 
following sections. These responses were measured both for subject safety and as an 
assessment of stimulant effects outside of the central nervous system . Subject 3 are 
not presented because he did not receive a placebo. His data was included in the 
statistical analysis however. 
4 . 5 . 2a Blood Pressure 
4 .5 .2a( l )  Results 
Plots of baseline and placebo corrected systolic and diastolic blood pressure 
versus time for each subject are presented in Appendix P. The blood pressure values 
plotted at each time point were obtained by subtracting the baseline (0 hr) value for 
each treatment from the values at later time points for that treatment. The baseline 
corrected placebo profile was then subtracted from the baseline corrected profiles for 
the active treatments. Representative plots for these response measures from Subject 
2 are presented in Figures 4 .40 - 4 .4 1 . 
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Figure 4 .40 Baseline and placebo corrected diastolic blood pressure versus time for 
Subject 2 
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Figure 4 .4 1  Baseline and placebo corrected systolic blood pressure versus time for 
Subject 2 
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A review of these plots for each individual indicates that in general , both 
systolic and diastolic blood pressure rises after the administration of 
dextroamphetamine. The average increase in the baseline and placebo corrected 
diastolic blood pressure was 1 2.2 ,  1 3 .6,  and 1 6.5 mmHg after the 5 ,  10 ,  and 20 mg 
doses respectively. The average increase in the baseline and placebo corrected 
systolic blood pressure was 15 . 3  mmHg after the 5 mg dose, 19 . 1 mmHg after the 10  
mg  dose, and 29 .5  mmHg after the 20 mg dose. The magnitude and duration of the 
effect varies among individuals. 
Statistical analysis of the I;..... values for diastolic blood pressure showed a 
significant treatment effect (p < 0.05) .  Power for this statistical analysis was high 
compared to the analysis of the eNS measures; power was 0 .97 for diastolic blood 
pressure. Statistical comparison of the treatments showed the 10 and 20 mg doses 
were significantly different than placebo and the 5 mg dose was significantly different 
from the 20 mg dose. The 5 mg dose was not different from the 10 mg dose, and the 
10  mg dose was not different from the 20 mg dose. Statistical analysis of the ET 
(defined in Section 4 .2 .4c) values for diastolic blood pressure revealed no significant 
difference between treatments. 
Statistical analysis of the I;..... values for systolic blood pressure revealed no 
significant differences between the treatments. The estimated power for this 
comparison was low (0.6) however. The variability between subjects in systolic 
blood pressure was greater than for diastolic blood pressure. Baseline systolic blood 
pressure was also a significant covariate in the analysis of covariance. As with 
diastolic blood pressure, statistical analysis of the ET values for systolic blood 
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pressure revealed no significant differences between treatments. 
A verage baseline values for diastolic and systolic blood pressure for each 
subject are presented in Table 4.23. The RSD% for baseline blood pressure was less 
than 20% for all subjects, but for most of the subjects, it was less than 1 0 % .  The 
baseline diastolic blood pressure was a significant covariate in the analysis of 
covariance. In general , subjects with higher baseline blood pressure showed a lower 
blood pressure increase. 
No consistent pattern of hysteresis is present in plots of baseline and placebo 
corrected blood pressure versus serum amphetamine concentration measured at the 
same time. Representative plots from Subject 4 are presented in Figures 4.42 - 4.44.  
4 .5 . 2a(2) Discussion 
The increase in blood pressure observed in this study is similar to the reported 
by other investigators (see Section 2 .2 .8) .  There was a statistically significant 
difference in maximum diastolic blood pressure between the treatments, with the 
largest increase observed for the highest dose level . The rise in systolic blood 
pressure was more variable between subjects, resulting in lower power for the 
statistical comparison of treatments. A larger sample size would be necessary to 
distinguish the treatments based on maximum systolic blood pressure. 
The highest diastolic blood pressures observed during the study were 102 ,  94, 
and 90 mmHg following the 20 mg dose for Subjects 2, 9, and 4 respectively. These 
blood pressures were observed 2 to 3 hours after dosing. Blood pressure remained 
above 90 mmHg for no longer than 1 to 2 hours. Blood pressure increases were not 
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Figure 4 .42 Baseline and placebo corrected blood pressure versus serum 
amphetamine concentration for Subject 4 (5 mg dose) 
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Figure 4 .43 Baseline and placebo corrected blood pressure versus serum 
amphetamine concentration for Subject 4 ( 1 0  mg dose) 
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Figure 4 .44 Baseline and placebo corrected blood pressure versus serum 
amphetamine concentration for Subject 4 (20 mg dose) 
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of sufficient magnitude or duration to require medical intervention for any of the 
subjects. 
Table 4 .23 Average Blood Pressure at Baseline (0 hr) for Each Subject 
Subject Diastolic Blood Pressure Systolic Blood Pressure 
(mmHg) (mmHg) 
Mean RSD % Mean RSD % 
70.5  4 .7  1 25 . 3  8 . 7  
2 70.0 1 1 .7  1 1 6.0 12 .9  
4 7 1 . 3  5 .4  127.0 6.4 
5 74 .0  13 .4  122.5 1 5 . 6  
6 69.0 9 .8 1 3 1 .0 8 .9  
7 66.5 2 .6 128 .8 4 . 1 
8 60. 3  5 . 7  1 25 . 8  6.3 
9 80.3  1 1 .4  1 36 .8  1 1 .0 
10 69.3  7 .2  1 12 .3  5 .5  
Baseline blood pressure was a significant covariate in the analysis of covariance, 
indicating that the baseline blood pressure accounts for a significant amount of the 
variability in response that was observed. In general , subjects with lower baseline 
blood pressures showed a higher increase in blood pressure. The variability in 
baseline values between periods was relatively low, and did not seem to be associated 
with the period in which it was measured. Baseline blood pressure during Period 1 
was not consistently higher or lower than during other periods. One exception to this 
generalization may be Subject 5, who was withdrawn from the study due to an intense 
dysphoric reaction. His baseline diastolic blood pressure was higher during Period 1 
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(8 1 mmHg) when he experienced dysphoria after the 5 mg dose than during Period 2 
(67 mmHg) when he received the placebo. At baseline during Period 1 ,  his blood 
pressure was elevated and his mood scale scores were lower. His baseline 
psychological and physical state may have contributed to his dysphoric episode. 
Because baseline blood pressure levels contribute to the blood pressure response 
observed, adequate characterization of the baseline levels is essential. In this study, 
all measurements were made after subjects had been supine for at least 5 minutes. 
Taking more than one baseline measurement may improve the determination of the 
baseline response. 
4 .5 .2b Heart Rate 
4 .5 .2b( l )  Results 
Plots of baseline and placebo corrected heart rate versus time for each subject 
are presented in Appendix Q. The heart rate values plotted at each time point were 
obtained by subtracting the baseline (0 hr) value for each treatment from the values at 
later time points for that treatment. The baseline corrected placebo profile was then 
subtracted from the baseline corrected profiles for the active treatments. A 
representative plot for this response measure from Subject 2 is presented in Figure 
4.45. 
A review of these plots for each individual indicates that, in general , heart rate 
increases after the administration of dextroamphetamine. The average increase in the 
baseline and placebo corrected heart rate was 10 .3 ,  16 .4 ,  and 23. 1  bpm after the 5 ,  
1 0, and 20  mg doses respectively. The magnitude and duration of the effect varies 
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Figure 4 .45 Baseline and placebo corrected heart rate versus time for Subject 2 
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among individuals, but appeared to increase as the dose level increased. 
Statistical analysis of the Emu values for heart rate showed a significant 
treatment effect (p < 0.05) . Power for this statistical analysis was similar to that 
observed for diastolic blood pressure; power was 0.90 for heart rate. Statistical 
comparison of the treatments showed the 10  and 20 mg doses were significantly 
different than placebo and the 5 mg dose was significantly different from the 20 mg 
dose. The 5 mg dose was not different from the 1 0  mg dose, and the 10 mg dose 
was not different from the 20 mg dose. The baseline heart rate was a significant 
covariate in the analysis of covariance. 
Statistical analysis of the ET values for heart rate also revealed significant 
differences between treatments. The average ET for each treatment was 3 .8 ,  3 .9 ,  
5 . 8 , and 9 . 1 for the placebo, 5 mg,  10  mg,  and 20 mg dose levels respectively. 
Comparison of the treatments showed that response after the 20 mg dose was 
significantly different than the 5 mg dose and placebo. Other treatments were not 
statistically different from each other. Power for this statistical analysis was 0.96. 
Average baseline values for heart rate for each subject are presented in Table 
4 .24 .  The RSD % for baseline blood pressure was less than 12 % for all subjects. 
A verage baseline heart rate ranged from 46 to 64 bpm.  Plots of baseline and placebo 
corrected heart rate versus serum amphetamine concentration measured at the same 
time demonstrated no consistent pattern of hysteresis. Representative plots from 
Subject 9 are presented in Figures 4 .46 - 4.48. 
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Figure 4 .46 Baseline and placebo corrected heart rate versus serum amphetamine 
concentration for Subject 9 (5 mg dose) 
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Figure 4 .47 Baseline and placebo corrected heart rate versus serum amphetamine 
concentration for Subject 9 ( 1 0  mg dose) 
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Figure 4.48 Baseline and placebo corrected heart rate versus serum amphetamine 
concentration for Subject 9 (20 mg dose) 
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Table 4 .24 Average Heart Rate at Baseline (0 hr) for Each Subject 
Subject Heart Rate (bpm) 
Mean RSD% 
1 55 . 5  4 . 3  
2 54.5  10.0 
4 58 .8  10. 1 
5 53.0 10.7 
6 46.5 4 . 1 
7 62 . 5  1 1 .4 
8 46. 3  9 .9 
9 64.0 4.2 
10  45 . 8  5 . 8  
4 .5 .2b(2) Discussion 
In this study, an increase in heart rate was observed for most subjects. Other 
investigators have reported both increases and decreases in heart rate after 
dextroamphetamine administration (see Section 2 .2 . 8) .  There was a statistically 
significant difference in maximum heart rate between the treatments, with the largest 
increase observed for the highest dose level . None of the subjects experienced an 
elevation of heart rate that would be considered tachycardia ( > 100 bpm) . 
The ET was also greater as the dose increased. ET is an indicator of the length 
of time that the response measure could distinguish a drug effect, weighted toward the 
later times (and lower concentrations). Heart rate is the only response measure for 
which there was a statistically significant treatment effect for ET. 
Baseline heart rate was a significant covariate in the analysis of covariance, 
indicating that the baseline heart rate accounts for a significant amount of the 
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variability in response that was observed. The variability in baseline values between 
periods for each subject was relatively low, and did not seem to be associated with 
the period in which it was measured . Baseline heart rate during Period 1 was not 
consistently higher or lower than during other periods. Baseline heart rate did not 
appear to be correlated with the magnitude of change in heart rate after 
dextroamphetamine dosing. As with blood pressure, adequate determination of the 
baseline heart rate is essential. 
4 .5 .2c Conclusions 
Blood pressure and heart rate increased after the administration of 
dextroamphetamine for most subjects at most dose levels. The increases were not of 
sufficient magnitude or duration to pose significant risk to the subjects. Only one 
subject briefly experienced a diastolic blood pressure greater than 100 mmHg. 
The maximum blood pressure and heart rate observed was greater as the dose 
increased . The was a statistically significant treatment effect for diastolic blood 
pressure and heart rate. The 10 and 20 mg doses were significantly different than 
placebo and the 5 mg dose was significantly different from the 20 mg dose. The 5 
mg dose was not different from the 10 mg dose, and the 10  mg dose was not different 
from the 20 mg dose. 
Adequate characterization of the baseline heart rate and blood pressure is 
important .  Baseline levels contribute to the variability in response observed. In 
future studies, more than one measurement of heart rate and blood pressure before 
dosing would be beneficial in establishing the baseline response. 
CHAPTER 5 
Comparison of Pharmacodynamic Response Measures 
In this chapter, the pharmacodynamic response measures used in this study are 
compared. The relationships between responses on different measures for each 
subject are examined .  The characteristics of each measure are evaluated relative to 
those an ideal pharmacodynamic measure, including sensitivity , reproducibility ,  and 
clinical relevance. 
5 . 1  Results 
The direction of change in baseline and placebo corrected response after 
dextroamphetamine dosing for each response measure at each dose level for each 
subject is presented in Table 5 . 1 .  A review of the data in this table reveals 
few obvious relationships among the response measures. Increased EEG alpha 
activity is observed in 3 of the 9 subjects. No other response measures (mood scales, 
serum prolactin ,  or psychometric tests), show a similar pattern of response. Serum 
prolactin decreases in a majority of the subjects, and this change does not directly 
reflect EEG activity, mood, or psychomotor performance. Mood scales show a 
dichotomous response. Some subjects experience euphoria and some dysphoria at a 
given dose level . Subjects with dysphoria do not appear to have unique responses on 
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Table 5 . 1  Comparison of Subject Responses on Each Pharmacodynamic Measure 
S Do"" EEG Serum Self- VilUal CFT CFT Finger Finger BP Heart 
u Total Prolactin Rlted Analog Average Percent Tip - TIp - Rate 
b Alpha uvel Mood Mood Latency COrTeCt IOght uft 
j Power Selle Selle 
1 5 - , - - t , - t t t 
1 0  - , - - t , - t t t 
20 - , t - t , - - t t 
2 5 - , - - - - , t , -
1 0  - , t t , - - t t t 
20 - , t t t - - t t t 
4 5 - , , - , - - t t t 
10 t , , - , - - t t t 
20 t , , - , - - t t t 
5 5 - - , , - - - - , t 
10 - - - - - - - - - -
20 - - - - - - - - - -
6 5 t , - - - - - - t t 
10 t , , - - - - t t t 
20 t - t t , t - t t t 
7 5 - , - t t t , t - t 
1 0  - , - , , , , , , , 
20 - - - , , - , , , , 
8 5 - - - - - - , , - t 
1 0  , - - - - - , , - , 
20 - - , , - - , t - t 
9 5 - - - - t , - t , -
1 0  - , - t t , - t t -
20 - - t t t , - t t -
10 5 - - t , - - t t t -
10 - - t , t - t t t t 
20 - - t t - - t t t t 
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other pharmacodynamic measures that could be used to predict the direction of the 
mood response. In general , the psychometric tests do not show consistent changes 
across subjects and doses, except that finger tapping rate with the left hand increases 
in most subjects. Heart rate and blood pressure increase for most subjects, but the 
cardiovascular changes do not mirror changes in any of the CNS response measures. 
To compare the time course of the pharmacologic effects as measured by each 
pharmacodynamic measure for individual subjects, plots of baseline and placebo 
corrected response after the 20 mg dextroamphetamine dose versus time were 
prepared. These are presented in Figures 5 . 1  - 5 . 8 . The first panel in each plot 
shows the serum amphetamine concentration for those time points were response 
measures were made on the left y-axis (-- -) and serum prolactin concentration (- + -) 
on the right y-axis. The second panel shows EEG total alpha power on the left y-axis 
(-- -) and self-rated mood scale score on the right y-axis (- +-) .  The third panel 
shows CPT average latency on the left y-axis (-- -) and finger tapping rate with the 
left hand on right y -axis (- + -) .  The fourth panel shows diastolic blood pressure on 
the left y-axis (-- -) and heart rate on the right y-axis (- + -) .  Examination of these 
plots shows that serum prolactin levels usually peak earlier than or at the same time 
as the serum amphetamine concentrations. Mood scale scores generally reach their 
maximum change in either direction before or coincident with the peak serum 
amphetamine concentrations .  When EEG alpha power increases, the time of 
maximum response does not appear to relate to the time of the maximum serum 
amphetamine concentration. Maximum diastolic blood pressure occurs before the 
maximum heart rate, with the peak heart rate usually occurring later than the 
i 
I � ________ __ I 
! '�------�------�------�------------�-------+. ! 
! , -------------------------------------------.-
I ,� 
r .. /�---_ .......... s ./'  .......... I · 
;I. 
� .,� 
---- - --
51 
� .'o+-------_------�------�----__ ------�------� 
� ,_r_�----------------------------------------__r2
• 
n"E (HIQ 
, . 
194 
Figure 5 . 1 Serum amphetamine concentration versus time and baseline and placebo 
corrected pharmacodynamic responses versus time plots after the 20 mg 
dose for Subject 1 .  (- - - refers to left y-axis and -+- refers to right y­
axis) 
i 
i 
i 
r 
� f 
;t 1 i * 
r .. 
i 
� 
10 � 
� 
i 
� 
o � 
� 
1.5 2' 
1 � t. 
-----?-----=:::::::::::---===--� . � 
t: 
• 
nME (HR! 
10 
J 
� 1 .... 
1 . � 
30 
12 
195 
Figure 5 .2  Serum amphetamine concentration versus time and baseline and placebo 
corrected pharmacodynamic responses versus time plots after the 20 mg 
dose for Subject 2 .  (-- - refers to left y-axis and - + - refers to right y­
axis) 
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Serum amphetamine concentration versus time and baseline and placebo 
corrected pharmacodynamic responses versus time plots after the 20 mg 
dose for Subject 4. (- - - refers to left y-axis and - + - refers to right y­
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Figure 5 . 5  Serum amphetamine concentration versus time and baseline and placebo 
corrected pharmacodynamic responses versus time plots after the 20 mg 
dose for Subject 7. (-- - refers to left y-axis and - + - refers to right y­
axis) 
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Serum amphetamine concentration versus time and baseline and placebo 
corrected pharmacodynamic responses versus time plots after the 20 mg 
dose for Subject 8 .  (-- - refers to left y-axis and - + - refers to right y­
axis) 
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Figure 5 . 7  Serum amphetamine concentration versus time and baseline and placebo 
corrected pharmacodynamic responses versus time plots after the 20 mg 
dose for Subject 9 .  (--- refers to left y-axis and -+- refers to right y­
axis) 
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maximum serum amphetamine concentration is achieved. 
To examine the relationship between maximum pharmacodynamic response and 
maximum serum amphetamine concentration, the maximum (or minimum) baseline 
and placebo corrected response observed after the 20 mg dextroamphetamine dose was 
plotted against the maximum serum amphetamine concentration. These plots are 
presented in Figure 5 .9 .  The first row of plots shows the maximum serum prolactin 
verses the maximum serum amphetamine concentration Oeft) and maximum EEG 
alpha power versus maximum serum amphetamine concentration (right) . The second 
row of plots shows the maximum absolute change (increase or decrease) in self-rate 
mood scale versus maximum serum amphetamine concentration Oeft) and the 
minimum CPT average latency versus maximum serum amphetamine concentration 
(right) . The third row shows the maximum finger tapping rate with the left hand 
Oeft) and maximum diastolic blood pressure (right) versus maximum serum 
amphetamine concentration . The fourth row shows the maximum heart rate (left) 
versus maximum serum amphetamine concentration . The correlations between the 
maximum CNS response and maximum serum amphetamine concentration are 
relatively low for most measures. Correlation coefficients of 0.07, 0 .34, 0.4 1 ,  and 
0.04 were obtained for serum prolactin levels, mood scale scores, CPT average 
latency, and finger tapping with the left hand.  Correlation with the EEG alpha power 
was the highest of the CNS measures, with r = 0.83. Correlation for the 
cardiovascular measures was higher than for the CNS measures, with r = 0.91  for 
diastolic blood pressure and r = 0 .87 for heart rate. 
Because this project was designed to evaluate the sensitivity and utility of 
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Figure 5 .9  Maximum baseline and placebo corrected pharmacodynamic response 
versus maximum serum amphetamine concentration after the 20 mg dose 
for each subject 
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quantitative EEG response to dextroamphetamine compared to other measures, the 
relationship between maximum EEG alpha power and maximum response for other 
pharmacodynamic measures after the 20 mg dose of dextroamphetamine was 
examined. Plots of maximum (or minimum) baseline and placebo corrected prolactin 
(first row - left) , mood (first row - right) , CPT average latency (second row - left), 
finger tapping rate with the left hand (second row - right) , diastolic blood pressure 
(third row - left) , and heart rate (third row - right) response versus maximum baseline 
and placebo corrected EEG alpha power are presented in Figure 5 . 10. Correlation of 
the EGG alpha power with the CNS measures is low, while correlation with the 
cardiovascular parameters is relatively high . 
Based on observations made in Part I and Part n of this study, each 
pharmacodynamic response measure was rated relative to criteria for an ideal 
pharmacodynamic measure. These ratings are presented in Table 5 .2 .  Justification 
for these ratings and discussion of the results noted above are addressed in the next 
section. 
5 .2  Discussion 
The onset, magnitude, and duration of pharmacologic effect observed after 
dextroamphetamine dosing appears to depend on the response measure and individual 
subject under consideration. Generalization about the relationships between response 
on the various pharmacodynamic measures has proven difficult. For example, mood 
scales show a heterogenous response, while none of the other measures seem to 
reflect this dichotomy. Physiological or psychological indicators of dysphoria could 
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Table 5 .2  Characteristics of each CNS Pharmacodynamic Response Measure 
Serum EEG Mood CPT Finger 
Prolactin Total Scales Tapping 
Levels Alpha 
Power 
Non-invasive - + +  + + +  + + +  + + +  
Quantitative + + +  + + +  + + +  + + +  + + +  
Objective + + +  + +  + + + +  + + +  
Suitable for ·Repeated + +  + + +  + +  + + 
Measures 
Clinically Meaningful + + + + +  + +  + +  
Susceptible to First Session + + +  + +  + +  + +  
Effects 
Low Between-Period + + + +  + + +  + + +  
Variability of Baseline 
Values 
Low Potential for Missing + + +  + + +  + +  + +  
Data 
Sensitivity for + +  + + +  - -
Distinguishing Dextro-
amphetamine Dose Levels 
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not be identified in the responses assessed by the other pharmacodynamic measures. 
EEG response was only observed in 3 subjects, but response on other measures do not 
reflect this observation. These subjects do not differ from other subjects in response 
on other measures. Maximum EEG alpha power after the 20 mg dose correlates most 
closely with the maximum cardiovascular parameters. This may be because EEG 
alpha power, diastolic blood pressure, and heart rate correlate most highly with serum 
amphetamine concentration. Patterns in the time course of the effects of the eNS 
measures were also obscure. Responses from different eNS measures do not seem to 
follow the same time course or relate directly to the serum amphetamine 
concentrations. None of the measures reflected the dose-related changes in the 
absorption rate of dextroamphetamine. This may indicate that the eNS response 
measures are not measuring the same thing, the measures differ in sensitivity or 
reproducibility, or the degree of eNS stimulation changes during the testing session. 
Based on observations made in Parts I and IT of this study, each response 
measure was evaluated against the criteria for an ideal pharmacodynamic response 
measure. An ideal measure should: 1 )  be noninvasive, quantitative and objective, 2) 
suitable for repeated measures, 3) be insensitive to first session effects, 4) show low 
variability between periods as baseline, 5) have low potential for missing data, 6) 
measure a response that relates to some clinically relevant outcome, and 7) be 
sensitive and reproducible so that changes in dose levels (or serum concentration) of 
the drug can be discerned. Each of the measures meet some of these criteria, but 
none fulfills them all .  The last criteria listed above, which these studies were 
designed to address, is  the most important. 
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Each of the measures investigated in this study permits quantitation of the 
response. The mood scales, CPT, finger tapping, and EEG are noninvasive although 
the recording the EEG does result in some discomfort to the subject. Collection of 
serum prolactin levels requires venipuncture, so it is the most invasive of all of the 
response measures. The serum prolactin levels, CPT, and finger tapping task are the 
most objective of the measures. The self-rated and visual analog mood scales are the 
least objective of the measures, since they depend on the subject's individual 
assessment of the drug effect .  The EEG data falls between mood scales and the other 
measures. The processing of the EEG requires editing, which is subjective in nature. 
Blinding of the EEG reviewer should reduce the subjectiveness of the process. 
Another approach , which was not utilized in this study, would be to automate the 
EEG artifact detection and elimination. 
The EEG is the most suitable for repeated measures. Once the electrodes are 
applied, recordings can be made continuously with little subject cooperation beyond 
remaining vigilant. Serum prolactin can also be measured repeatedly, but the 
frequency is limited by the total volume of blood that can be drawn from the subject. 
Mood scales can also be measured repeatedly, but if administered too frequently, 
subjects become bored with the questions or their answers may become unduly 
influenced by the answers on the previous test session . The CPT and finger tapping 
tasks are the least suitable for repeated measures. During Part I of the study, learning 
effects were demonstrated for the computerized tests. Although the learning effects 
can be minimized with adequate practice sessions, these tasks require a higher degree 
of subject cooperation and motivation than the other tasks. Some subjects complained 
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that their hand became tired during the finger tapping task, which limits how 
frequently it can be repeated. The CPT requires that the subject maintain attention 
and motivation. During Part II of this study, the frequency of the computerized test 
sessions did not appear to seriously interfere with measurement of response. 
In Part I of the study, each measure except serum prolactin was evaluated for 
first session effects. Scores on the self-rated mood scale, finger tapping with the right 
hand, percent correct on the CPT and EEG total power in the delta frequency band 
showed different responses on the first study day than on subsequent study days. This 
difference may be due to anxiety about participating in the study or other factors 
associated with being unacquainted with the study procedures. Serum prolactin has 
the potential to show first session effects as well, since prolactin levels are affected by 
stress. Prior to Part II of the study, subjects underwent a familiarization session that 
was similar to a study day except it was shorter and did not involve blood drawing, 
urine collection or drug administration . When the results of Part II were examined, a 
first-period effect was not present for most of the subjects, suggesting that the 
familiarization session was adequate. Study period was not significant in the 
statistical analysis and the baseline values were not noticeably different during Period 
1 than during other periods. One notable exception to this observation is the 
experience of Subject 5 .  During Period I ,  his baseline CNS and cardiovascular 
responses were quite different than those measured in Period 2 ,  which may have 
contributed to the intense dysphoria experienced by the subject. To minimize this 
type of effect in future studies of CNS active drugs, a familiarization session that is 
identical to a study period where the subjects receive a placebo and are blinded should 
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b e  incorporated into the study design. 
An ideal pharmacodynamic measure should also show low variability between 
periods as baseline. The measure should not vary significantly due to confounding 
factors, but show a stable response at baseline throughout the study. In our studies, 
EEG variables and serum prolactin showed the highest baseline variability. These 
measures are influenced by a number of factors including psychological state, stress, 
and level of vigilance. The mood scales and psychometric tests showed much lower 
variability at baseline than the EEG and prolactin. With significant variability at 
baseline, careful control of the study conditions and accurate determination of the 
baseline response is necessary. 
Pharmacodynamic measures should also have low potential for missing data. 
The self-rated mood scales are least likely to show missing data. The only time they 
are missing is if the subject refuses to complete it, the investigator forgets to 
administer it, or the rating scale forms are misplaced, all of which are highly unlikely 
and could occur for any of the measures. Psychometric test data and serum prolactin 
values are also unlikely to show missing data, except when the computer, heparin 
lock, or RIA assay fails. The EEG is most likely to result in missing data. In our 
studies, 5 - 1 0 %  of the data was classified as missing because less than 24 artifact­
free epochs were present after the editing was complete. This occurred despite efforts 
to minimize artifacts. Missing data complicates statistical analysis and may 
necessitate studying a larger number of subjects to obtain conclusive results. 
A pharmacodynamic measure ideally should have clinical relevance. Change in 
the measure should have clinically important meaning. This goal has proven elusive 
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for many CNS pharmacodynamic measures. Intuitively,  mood scales seem to be 
measuring mood alteration, which is clinically relevant for CNS stimulants. The 
mood scales used in these studies, particularly the self-rated mood scale, have face 
validity for measuring euphoria or dysphoria. This may be more or less true for a 
given scale, but in general , changes in these scales have clinical meaning. Each scale 
must be validated and results with a particular scale may not be consistent with other 
validated scales. Psychometric tests may also reflect clinically meaningful changes. 
The tasks used in this study were fairly simple however, and their relevance to 
complex, "real life" situations is unknown. The behavioral or psychological meaning 
of changes in serum prolactin levels and EEG variables are much less clear. They 
may be surrogate measures of more clinically relevant effects, but more work is 
needed to define these relationships. 
Surrogate measures are useful only if response on these measures reflect 
clinically important changes. One of the objectives of this study was to determine if 
EEG changes observed after the administration of CNS stimulants correlated with 
clinical outcomes. The results of this study provided no evidence that the drug­
induced EEG changes are correlated with changes in mood or psychometric 
performance. Similar EEG changes were observed in subjects who experienced 
euphoria and subjects who experienced dysphoria. The pattern of EEG changes also 
did not mirror changes in psychometric performance. This study did not suggest 
psychological or behavioral meaning for changes in serum prolactin levels either. 
Despite the unclear meaning of surrogate measures, they are still useful in drug 
development. Changes in these measures can indicate that a drug is influencing CNS 
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activity an d  may b e  useful i n  studying the influence o f  disease processes, aging, or 
other drugs on the CNS. Further work is needed to elucidate clinical correlates for 
EEG and serum prolactin changes. 
Most importantly, pharmacodynamic measures should be reproducible and 
sensitive to the dose of the drug administered or the concentration of the drug at some 
collection site (usually serum or plasma). The primary objective of this research was 
to examine the sensitivity and reproducibility of quantitative EEG compared to other 
pharmacodynamic measures for the assessment of CNS stimulation. Based on Part I 
of this study,  within-day variability, between-day variability, and intersubject 
variability was greatest for the EEG measures when no drug was administered. The 
psychometric tests were the least variable. These results indicate that EEG measures 
are less reproducible than the other measures under the testing conditions employed in 
our studies. This was also evident in the variability of the baseline values in Part II 
of the study. It may be possible to reduce this variability by selecting subjects with 
very similar background EEG patterns (especially alpha activity) and personality 
characteristics, more carefully controlling the level of vigilance, and controlling 
factors in the testing environment such as noise level , temperature, and interaction 
with staff. Reproducibility also impacts the sensitivity of a measure. If measures are 
not reproducible, they are less likely to be sensitive to small changes in drug 
concentration or dose. 
The results of Part II of this study provide evidence of the comparative 
sensitivity of the pharmacodynamic measures investigated. Indicators of sensitivity 
include: 1 )  ability to distinguish dose levels based on the maximum or minimum 
response observed on the various measures by statistical analysis, 2) the 
discriminating ability of the measures as indicated by the estimates of power 
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for the statistical analyses, 3) the ability to measure drug effect as serum 
concentrations of dextroamphetamine are declining as assessed by the ET parameter, 
and 4) the correlation between maximum serum amphetamine concentrations and the 
maximum response determined with each response measure. 
Statistical analysis of the E...u (or E..uJ values for each response measure showed 
that not all of the measures could distinguish the dose levels of the drug. Significant 
treatment effects consistent with dose were observed for serum prolactin , diastolic 
blood pressure, and heart rate. The mood scales, EEG, psychometric tests, and 
systolic blood pressure showed no significant differences. Estimated statistical power 
was also highest for serum prolactin (0. 85),  diastolic blood pressure (0.97) , and heart 
rate (0.90) . Estimated power for the EEG alpha power (0.25) , the self-rated mood 
scale ( < 0 .20) , the visual analog mood scale (0.30) , CPT average latency (0.45) , 
CPT percent correct (0.50) finger tapping with the right hand (0.45) and systolic 
blood pressure (0.60) were lower. Finger tapping with the left hand showed adequate 
statistical power (0. 88) , but no treatment effects were observed. Statistical power for 
the mood scales were low primarily because of the dichotomous response observed in 
the small study sample. EEG changes were also only present in a portion of the 
subjects. A larger sample size that permitted subgroup analysis may have shown 
statistical differences for these measures. Power for the psychometric tests was 
higher than for the mood and EEG measures, so the performance on psychometric 
tests, indeed, may not be correlated with dose. Results from the statistical analysis of 
E...u (or E.wJ values suggest that the cardiovascular parameters are more sensitive 
than the CNS measures, and that serum prolactin is the most sensitive of the CNS 
measures. 
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The ET was calculated as an indicator of whether the measure was able to 
detect drug effect as concentrations became lower at later time points. The only 
measure able to distinguish between treatment based on ET was heart rate. None of 
the CNS measures showed a significant difference in ET between treatments. These 
results again indicate that the cardiovascular measures are more sensitive than the 
CNS measures. 
Correlations between maximum serum amphetamine concentration and 
maximum pharmacodynamic response show a strong correlation for maximum total 
EEG alpha power (r = 0 .83), diastolic blood pressure (r = 0 .91 )  and heart rate 
(0. 87) . Correlation coefficients are less than 0.5 for the other measures. These 
results imply that the cardiovascular parameters and EEG total power are most 
sensitive to the maximum serum concentrations of amphetamine. 
The indicators of sensitivity evaluated suggest that the cardiovascular measures, 
especially heart rate and diastolic blood pressure, are sensitive measures of stimulant 
effects. The cardiovascular measures are more sensitive than the CNS measures. Of 
the CNS measures, serum prolactin appears to be the most sensitive. The 
psychometric tests appear to be the least sensitive of the measures. Review of the 
response versus time plots at each dose level for the self-rated mood scale suggest that 
the mood scale may also be a sensitive measure. The largest effect is usually 
observed at the highest dose level . Because the response is dichotomous, statistical 
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comparisons appear to mask treatment differences. With a larger sample that 
permitted sub-group analysis, it is likely that significant differences between doses 
would be apparent. The EEG alpha power may also be a sensitive measure. In this 
study, there appeared to be a relationship between maximum increase in alpha power 
and maximum serum amphetamine concentration. Unfortunately,  only three subjects 
showed changes in alpha power after amphetamine dosing, so statistical power was 
very low. If only subjects with greater than 35 % alpha power at baseline were 
included in the study, significant differences between the treatments may have been 
apparent. 
Our studies did not provide evidence that quantitative EEG is more sensitive 
than other eNS measures for assessing eNS stimulation. Other investigators have 
reported that EEG has proved to be sensitive to drug action at drug concentrations 
lower than where changes are seen in neuropsychological tests.41 Studies that report 
this finding have all been performed with benzodiazepines, which cause a decrement 
in psychomotor performance and cause significant and characteristic EEG changes. 
This phenomenon has not been reported for eNS stimulants. This has also been 
viewed as a criticism of quantitative EEG, because EEG changes are present at drug 
concentrations when no behavioral changes are evident, so the meaning of the changes 
is unclear. It has been postulated that the sensitivity of EEG may be even greater 
when specific sensory stimulation modalities are employed , because situational 
variability (that decreases reproducibility) will be better controlled.41 
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5 . 3  Conclusions 
Each of the CNS measures evaluated in this study fulfills one or more of the 
criteria for an ideal pharmacodynamic measure to a greater or lesser extent, but none 
of them can be considered an ideal measurement tool. The study was designed to 
evaluate quantitative EEG as a pharmacodynamic measure of CNS stimulation, and 
the following can be concluded from these studies: 1 )  Quantitative EEG is 
noninvasive, although it results in more discomfort to the subjects than mood scales 
and psychometric tests, 2) It is more objective than subject-rated mood scales, but due 
to the editing process, may not be as objective as the psychometric tests, 3) EEG is 
the most suitable for repeated measures of all the tools assessed in this study, 4) The 
behavioral and psychological meaning of quantitative EEG changes is unclear, and the 
results of this study did not shed much light on this problem, 5) The EEG and other 
measures evaluated are susceptible to first session effects, so a familiarization period 
is necessary, 6) The EEG shows the most baseline variability between periods and the 
lowest within-day, between-day, and intersubject reproducibility of the measures 
studied , 7) Quantitative EEG has the highest potential for missing data of the 
measures evaluated , and 8) EEG is not more sensitive than the other measures under 
the conditions of this study. Further work is needed to identify subject groups or 
study conditions that can improve the sensitivity of EEG for measuring CNS 
stimulation . 
CHAPTER 6 
Overall Conclusions and Significance of Findings 
The primary objective of these studies was to test the following hypotheses: 1 )  
quantitative EEG i s  a sensitive and reproducible measure of the CNS's  response to 
sympathomimetic drugs as compared to more widely used methods such as 
psychometric testing, subjective rating scales, or neuroendocrine tests and 2) changes 
in the EEG after sympathomimetic drug administration are related to the behavioral , 
psychological and neuroendocrine effects observed as well as the plasma concentration 
of the drug. Based on the results obtained in these studies, quantitative EEG 
conducted under our study conditions and subject population was not more sensitive 
for assessment of CNS stimulation than the other CNS response measures evaluated . 
Quantitative EEG showed higher within-day, between-day , and intersubject variability 
than the other CNS measures studied , indicating that it is less reproducible under 
baseline conditions. Dose levels of dextroamphetamine could not be distinguished 
from placebo in the study population as a whole. A subset of the subjects studied 
showed notable EEG changes consistent with dose after dextroamphetamine 
administration . All of these subjects showed higher ( > 35 %) alpha activity at 
baseline. Differences in mood, inhibition of prolactin secretion , and psychomotor 
performance in these subjects compared to the rest of the subjects were not apparent. 
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Relationships between EEG changes and changes on other eNS measures could not be 
identified, although maximum change in EEG alpha JX>wer was related to the 
maximum serum amphetamine concentration . 
In addition to the findings addressing the primary objectives of the studies, 
conclusions can be drawn from secondary objectives and observations made during 
the course of the data collection and analysis: 
1 )  A gas chromatographic method with electron-capture detection of the 
pentafluorobenzoyl derivative of amphetamine is suitable for the 
determination of serum amphetamine concentrations as low as 2 ng/mL, 
which permits characterization of the pharmacokinetics of amphetamine 
following a 5 mg oral dose. 
2) Dextroamphetamine appears to show dose-dependent effects on the rate of 
absorption , with the fastest rate of absorption observed after the 5 mg dose. 
This phenomenon has not been described previously for amphetamines. 
3) The is an inverse relationship between dose and inhibition of prolactin 
secretion . The largest decrease in serum prolactin levels occurs after the 
lowest dose. This dose-resJX>nse relationship has not been reJX>rted 
previousl y.  
4) In general , the cardiovascular measures (heart rate and blood pressure) were 
more sensitive than the eNS measures employed in this study. Results from 
cardiovascular measures can be used to distinguish dose lower doses of 
dextroamphetamine than results from the eNS measures. 
5) The self-rated mood scale (adapted from the scale proJX>sed by Martin ,  et al . ,  
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based on the ARCI scales) was able to distinguish dose-related euphoria and 
dysphoria. 
6) The psychometric tests employed in this study were not useful for 
distinguishing dose levels of amphetamine under our study conditions. 
The primary significance of the findings from these studies is their importance 
for the design of future studies in the area. The studies were pilot in nature and 
intended to generate new hypotheses as well as provide evidence that supports or 
refutes the h ypotheses stated at the start of the investigation . Our results indicate that 
the placebo-controlled , crossover design is appropriate for pharmacodynamic studies 
using the CNS measures we investigated . Several of the tests show within day 
variability and circadian variation in the response, and the intersubject variability is 
higher than the intrasubject variability . Because many of the responses to drug 
depend on the baseline response, it is important to accurately characterize the baseline 
response by carefully controlling the prestudy conditions and measuring the baseline 
response more than once. In addition , a familiarization period is necessary for all of 
the tests , and our observations suggest that it should be identical to a study period. 
This could be accomplished by incorporating two placebo periods into the study ,  one 
at the beginning of the study (single-blind) and one randomized with the treatments 
(double-blind) . These design considerations are relevant for any pharmacodynamic 
study using quantitative EEG . For studies using quantitative EEG specifically to 
study CNS stimulation , our investigations suggest that prescreening of subjects for 
background alpha activity greater than 35 % is necessary to obtain measurable changes 
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in the EEG activity after drug administration. Screening subjects for similar 
personality traits may also improve the reproducibility of quantitative EEG for 
measuring eNS stimulation . These design modifications should improve the 
sensitivity and reproducibility of quantitative EEG to measure eNS stimulation. 
Quantitative EEG shows promise as a measure of eNS effects, but further work is 
needed before the technique will improve our ability to investigate the 
pharmacodynamics of weaker eNS stimulants or the effects of age, disease , and other 
drugs on the pharmacodynamics of eNS stimulants. 
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HYPOTHESIS AND SPECIFIC AIMS:  
Hypothesis 
The hypotheses guiding this research project are that 1 )  quantitative EEG is a more 
sensitive and reproducible measure of the central nervous system' s  response to 
sympathomimetic drugs than more widely used methods such as psychometric testing, 
subjective rating scales, or neuroendocrine tests and 2) changes in the EEG after 
sympathomimetic drug administration are related to the behavioral, psychological and 
neuroendocrine effects observed as well as the plasma concentration of the drug. 
Dextroamphetamine is a sympathomimetic amine with demonstrated effects on the 
CNS, and will be used as a model compound for studying quantitative EEG as a 
response measure. 
Specific Aims: 
The purpose of this study is to investigate the inter-and intra-individual 
variability associated with a series of potential CNS pharmacodynamic 
response measures under baseline (no drug) conditions. These measures 
include quantitative EEG, automated psychometric tests, and subjective self­
rating mood scales. Within day and between day reproducibility will be 
evaluated. Responses for each measure will be examined for evidence of 
circadian changes and learning effects. 
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The purpose of this study is to evaluate the usefulness of quantitative 
electroencephalography (EEG) as a measure of CNS response to stimulants. 
The study will examine the relationship between EEG changes after 
administration of dextroamphetamine and 1 )  performance on automated 
psychometric tests, 2) serum prolactin levels, 3) subjective response as 
assessed by self-rating mood scales, and 4) serum concentration of 
dextroamphetamine. The sensitivity of EEG parameters to dextroamphetamine 
concentration in serum will be compared with that of more subjective 
measures. 
BACKGROUND AND SIGNIFICANCE: 
Accurate and reproducible measures of drug effect on the central nervous 
system (CNS) are needed in order to study the pharmacodynamics of centrally­
acting drugs. ( 1 )  Understanding pharmacodynamics, or the relationship 
between drug concentration in the systemic circulation and effect, is important 
because it contributes to the interindividual variability observed in drug 
response. Determining the association between drug concentration and 
subsequent response is necessary for optimizing drug therapy. Studies of the 
pharmacodynamics of centrally-acting drugs have been limited primarily by the 
difficulty in obtaining quantitative measures of CNS response. (2) 
Ideally, the measures of drug effect used in pharmacodynamic studies should 
be quantitative, objective, and non-invasive. There should be a gradual, rather 
than an all-or-none, change in the response measure with changing drug 
concentration .  The measure should be sensitive to small differences in drug 
concentration. The pharmacodynamic measure should be reproducible both 
within and between individuals. It is important to be able to measure the 
response repeatedly in the same individual without changes occurring due to 
learning or tolerance. Lastly, the response measure should be meaningful; the 
measured response should relate to the therapeutic or toxic clinical effects of 
the drug. (2 ,3) 
Various psychometric tests, ranging from self-rating scales of psychologic state 
to computerized performance tasks, have been used to assess the 
pharmacodynamics of centrally-acting drugs. (2 ,4,5) Psychometric tests are 
noninvasive and the response can be quantitated. However, these tests are not 
ideal pharmacodynamic measures. Although some tests can measure certain 
aspects of behavior as a function of drug response, they are more or less 
subjective and may not be reproducible. Many psychometric tests are not 
suitable for repeated measures, since learning and motivational factors 
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influence the results of subsequent tests. These limitations may contribute to 
insensitivity of the measures to small changes in serum drug concentrations. 
The relationship of performance on psychometric tests to the "real life" 
behavioral and psychologic effects of drugs are also difficult to define. 
Therefore, psychometric tests are not entirely acceptable as eNS response 
measures. 
More recently, quantitative EEG has been employed to measure eNS 
pharmacodynamics (2 ,6) .  Many studies using EEG to profile or classify 
psychoactive drugs have been conducted, but few studies have attempted to 
correlate EEG parameters with concurrently measured drug concentrations 
and/or response to psychometric tests. Pharmacodynamic modelling of the 
EEG effects of anesthetic agents (7, 8 ,9, 10) and benzodiazepines ( 1 1 , 12) has 
been successfully performed. Quantitative EEG is objective, noninvasive, and 
derived parameters change gradually with changes in plasma drug 
concentration. Repeated or continuous measures of the EEG can be made, 
although a familiarization session before the study is advisable to avoid a first­
session effect due to anxiety. ( 13) Learning effects on the EEG have not been 
reported. (2) Recording of the EEG also requires less subject cooperation than 
completion of psychometric tests. The reproducibility and sensitivity of 
quantitative EEG parameters however, requires further evaluation. The 
behavioral or psychologic meaning of changes in EEG parameters is also 
unclear. If these issues can be addressed, quantitative EEG may become a 
preferred measure of eNS pharmacodynamic response. 
This study is designed to evaluate quantitative EEG as a pharmacodynamic 
tool. Dextroamphetamine was chosen as a model compound for this 
evaluation. Dextroamphetamine is a sympathomimetic amine known to have 
potent eNS stimulant effects. Single doses have been administered safely to 
normal volunteers. Its concentration in the systemic circulation can be 
measured adequately by gas chromatographic assay methods and it does not 
have clinically significant active metabolites. It appears to have dose­
proportional pharmacokinetics over the dosage range to be used in this study 
which can be adequately described by a one-compartment body model. ( 14) 
The renal excretion of dextroamphetamine is dependent on urinary pH and 
volume, so acidifying the urine will result in constantly enhanced excretion. 
With urine pH between 5 and 5 .5 ,  the elimination half-life of 
dextroamphetamine is approximately 7 hours. ( 15) Dextroamphetamine causes 
a decrease in delta activity and an increase in alpha and beta activity on the 
EEG. ( 1 6, 1 7) Mood changes after dextroamphetamine have been measured 
using a variety of rating scales. ( 1 8, 19,20,2 1 ,22) It also produces measurable 
effects on performance tasks. (23,24,25,26,27) The duration of the central 
effects of a single dose of amphetamine has been reported to be between 3 and 
24 hr. (28) For these reasons, dextroamphetamine will be used to test the 
sensitivity of quantitative EEG as a pharmacodynamic measure of central 
stimulation. 
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Dextroamphetamine affects the neurotransmitters dopamine, norepinephrine 
and serotonin. (29) The output of pituitary hormones and hypothalamic 
releasing factors have been used to examine the neurotransmitter pathways 
involved. (30,31) Following a 20-mg oral dose of dextroamphetamine in 
normal subjects, statistically significant rises in cortisol, prolactin, growth 
hormone, TSH, FSH, and LH were observed compared to placebo. (32) The 
prolactin release after dextroamphetamine administration will be used in this 
study as an additional pharmacodynamic response measure to aid in the 
physiologic interpretation of the EEG response. 
The significance of this project is two-fold. First, the study will provide 
information about the usefulness of quantitative EEG as a pharmacodynamic 
response measure compared with more traditional measures of CNS activity 
such as psychometric tests. A more sensitive, reproducible measure of CNS 
response to sympathomimetic drugs is important to evaluate the CNS­
stimulating properties of other sympathomimetic drugs such as 
phenylpropanolamine where the degree of CNS stimulation and its potential 
clinical significance in man is controversial. (33) Second, an improved 
measure of CNS response is necessary for evaluating the effects of the aging 
process and various disease states on the pharmacodynamics of centrally-acting 
drugs. This study will evaluate quantitative EEG relative to the criteria for an 
ideal pharmacodynamic measure discussed above, to provide a better 
understanding of its sensitivity, reproducibility, and behavioral and 
psychological meaning. 
METHODS AND PROCEDURES: 
I. Subjects 
Eight healthy volunteers will participate in each study. Volunteers will be 
considered for inclusion if they conform to the following criteria: 
1 .  Dem0l:raphic: Subjects must be healthy male or nonpregnant female 
volunteers between the ages of 1 8  and 30 years and must not deviate 
more than 15  % above or below the range of desirable weights 
according to the 1979 Build Study, Society of Actuaries and 
Association of Life Insurance Medical Directors of America 
(Attachment I.) 
To participate in Part II, female subjects must meet the following 
criteria: 
As determined by thorough inquiry, women must be found to practice 
acceptable methods of birth control and have a negative serum beta­
hCG pregnancy test. Abstention, oral contraceptives, vaginal 
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contraceptives or use of contraceptives by the women's  partner, do not 
constitute acceptable birth control. Acceptable methods of birth control 
will be limited to intrauterine contraceptive devices or surgical sterility. 
The method of birth control must be recorded in the subject's medical 
history. A negative pregnancy test is required before enrolling in the 
study and before each dosing period. 
This restriction is mandatory because pregnancy is a contraindication to 
amphetamine use, especially during the first trimester. (28) The risks 
to the pregnancy clearly outweigh the benefits of participating in this 
study. 
2.  Medical Hist0O': Subjects must have no history of renal , hepatic , 
cardiovascular, gastrointestinal, neurological, pulmonary, or 
hematologic disease; have no history of drug addiction, alcohol abuse, 
psychologic dependence on drugs, or psychiatric illness. Subjects must 
have no first degree relatives (mother, father, or siblings) with a history 
of mental illness or alcohoUdrug abuse. Subjects participating in Part 
II must also have no history of glaucoma or hypersensitivity to 
tartrazine (FD&C Yellow dye No.5) or dextroamphetamine. Tartrazine 
hypersensitivity frequently occurs in those who have hypresensitivity 
reactions to aspirin. 
3 .  Physical: Subjects must successfully pass a physical examination, 
demonstrating no evidence of an active disease state or physical or 
psychologic impairment. 
4.  Laboratory screen : Subjects must have no clinically significant 
abnormal laboratory values on a laboratory screen consisting of I )  
SMAC-20, 2) CBC and 3) urinalysis. Subjects must have a negative 
urine drug screen and blood alcohol test. Females must have a 
negative serum beta hCG test. 
5 .  Electrocardio�ram: Subjects must have no clinically significant 
abnormalities on a 12-lead EKG including a 30 sec rhythm strip. 
6. Vital si�ns: Supine and standing systolic and diastolic blood pressure, 
heart rate, and oral body temperature must be within normal limits. 
7.  Other medications: Subjects must not be taking medications chronically 
and must not have taken any prescription medication or investigational 
drugs for at least 4 weeks before entering the study. Subjects must 
have a normal daily caffeine intake equivalent to or less than two cups 
of coffee. No medication (including OTC medications and vitamins) , 
caffeine or alcohol will be allowed in the 72-hr period before each 
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study day and on each study day. Subjects must be non-smokers, 
meaning that they have abstained from smoking for at least 1 2  months 
before the start of the study. 
8.  All subjects participating in  Part II will undergo an EEG and 
psychometric testing familiarization period before enrolling in the 
study. Subjects with a high number of artifacts on the EEG or who 
cannot tolerate wearing the electro-cap for extended periods of time 
will be excluded. 
Subjects participating in Part II will be instructed to maintain a low 
monoamine diet beginning 3 days prior to the start of the study and continuing 
through the duration .of the study. 
Within 1 week after study completion, the physical examination, laboratory 
tests , and electrocardiography will be repeated for subjects participating in Part 
ll. Possible clinically significant abnormalities will be followed up until return 
to pre-study baseline. 
Subje<;ts for this study will be recruited from within the hospital and schools at 
MCVIVCU. 
ll. INFORMED CONSENT 
Each subject will give written informed consent for study participation before 
the start of the study. The signed consent forms will be kept in the subjects' 
confidential medical record as a permanent document. 
lll . PROCEDURE 
A. EillJ 
During each of the three study periods, the following procedure will be 
followed: 
Subjects will enter the study facility at 7:00 a.m. on the study day and 
will be released after completion of the 1 2  hr test battery on the same 
day (approximately 8:00 p.m.) .  
Subjects will fast from midnight on the evening before the study day 
until after the 4 hr test battery. Lunch will be served after the 4 hr test 
battery and dinner at 10  hrs after the baseline test battery. The same 
menu will be served during each study period. Water will be permitted 
during the fasting period. Beverages not containing caffeine may be 
served with meals. 
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Electroence.phalo�raphy 
For each subject, five minute segments of 28 channel EEG will be 
recorded using a NeuroScience Brain Imager with eyes closed at the 
following times: 0, 1 ,  2, 3 ,  4 ,  6, 8, and 12 hrs. Subjects will be 
reclined in a reclining chair during the recordings. Subjects will be 
asked to count back from 500 by 3s to maintain vigilance. The 
electrodes will be placed using an Electro-cap according to the 10/20 
International System with 8 additional electrodes located 50 % between 
the standard 10/20 placement. Linked ears will be used as a reference. 
Four additional channels will be used to monitor for vertical and lateral 
eye movements and electro myographic activity. The electrode 
impedances will be checked before each recording. Impedances should 
be less than 4.0k ohms and similar between electrodes. Any 
disturbances in the room or subject movement during the EEG will be 
recorded by the BEG technician. The raw BEG will be stored on an 
optical disk. 
Psychometric tests 
1 .  A computerized visual continuous performance task (NeuroScan, 
Inc.) will be completed by each subject at the following times: 
0, 1 ,  2, 3, 4, 6, 8 and 12 hours. 
2 .  A computerized motor task, finger tapping (NeuroScan, Inc.) ,  
will be completed by each subject at the following times: 0,  1 ,  
2, 3,  4 ,  6, 8,  and 12 hours. 
3 .  Prior to the 0 hr testing, subjects will practice the computerized 
tasks two times. 
Rating Scales 
A self rating scale (Attachment II) based on the MBG (a measure of 
euphoria) and A (a measure of amphetamine effects) sub scales of the 
Addiction Research Center Inventory Scales described by Martin et al. 
( 18) will be completed by each subject at the following times: 0, 1 ,  2 ,  
3, 4 ,  6 ,  8 ,  and 12 hours. 
A 100 mm visual analog mood scale (Attachment III) will be completed 
by each subject at the following times: 0, 1 ,  2 ,  3 ,  4 ,  6, 8, and 1 2  
hours. 
The tests will be conducted in the following sequence: 1) EEG, 2) 
CPT, 3) rating scales, 4) finger tapping. A study flow sheet is 
presented in Attachment IV. 
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During each of the four study periods, the following procedure will be 
followed: 
Subjects will enter the study facility on the evening of the day 
preceding each day of dextroamphetamine or placebo dosing and will 
not be released until after the collection of the last blood sample of the 
study period. Subjects will fast from midnight on the evening before 
dextroamphetamine or placebo dosing until after the 4 hr blood sample 
is drawn. Water will be permitted during the fasting period. Subjects 
will begin a period of bed rest one hour before dextroamphetamine or 
placebo administration that will continue until after the 6 hr test 
battery. 
All subjects must have a negative urine drug screen and blood alcohol 
test each study period before receiving dextroamphetamine or placebo. 
Female subjects must have a negative pregnancy test (urine beta-hCG) 
each study period prior to receiving dextroamphetamine or placebo. 
All subjects will complete a verbal probe concerning recent medical 
history and medication use. 
Repeated 2 gram oral doses of ammonium chloride will be given to 
acidify the urine and enhance the excretion of dextroamphetamine at the 
following times: - 12 ,  -8, -2, 2 ,  6, 10,  14 ,  and 1 8  hr after 
dextroamphetamine or placebo dosing as described by Wan et al. ( 15) 
Subjects will receive one of the four treatments: dextroamphetamine 20 
mg, dextroamphetamine 10 mg, dextroamphetamine 5 mg, or placebo 
orally. Both the subjects and the investigator will be blinded to 
treatment. The time of dosing will be 8:00 a.m.  for the first of the two 
subjects and 8 :30 a. m. for the second. Capsules will be taken with 240 
mL of water. 
Tablets containing 5 mg dextroamphetamine sulfate will be used for 
dosing, with doses placed in opaque gelatin capsules to maintain 
blinding. Lactose will be added to prepare capsules with the same 
weight for all doses of amphetamine. Placebo capsules will contain 
lactose only. 
Blood samplin� 
Prior to dosing, a heparin containing catheter will be inserted into a 
forearm vein for access to blood sampling. 
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1 .  7-mL samples for determination of dextroamphetamine 
concentration will be collected in red-top tubes with no additives 
at the following times: pre-dose, 1 ,  1 .33, 2 ,  2.33, 3 ,  3 .33 , 4,  
6, 8,  12,  18 ,  and 24 hr after dextroamphetamine or placebo 
dosing. Blood samples will be allowed to clot, centrifuged 
(within 1 hour of venipuncture) for 10 minutes, serum 
harvested, and stored at -20 degrees Celsius until analysis by a 
sensitive, specific, and reproducible gas chromatographic 
method using isothiocyanate derivatization and a nitrogen 
detector, modified from the method described by 
Narasimhachari and Friedel. (34) 
2 .  5-mL samples for the determination of prolactin concentration 
will be collected in red-top tubes with no additives at the 
following times: pre-<iose, 1 ,  2 ,  3 ,  4 ,  5 and 6 hr after 
dextroamphetamine or placebo dosing. Blood samples will be 
allowed to clot, centrifuged (within 1 hour of venipuncture) for 
10 minutes, serum harvested, and stored at -20 degrees Celsius 
until analysis by a radioimmunoassay method described by Sinha 
et al. (35) 
The total volume of blood drawn for dextroamphetamine and prolactin 
determinations during the study will be 504 mL. 
Urine collection 
Subjects will void just before dextroamphetamine or placebo dosing and 
the urine pH will be determined immediately at room temperature after 
shaking using a pH meter. Two 25 mL aliquots of the urine will be 
retained and frozen until analysis. Urine will then be collected over the 
following intervals after dextroamphetamine or placebo dosing: 0-2 hr, 
2-4 hr, 4-8 hr, 8- 12 hr, 12- 1 8  hr, 1 8-24 hr. The pH of the urine 
voided at the end of each collection interval will be determined 
immediately at room temperature after shaking using a pH meter. The 
total volume of urine collected during the interval will be measured in a 
graduated cylinder and two 25 mL aliquots of the urine will be retained 
and frozen until analysis for dextroamphetamine concentration. 
Subjects will drink 120 mL of water every hour beginning one hour 
before dextroamphetamine dosing and continuing through the four 
hours after dosing. Water will then be available to the subjects as 
desired. 
Electroenc;e.phalo�raphy 
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Five minute segments of 28 channel EEG using a NeuroScience Brain 
Imager will be recorded for each subject with eyes closed at the 
following times: pre-dose, 1 ,  2 ,  3 ,  4 ,  6, 8 ,  and 12  hours after 
dextroamphetamine or placebo dosing. Subjects will be asked to count 
back from 500 by 3s to maintain vigilance during the recordings. The 
electrodes will be placed using an Electro-cap according to the 10/20 
International System with 8 additional electrodes located 50% between 
the standard 10/20 placement. Linked ears will be used as a reference. 
Four additional channels will be used to monitor for vertical and lateral 
eye movements and electromyographic activity. The electrode 
impedances will be checked before each recording. Impedances should 
be less than 4 .0k ohms and similar between electrodes. Any 
disturbances in the room or subject movement during the EEG will be 
recorded by the EEG technician. The raw EEG will be stored on an 
optical disk. 
Psychometric tests 
I .  A computerized visual continuous performance task (CPT) will 
be completed by each subject at the following times: predose, 
1 ,  2, 3, 4, 6, 8, and 12 hours after dextroamphetamine or 
placebo dosing. 
2 .  A computerized motor performance task, finger tapping, will be 
completed by each subject at the following times: predose, 1 ,  
2 ,  3 ,  4 ,  6, 8, and 1 2  hours after dextroamphetamine or placebo 
dosing. 
3 .  On  the evening before dosing for each period, subjects will 
practice the computerized tasks several times. The exact 
number of times will be determined based on the results of Part 
I of this study. 
Rating Scales 
A self-rating scale (Attachment II) based on the Addiction Research 
Center Inventory Scales, the MBG scale (a measure of euphoria) and 
the A scale (a measure of amphetamine effects) described by Martin et 
al. ( 1 8) will be completed by each subject at the following times: 
predose, 1 ,  2, 3, 4, 6, 8, and 12 hours after dextroamphetamine or 
placebo dosing. 
A 100 mm visual analog mood scale (Attachment III) will be completed 
by each subject at the following times: predose, 1 ,  2 ,  3 ,  4 ,  6, 8 ,  and 
1 2  hours after dextroamphetamine or placebo dosing. 
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vital shms 
Blood pressure (sitting) and heart rate will be measured at the following 
times: predose and 1 ,  2 ,  3 ,  4, 6, 8, 1 2 ,  and 24 hr after 
dextroamphetamine or placebo dosing. 
When above measurements are scheduled at the same time, they will be 
conducted in the following sequence: 1 )  urine collection, 2) blood 
samples, 3) EEG, 4) CPT, 5) rating scales, 6) finger tapping and 7) 
vital signs with the blood sample being collected at exactly the 
scheduled time. A study flow sheet is presented in Attachment V. 
On the evening prior to dosing, subjects will receive a light snack prior 
to the - 1 2  and -8 hr ammonium chloride dosing. 
No food or beverages, other than water, will be permitted from 8 hr 
before dosing until after the 4-hr blood sample has been drawn . Lunch 
will be served after the 4-hr blood sample and dinner at 1 0  hours after 
dosing. A snack will be served in the evening before the 14  hr 
ammonium chloride dose. All meals and snacks will be low in 
tyramine content. Large amounts of foods potentially promoting 
alkalinization of the urine (such as milk and milk products, nuts, 
vegetables and fruits) will be avoided. Beverages not containing 
caffeine may be served with meals.  The same menu will be served on 
corresponding days of each study period. 
Adverse Effects 
All subjects will be observed for symptoms and signs of clinical 
intolerance to the drugs or procedures and asked to report any adverse 
effects. These will be evaluated by the physician monitor for their 
clinical significance and potential need for treatment. For subjects who 
develop significant nausea, vomiting, or diarrhea, ammonium chloride 
will be discontinued. 
BIOSTATISTICAL DESIGN AND ANALYSIS : 
Design: During this open-labeled pilot study, healthy volunteers will undergo 
a series of tests (electroencephalography, automated psychometric tests, and 
subjective rating scales) on 3 occasions one week apart. On each of the 3 
study days, the series of tests will be repeated 8 times over a 1 2  hr period. 
Subjects will undertake the study in groups of two. 
Data analysis 
A. Electroencephalography 
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Each of the five-minute recordings will be reviewed by a board certified 
electroencephalographer and edited to remove each 2.5  second epoch that is 
contaminated with artifacts (eye movement, muscle movement, electrode 
artifacts, or disturbances noted during the recording) . The remaining 2.5  
second epochs or artifact-free frames will be averaged to form an average 
topographical map for each 5 minute recording. The amplitude, power, and 
relative power of the EEG signal in the 5 classical frequency bands (delta: 
0.39 - 3 .9  Hz; Theta: 4.3  - 7.8 Hz; Alpha: 8.2 - 1 1 .7 Hz; Beta I: 12. 1 - 16.0 
Hz; and Beta ll: 16.4 - 30.0 Hz) at each electrode will be calculated for each 
average topographical map. The total amplitude and power for each average 
map will be calculated. The ratio of total alpha plus beta power to total delta 
plus th.eta power will also be calculated. 
B. Psychometric tests 
1 .  Visual Continuous Performance Task 
Latency of response will be determined for each trial. The 
average latency of response and the percent of correct responses 
for each set of testing will be calculated. 
2. Finger Tapping Task 
The average rate (taps/sec) of finger tapping for each hand will 
be determined based on three trials at each time point. 
C. Rating Scales 
A total score on the self-rating scale will be determined at each time 
point by adding the scores obtained for each item. 
A score between 0 and 100 will be obtained for the visual analog scale 
at each time point by measuring the number of millimeters between the 
left end of the scale and the mark placed by the subject. 
D. Statistical Analysis 
The results from each of these tests for each day of testing will be 
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compared using a multivariate repeated measures analysis of variance 
with day, time and subject as factors and all responses as dependent 
variables. Within-day and between-day variance will be determined for 
each response variable. 
Desi�n: This study will be a randomized, double-blind, placebo-controlled 
four-period crossover study in healthy volunteers. Subjects will undertake the 
study in groups of two. The start of each study period will be separated by at 
least 1 week washout period. Subjects will receive one of four treatments 
during each study period: dextroamphetamine 20 mg, dextroamphetamine 10 
mg, dextroamphetamine 5 mg or placebo as a single oral dose. Each subject 
will receive each treatment exactly once. 
Data analysis 
A. Pharmacokinetic analysis 
1 .  Dextroamphetamine serum concentration data 
The serum concentrations of dextroamphetamine obtained during 
the study will be presented in tabular and graphic form for each 
subject and treatment. Pertinent pharmacokinetic parameters for 
dextroamphetamine, including elimination rate constant (ke) , 
volume of distribution, apparent total body clearance, mean 
residence time, maximum concentration (Cmax) and time to 
maximum concentration (tmax) will be estimated for each 
treatment for each subject. Descriptive statistics will be 
calculated for each parameter. 
2. Dextroamphetamine urine concentration data 
Dextroamphetamine excretion rates during each collection 
interval will be used to determine the elimination rate constant 
(ke) and the renal clearance of dextroamphetamine for each 
treatment. Data will be presented in tabular and graphic form. 
Descriptive statistics will be calculated for each parameter. 
3 .  Prolactin plasma concentration data 
The prolactin plasma concentrations obtained after each 
treatment will be presented in tabular and graphic form. 
Secondary parameters such as Cmax, tmax, and area under the 
effect-time proftle (AUE) will be calculated and tabulated . 
Descriptive statistics will be calculated for each parameter. 
B.  Electroencephalography 
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Each of the 5-minute recordings will be reviewed by a board certified 
electroencephalographer and edited to remove each 2.5 second epoch 
that is contaminated with artifacts (eye movement, muscle movement, 
electrode artifacts, or disturbances noted during the recording) . The 
remaining 2.5 second epochs or artifact-free frames will be averaged to 
form an average topographical map for each 5-minute recording. The 
amplitude, power, and relative power of the EEG signal in the 5 
classical frequency bands (delta: 0.39 - 3 .0 Hz; theta: 4.3 - 7 . 8  Hz; 
alpha: 8.2 - 1 1 .7 Hz; Beta I: 12. 1 - 16.0 Hz; and Beta II: 16.4 - 30.0 
Hz) at each electrode will be determined for each average topographical 
map. The total amplitude and power for each average map will be 
calculated. The ratio of total alpha plus beta power to total delta plus 
theta power will also be calculated. Differences from placebo for each 
of these parameters will be calculated. 
C.  Psychometric tests 
1 .  Visual Continuous Performance Task 
Latency of response will be determined for each trial. The 
average latency of response and the percent of correct responses 
for each set of testing will be calculated. 
2.  Finger Tapping Task 
The average rate (taps/sec) of finger tapping for each hand will 
be determined based on three trials at each time point. 
D. Rating Scales 
A total score on the self-rating scale will be determined at each time 
point by adding the scores obtained for each item. 
A score between 0 and 100 will be obtained for the visual analog scale 
at each time point by measuring the number of millimeters between the 
left end of the scale and the mark placed by the subject. 
E. Pharmacodynamic analysis 
Response-time profIles for each subject during each period will be 
tabulated and plotted for each response measure. If appropriate, 
secondary parameters such as baseline responses, maximum response 
(Emax), time to reach maximum response, and area under the effect-
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time profile (AUE) for each treatment will be listed and descriptive 
statistics will be calculated. Pharmacokinetic/dynamic modelling will 
be performed if appropriate. 
F.  Statistical analysis 
Results of the abOve response measures for each treatment will be 
compared using statistical techniques appropriate for a 4-way crossover 
study design with repeated measures. Residuals will be tested for 
normality. If normally distributed, a repeated measures analysis of 
variance with subject, dose, period and time as factors will be 
performed. If not normally distributed, either the data will be 
transformed or appropriate non-parametric tests will be used. Analysis 
of variance will be used to examine the dose-dependency of calculated 
pharmacokinetic and pharmacodynamic parameters. 
HUMAN SUBJECT CONCERNS : 
The first part of this study involves undergoing a test battery consisting of 
EEG, computerized psychometric tests, and self-rating mood scales 8 times on 
3 separate occasions for a total of 24 times. Subjects will remain in the study 
unit for the duration of each day's tests (approximately 1 3  hours) . There risks 
associated with these tests are minimal. Subjects will be expected to wear the 
electro-caps throughout the day, which may result in some minor discomfort. 
No drugs will be administered and no blood samples will be drawn during this 
part of the study. Subjects may experience smoe discomfort during the pre­
study physical exam, EKG and laboratory tests. Subjects will receive no 
personal benefits to their health from participating in the study, but the 
procedures will be conducted at no cost to them and they will receive an 
honorarium for their participation. Any information obtained about subjects 
from this research will be kept strictly confidential. Subjects will give written 
informed consent and have the right to withdraw from the study at any time. 
In the second part of this study, subjects will receive oral dextroamphetamine 
(a controlled substance) and ammonium chloride, have blood samples drawn 
for dextroamphetamine and prolactin determination, and undergo a series of 
tests including EEG, automated psychometric tests, and rating scales, 
repeatedly over a 36 hour period on 4 occasions. Subjects will remain in the 
study unit for the duration of the testing (approximately 38 hours for each 
period) . 
A. Study drugs 
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Subjects will receive single doses of dextroamphetamine sulfate (5 , 10, 
and 20 mg) and placebo orally in a crossover fashion. 
Dextroamphetamine is indicated for the treatment of narcolepsy, 
attention deficit disorder, and obesity. The usual adult dosage of 
dextroamphetanline sulfate is 5 - 60 mg/day in 2 or 3 divided doses. 
The dosages administered in this study are within this dosage range. 
Adverse effects associated with single doses of dextroamphetamine may 
include: nervousness, insomnia, irritability, talkativeness, increased 
libido, dizziness, headaches, increased motor activity chilliness, pallor 
or flushing, blurred vision, mydriasis, hyperexcitability, hypertension 
or hypotension, tachycardia, palpitations, nausea, vomiting, abdominal 
cramps, diarrhea, constipation, dryness of the mouth, and metallic 
taste. (28) 
Subjects will also receive a total of 16 grams of oral ammonium 
chloride over a period of 36 hours during each study period to acidify 
the urine. The normal adult oral dose of ammonium chloride is 4 - 12 
grams daily given in divided doses every 4 - 6 hours. The dosage in 
. this study falls within this range. Adverse effects associated with oral 
ammonium chloride include: gastric distress, anorexia, nausea, 
vomiting, thirst, rash, and headache. Symptoms of ammonium toxicity 
associated with very high doses include pallor, sweating, irregular 
breathing, vomiting, bradycardia, cardiac arrhythmias, local or 
generalized twitching, asterixis, tonic seizures, and coma. (36) 
Subjects will be monitored for the development of adverse effects to 
either dextroamphetamine or ammonium chloride by nurses in the 
CRC. Blood pressure and pulse rate will be determined periodically 
throughout the study. If subjects develop significant nausea, vomiting 
or diarrhea, ammonium chloride will be discontinued. Headache may 
be treated with acetaminophen if necessary. If systolic BP rises above 
1 80 mmHg or greater than 30 mmHg above baseline, the subject will 
be given 10 mg of nifedipine sublingually.  Other adverse effects will 
be managed as deemed necessary by the medical monitor. 
B. Blood sampling 
Subjects will have thirteen 7-mL blood samples and 7 5-mL blood 
samples drawn during each period. A total of 504 mL of blood will be 
drawn during the study. 
C. Test battery 
The risks associated with these tests are minimal. Subjects will be 
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expected to wear the electro-caps throughout the day, which may result 
in some minor discomfort. 
D .  Pre- and post-study physical exam and laboratory tests 
Some discomfort may be associated with the physical exam, EKG and 
laboratory tests to be perfromed during screening and at the conclusion 
of the study. 
Subjects will receive no personal benefits to their health from participating in 
the study, but the procedures will be conducted at no cost to them and they 
will receive an honorarium for their participation. Any information obtained 
about subjects from this research will be kept strictly confidential. Subjects 
will give written informed consent and have the right to withdraw from the 
study at any time. 
Female subjects must be using an acceptable method of birth control 
(intrauterine contraceptive devices or surgical sterility) . They must also have a 
negative pregnancy test (serum beta-hCG) as a criteria for enrolling in the 
study and during each period before receiving study drugs. Amphetamine use 
is contraindicated during pregnancy, especially during the first trimester (28), 
and teratogenicity studies in animals have not been performed with ammonium 
chloride, so the risks are unknown. (36) For participation in this study, risks 
to pregnant females clearly outweigh the benefits. 
NEED FOR CRC: 
The CRC is needed for the conduct of this study because: 
1) A number of specialized tests such as BEG and automated psychometric 
tests will be performed, requiring a controlled environment. 
2) The extensive blood sampling and urine collection schedule in Part II 
require trained personnel sensitive to the strict timing requirements 
necessary for pharmacokinetic and pharmacodynamic research. 
3) A special diet is necessary during Part II of the study, requiring the 
services of a dietician for planning and preparing meals. 
4) Subjects must be housed overnight due to the blood and urine sampling 
schedule during Part II. 
5) Plasma prolactin determinations are necessary, requiring a laboratory 
equipped to perform radioimmunoassays. 
6) Trained nurses are available throughout the study to handle study­
related adverse events. 
GRANT SUPPORT: 
Sources of funding for this study include: 
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1 .  Departmental funds (approximately $ 1 ,(00) will be used to cover the 
costs of analysis of samples for dextroamphetamine concentration. 
2 .  A portion of  a grant from NeuroScience (approximately $9,(00) will be 
used to cover the costs of subject honoraria, EEG supplies, and 
screening laboratory tests. 
3 .  The remainder of the study costs are unfunded. 
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AMPHETAMINE RATING SCALE 
Subject Initials: Date: 
Subject Number: Time: 
Please respond to the statements below, indicating how you feel at this time. 
disagree disagree neutral agree agree 
strongly somewhat somewhat strongly 
1 .  Today I say things in 
the easiest possible 
way. 
2. Things around me seem 
more pleasing than 
usual .  
3 .  I have a pleasant feeling 
in my stomach. 
4 .  I feel I will lose the 
contentment that I have 
now. 
5 .  I feel in complete 
harmony with the world 
and those around me. 
6.  I can completely 
appreciate what others 
are saying when I am in 
this mood. 
7 .  I would be happy a l l  o f  
the time i f  I felt as I 
feel now. 
8 .  I feel so good that I 
know other people can 
tell i t .  
9. I feel as if something 
pleasant had just 
happened to me. 
10 .  I would be happy all 
the time i f  I felt as I do 
now. 
1 1 . I feel more clear-headed 
than dreamy. 
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1 2 .  I feel as if I would be 
more popular with 
people today. 
1 3 .  I feel a very pleasant 
emptiness. 
14.  My thoughts come 
more easily than usual. 
1 5 .  I feel less discouraged 
than usual. 
16 .  I a m  in  the mood to 
talk about the feelings I 
have. 
17 .  I feel more excited than 
dreamy. 
1 8 .  Answering these 
questions was very easy 
today. 
1 9 .  My memory seems 
sharper to me than 
usual. 
20. I feel as if  I could write 
for hours. 
2 1 .  I feel very patient. 
22. Some parts of my body 
are tingling. 
23. I have a weird feeling. 
AMPHETAMINE SCALE 
Subj ect i n it i a l s : Date : 
Subj ect number : Time : 
P lease mark on the l ine be low how you feel r ight now . 
1 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  1 
1 1 
The worst you 
have ever felt 
The best you 
have ever felt 
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A TTACHMENT I V  
STUDY DAY FLOW SHEET -- PART I .  
Rel!.t ive t ime (hours ) 
0 1 2 :3 4 6 S 1 0  1 2  
EEG X Yo X >: X X X X 
C":''"t'I XX X X X X >: X >: X 
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\l a t e r  
B e d  rest 
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Hours r e l a t i ve to d- afl1Jh e t am i ne ( or pl ac e bo )  dos i ng 
- 1 0 1 . 3 2 2 . 3  3 3 . 3  4 5 6 8 1 0  1 2  1 4  18 24 
X X X X X 
X X X X X X X X X X X 
X X X X X X X 
X - - - - - - - · - - · - - X - - - - - - - - - - - - - - - - - - X - - - - - - - · - - - - - X - - - - - - - - X - - - - - - - - X - - - x 
X X X X X X X X 
X X X X X X X X 
X X X X X X X 
X X X X X X X X 
X X X X X X X X 
X X X X X X X 
X X X 
X X X X X X 
X - - - - .  - - - - - - - - - - .  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - X 
:t-
>-3 >-3 :t-O 
:r: 
3: 
tr1 
Z 
>-3 
< 
N 
0-
..-
262 
CONSENT FORM 
Eva luat ion of quant i tative e lectroencepha lography ( EEG ) for 
assessment of centra l nervous system ( CNS ) stimu l ant response 
Part I .  Reproduc ibi l ity o f  control responses 
I nvestigators 
Patr i c i a  W .  S l attum , Pharm . D . / Ph . D .  candidate 
W i l l iam H .  Barr , Pharm . D . , Ph . D .  
Jurgen Ven i t z , M . D . , Ph . D .  
Joseph A .  Sgro , M . D . , Ph . D .  
Ananda K .  Pandurangi ,  M . D .  ( Medica l director ) 
I ntroduction 
You are be ing asked to part ic ipate i n  this study because you 
are hea lthy and not tak ing st imu l ant drugs or other 
med i cat i ons on a chronic bas is . Thi s  study i s  des igned to 
he lp us learn how peop le not tak ing med ication perform on 
var ious ment a l  tests , and whether performance on the tests 
changes dur ing the day . We a l so w i l l  study your bra i n  waves 
( EEG ) at var ious t imes dur ing the day . The data col lected 
wi l l  enable us to better plan future stud ies l ook ing at the 
e f fects of medications on the tests . Eight subj ects l ike 
yourse l f  w i l l  be selected to part icipate in the present study . 
I f  you agree to part ic ipate , you w i l l  be expected to provide 
informat ion about your medi c a l  h i story , have laboratory work 
done ( including blood and urine tests ) , have a physical 
examinat ion , and an EKG ( e l ectr ical trac i ng of the heart ) to 
determine whether you have any medical cond ition that wou ld 
prevent you from partic ipat ing in the study . Your urine w i l l  
be tested for drugs of abuse . You w i l l  not be permitted to 
take any over the counter med ications ( such as antacid , 
asp i r in , vitamins or cold preparations ) or any beverages 
conta i n ing caf fe ine or a l coho l for the 7 2  hours before each 
study day and on each study day . 
You w i l l  be expected to report to the study unit one day each 
week for three consecut ive weeks . On each day of the study , 
you wi l l  come to the unit at 7 : 0 0 a . m .  a fter an overnight fast 
( start ing at midnight ) . You may have water , but no other 
beverage or food . Lunch w i l l  be provided 4 hours a fter the 
testing has started ( approximately 1 2 : 0 0 noon ) and d i nner at 
10 hours ( approximately 6 :  0 0  p .  m . ) after the testing has 
started . After 1 2  hours of test ing , you may go home 
( approximate ly 9 : 0 0 p . m . ) . 
I n i t i ta l s  
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The tests that you w i l l  be taki ng repeatedly throughout the 
day inc lude : two computer i zed tests , answering 2 
questionna ires about you mood , and record ing your bra i n  waves 
( EEG ) . To have your EEG recorded , you must wear a bathi ng 
cap- l ike apparatus with 2 8  d i sks / e l ectrodes . Through a hole i n  
each e l ectrode , your sca lp wi l l  be c leaned and a sma l l  amount 
of j e l ly - l ike substance w i l l  be app l ied to your sca lp to make 
the contact . In addition , s i x  sma l l ,  round e lectrodes w i l l  be 
attached to your earlobes and taped on your face above and 
below your eyes . The cap wi l l  rema i n  on your head for most of 
the day . Each of the individua l tests ( includ i ng EEG ) takes 
l ess than 5 minutes to comp l ete . These tests w i l l  be repeated 
8 t imes dur ing each study day . 
Bene f its 
You are be ing asked to part ic ipate in th i s  study as a 
vo lunteer . The study i s  of no direct med i c a l  bene f i t  to you . 
There wi l l  be no charge to you for the screen ing examination 
and the results wi l l  be made ava i lable to you i f  you want 
them . 
You wi l l  be paid $ 1 5 0 . 0 0 for the completion of this study . I f  
you e lect t o  withdraw before the end o f  the study , you w i l l  be 
paid on a prorated bas i s  as descr ibed under W ithdrawa l .  
Alternative Therapy 
There i s  no therapeut ic benef i t  to you for part ic ipating in 
this study . Your part ic ipat ion is ent irely voluntary ; the 
a l ternat ive is not to part ic ipate in the study . 
Ri sks . I nconveniences. Di scomforts 
None of the tests in th is study are harmfu l . There may be 
some discomfort associated with the physical exam , EKG , and 
laboratory tests , and with the EEG when apply ing the cap and 
wear ing it throughout the day . Although the tape and gel used 
for the EEG are hypoa l l ergen i c , they may rarely cause skin 
irritat ion . After the cap i s  removed , you wi l l  be able to 
wash and dry your hair . 
Costs of Part i c ipat i on 
There w i l l  be no charge to you for any laboratory tests or 
physical examination related to the conduct of th i s  study . 
Th i s  is a t ime consuming study that may interfere with your 
emp l oyment or other activities . You w i l l  be con f ined to the 
study unit for the ent ire day on each study day . You must 
provide your own transportation to and from the study s ite . 
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Pregnancy 
Pregnant f ema les are not exc luded from this study . 
Research Re lated I njury 
Every e f fort w i l l  be made to prevent any i n j ury that cou ld 
result from your part ic ipation in this study . In the event of 
any physical and or mental inj ury resulting from your 
partic ipat ion i n  th is research proj ect , Virg i n i a  Commonwea lth 
Univers ity/Medical Co l lege of Virg in i a  w i l l  not offer 
compensat ion . I f  i n j ury occurs , medical treatment w i l l  be 
ava i lable at MCV Hosp ita l s . Fees for such treatment w i l l  be 
b i l l ed to you or appropriate third party insurance . 
Con f ident i a l ity of Records 
The invest igators wi l l  treat your identity with professional 
standards of conf ident i a l ity . Information obt a i ned i n  th is 
study may be pub l i shed , but your ident ity w i l l  not be 
revea led . 
withdrawa l 
Your part ic ipat i on in this study is voluntary . I f  you decide 
to part ic ipate , you may withdraw at any t ime . Neither refusa l 
to part ic ipate nor withdrawa l w i l l  resu l t  in any penalty or 
loss of benefits to which you are otherwise entit led . I f  you 
do not comp lete the study because of premature withdrawa l ,  the 
honorar ium w i l l  be prorated based on the amount of usable 
i nformat ion wh ich has been col lected . 
I f  you have any quest ions at any t ime concern ing the study 
procedures , you may contact the study i nvest igators at : 
Patr i c i a  W .  S l attum 
Wi l l i am H .  Barr 
Jurgen Venitz 
Joseph A.  Sgro 
Off ice Home 
Dr . Pandurangi i s  the medical director for th i s  study . He can 
be reached dur ing off ice hours at  and other t imes at 
. I f  Dr . Pandurang i is unava i labl e ,  you may ca l l  Dr . 
Anthony Pe l onero at the same numbers . 
You w i l l  receive a copy of th i s  consent form . 
I n i t i a l s  
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I have read the above informat ion , and I have had an 
opportun ity to ask quest ions to help me understand what my 
part i c ipat ion w i l l  i nvolve . I free ly g ive my consent to 
partic ipate i n  this study . 
S igned Date 
( volunteer ) 
S i gned 
(witness ) 
Date 
S i gned 
( investigator ) 
Date 
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CONSENT FORM 
Eva luat ion of quanti tative electroencepha lography ( EEG ) for 
assessment of central nervous system ( CNS ) st imu l ant response 
Part I I . Compari son of quantitative EEG to behaviora l ,  
psychol ogical and neuroendocrine measures of 
response to dextroamphetamine 
I nvestigators 
Patri c i a  W .  S lattum , Pharm . D . / Ph . D .  candidate 
W i l l i am H .  Barr , Pharm . D . , Ph . D .  
Jurgen Ven i tz ,  M . D . , Ph . D .  
Joseph A .  Sgro , M . D . , Ph . D .  
Ananda K .  Pandurang i ,  M . D .  (Medical director ) 
Introduct ion 
You are being asked to part ic ipate i n  th i s  study because you 
are hea l thy and not taking st imu lant drugs or other 
med i cations on a chronic bas i s .  Th is study is designed to 
study the relationship between changes in your bra i n  waves 
( EEG ) and other menta l tests after tak ing dextroamphetamine . 
Dextroamphetamine is a centra l nervous system st imulant drug . 
E ight subj ects l ike yourse l f  w i l l  be sel ected to part ic ipate 
i n  the present study . 
I f  you agree to part i c ipate , you w i l l  be expected to provide 
i n format i on about your med ica l h i story , have laboratory work 
done ( includ i ng blood and urine tests ) , have a physical 
examinat ion , and an EKG ( e lectr ical tracing of the heart ) to 
determine whether you have any medical condi t ion that wou ld 
prevent you from part ic ipat i ng in the study . Your ur ine w i l l  
be tested for drugs of abuse . You wi l l  not be permitted to 
take any prescript i on med ications for four weeks before the 
start of the study or during the study . You w i l l  not be 
permitted to take any over the counter medi cat ions ( such as 
antacid , aspirin , vitamins or cold preparat i ons ) or any 
beverages conta i n ing caf fe ine or a lcoho l for the 7 2  hours 
before each study day and on each study day . You must 
mainta i n  a d iet l ow in monoamines for three days before the 
study accord ing to the i nstruct ions the i nvest igators g ive 
you . Prior to the start of the study you must undergo a 
practice sess ion with the EEG (measur ing your bra in wave s )  and 
other tests that w i l l  be used dur ing the study . 
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You w i l l  be expected to report to the study unit for a tot a l  
o f  4 study per i ods o n  4 consecutive weeks . Dur i ng each 
peri od , you w i l l  come to the unit at 7 : 0 0 p . m .  on the evening 
before dextroamphetamine dos ing and w i l l  not be released unt i l  
9 : 0 0 a . m .  o n  the day a fter dextroamphetamine dos ing . 
You w i l l  rece ive e ight , 2 gram oral doses ( one every 4 hour s )  
of ammonium chloride tablets t o  acidify your urine dur ing each 
study per i od . On the morn ing of dos ing , you w i l l  begi n  a 7 
hour per i od of bedrest . A catheter w i l l  be inserted i nto your 
ve i n  and two blood samples ( about 12 ml or 2 . 5 teaspoonsful ) 
w i l l  be drawn . You w i l l  then rece ive a s ingl e  oral dose of 
dextroamphetamine ( 5 ,  1 0 ,  or 20 mg ) or a p lacebo capsu le (a 
capsu le with no act ive agent ) with 8 oz . water dur ing each 
per i od . You w i l l  rece ive a l l  four treatments by the end of 
the study . You w i l l  not be told which dose you are rece iving 
dur ing a g iven per i od . 
After dos i ng , 1 8  addition a l  blood samples w i l l  be col lected 
through the catheter dur ing each per i od . A tota l of 5 0 4  ml 
( about one pint)  of bl ood w i l l  be col l ected dur ing the ent ire 
study . I f  the catheter f a i l s  to work , a new catheter wi l l  be 
i nserted or it may be necessary to obta i n  blood samples by 
stick ing a need le direct ly into the ve i n . A l l  of your urine 
w i l l  a l so be col lected for 2 4  hours a fter tak i ng the 
dextroamphetamine or placebo . 
Begi nn i ng j ust prior to dos ing , you wi l l  be taki ng a series of 
tests repeated ly throughout the day . These tests inc lude : 
two compute r i z ed tests , answer ing 2 questionnaires about you 
mood , and record i ng your bra in waves ( EEG ) . To have your EEG 
recorded , you must wear a bathing cap- l ike apparatus with 2 8  
d i sks / e lectrodes . Through a hole i n  each e l ectrode , your 
sca lp w i l l  be c leaned and a sma l l  amount of j e l ly - l ike 
substance w i l l  be appl i ed to the sca lp to make a good contact . 
I n  add i t ion , s ix sma l l , round e lectrodes w i l l  be attached to 
your ear lobes and taped on your face above and be l ow your 
eyes . The cap w i l l  rema i n  on your head for most of the day . 
Each of the individua l tests ( including EEG ) takes l ess than 
5 minutes to comp lete . These tests w i l l  be repeated 8 t imes 
duri ng each study per i od . Your heart rate and blood pressure 
wi l l  be mon itored per i odica l ly throughout the day . 
The pre study physical examinat ion and laboratory tests wi l l  be 
repeated at the end of the study . 
Benefits 
You are be i ng asked to part ic ipate i n  th i s  study as a 
volunteer . The study is of no d i rect medical benef i t  to you . 
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There w i l l  be no charge to you for the screening examinat ion 
and the results w i l l  be made ava i lable to you if you want 
them . 
You w i l l  be paid $ 6 0 0 . 0 0 for the completion o f  this study . I f  
you w ithdraw early o r  are withdrawn by the med ical monitor , 
the fee w i l l  be prorated ( See Withdrawa l )  . 
A lternat ive Therapy 
There is no therapeut ic benef i t  to you for part i c ipating in 
this study . Your part ic ipation is ent ire ly voluntary . The 
a l ternative is not to parti cipate in the study . 
Risks. I nconven iences. D i scomforts 
A tot a l  of 8 0  blood samples wi l l  be drawn dur ing the study . 
The tot a l  amount of blood wi l l  be 5 0 4  m l  or about one pint 
over the four weeks of the study , wh i ch i s  about the same as 
the amount of blood donated at a s ingle donor sess ion . To 
obt a i n  the blood samples a sma l l  catheter w i l l  be inserted 
into a ve i n  in your arm . Th is procedure may cause some 
d i scomfort , pa i n , or s l ight bru is ing around the s ite of the 
needl e  st i ck . I f  the catheter f a i l s  to work , a new catheter 
w i l l  be inserted or blood samp les w i l l  be co l l ected d i rectly 
through a need le inserted i nto the ve in . A l l  of your ur ine 
produced dur i ng the 24 hours a fter dos ing must be col lected . 
You must rema i n  at bedrest ( except for ur i ne col lection ) for 
7 hours dur ing each study per i od . Wh i l e  on the study unit you 
w i l l  eat only the mea ls provided by the i nvestigators at t imes 
prescribed by the investigators . You wi l l  requ ired to rema in 
on the unit for 37 hours dur ing each per iod . You may rece ive 
phone ca l l s  dur ing the study , but no v i s i tors w i l l  be a l lowed . 
Dextroamphetamine i s  a st imU lant which may cause s ide e f fects : 
nervousness , d i z z iness , headache , irr itab i l ity ,  d i f f i culty 
s l eeping , rapid heart rate , changes i n  blood pressure , l oss of 
appet ite , dry mouth , nausea , changes i n  sexua l desire or f a l se 
sense of wel l-be ing . Ammonium ch lor ide , used to a c i d i fy the 
urine , may cause upset stomach , loss of appetite , nausea , 
thirst , rash , or headache . 
I f  any undesirable e f fects occur , you shou ld report them 
d irectly to the i nvest igators .  Dr . Pandurang i i s  the medical 
d irector for this study and i s  the person you can contact i n  
the c a s e  of a med ica l emergency . I f  you can not reach Dr . 
Pandurang i ,  you may contact Dr . Anthony Pelonero or proceed to 
the emergency room for med ica l  treatment . 
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None of the tests in this study are harmfu l . There may be 
some d i scomfort associated with the EEG when apply i ng the cap 
and wearing it throughout the day . Although the tape and gel 
used for the EEG are hypoa l lergen i c , they may rarely cause 
skin irr itation . After the cap i s  removed , you w i l l  be able 
to wash and dry your hair . 
There may be some d iscomfort associated with the phys ica l 
exam , EKG , and l aboratory work conducted before and a fter the 
study . 
Costs of Part i c ipat ion 
There wi l l  be no charge to you for any laboratory tests , 
phys i c a l  examinat ion , hosp ita l care , or other tests related to 
the conduct of th i s  study . Thi s  i s  a t ime consuming study 
that may interfere with your employment or other act ivities . 
You wi l l  be conf ined to the study unit overni ght and for an 
entire day at each of 4 study per i ods . You must provide your 
own transportation to and from the study s ite . 
Pregnancy 
For fema le sUbj ects : You must be using an i ntrauter ine 
contracept ive device ( IUD ) or be surg ica l ly ster i le i n  order 
to part i c ipate in th is study . You w i l l  be tested for 
pregnancy pr i or to the start of the study and before each 
dextroamphetamine dose . You w i l l  be dropped from the study i f  
you are pregnant . 
Research Rel ated I njury 
Every e ffort wi l l  be made to prevent any i n j ury that could 
result from your part ic ipat ion in th i s  study . I n  the event of 
any phys ical and or mental inj ury resu lting from your 
parti c ipat ion in this research proj ect , Virg i n i a  Commonwea lth 
Un ivers ity /Med ical Col lege of Virg i n i a  wi l l  not provide 
compensat i on . I f  inj ury occurs , med ical treatment w i l l  be 
ava i lable at Mev Hosp ita l s . Fees for such treatment w i l l  be 
b i l l ed to you or appropr iate third party insurance . 
Con f ident i a l ity of Records 
The i nvestigators w i l l  treat your identity with profess iona l 
standards of conf ident i a l ity . I t  i s  important for the united 
states Food and Drug Administration to be able to i nspect the 
results of th i s  study . By s igning th is consent form , you 
authori z e  release of the port i on of your medical records 
dea l ing with this study to the FDA . I nformation obta ined in 
this study may be pub l i shed , but your identity w i l l  not be 
revea led . 
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w i thdrawa l 
Your part icipation in th i s  study is voluntary . I f  you decide 
to part ic ipate , you may w ithdraw at any t ime . Neither refusal 
to part ic ipate nor w ithdrawal w i l l  result i n  any penalty or 
l oss of benef its to wh ich you are otherwise entit led . I f  you 
have any quest ions at any t ime concerning the study 
procedures , you may contact the study i nvest igators :  
Patr i c i a  W .  S lattum 
W i l l i am H .  Barr 
Jurgen Ven itz 
Joseph A.  Sgro 
O f f ice Home 
Dr . Pandurang i i s  the medical d i rector for this study . He can 
be rea ched dur ing off ice hours at  and other t imes at 
. Th i s  i s  the Mev telepage . They can d irectly 
contact e ither Dr . Pandurangi or Pe lonero at home . I f  Dr . 
Pandurangi is unava i lable , you may ca l l  Dr . Anthony Pelonero 
at the same numbers . 
I f  you do not complete the study because of premature 
w ithdrawa l , the honorar ium w i l l  be prorated based on the 
amount of usable i nformation wh ich has been col l ected . I f  the 
med i ca l  mon itor terminates your part ic ipat ion in the study you 
w i l l  rece ive the ent ire amount . 
You w i l l  rece ive a copy of this consent form . 
I have read the above informat i on , and I have had an 
opportun ity to ask quest ions to help me understand what my 
part ic ipat ion w i l l  involve . I freely g ive my consent to 
part ic ipate in th is study . 
S i gned Date 
( vo lunteer)  
S i gned Date 
(w itnes s )  
S i gned Date 
( invest igator ) 
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AMPHET AMINE RATING SCALE 
Subject Initials: Date: 
Subject Number: Time: 
Please respond to the statements below, indicating how you feel at this time. 
disagree disagree neutral agree agree 
strongly somewhat somewhat strongly 
1 .  Today I say things in 
the easiest possible 
way. 
2 .  Things around me seem 
more pleasing than 
usual . 
3 .  I have a pleasant feeling 
in my stomach. 
4 .  I feel I will lose the 
contentment that I have 
now. 
5 .  I feel i n  complete 
harmony with the world 
and those around me. 
6.  I can completely 
appreciate what others 
are saying when I am in 
this mood . 
7 .  I would be happy all of 
the time if I felt as I 
feel now. 
8 .  I feel so good that I 
know other people can 
tell it. 
9. I feel as if something 
pleasant had just 
happened to me. 
10.  I would be happy all 
the time if l felt as I do 
now. 
1 1 .  I feel more clear-headed 
than dreamy. 
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1 2 .  I feel as if I would be 
more popular with 
people today. 
1 3 .  I feel a very pleasant 
emptiness. 
1 4 .  My thoughts come 
more easily than usual . 
1 5 .  I feel less discouraged 
than usual . 
1 6 .  I a m  i n  the mood to 
talk about the feelings I 
have. 
1 7 .  I feel more excited than 
dreamy. 
1 8 .  Answering these 
questions was very easy 
today . 
19.  My memory seems 
sharper to me than 
usual . 
20. I feel as if I could write 
for hours. 
2 1 .  I feel very patient. 
22. Some parts of my body 
are tingling. 
23 .  I have a weird feeling. 
APPENDIX C 
AMPHETAMINE SCALE 
Subj ect init i a l s : Date : 
Subj ect number : T ime : 
P l ease mark on the l ine be low how you feel r ight now . 
: - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - : 
The worst you 
have ever felt 
The best you 
have ever felt 
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Figure D. l Learning curve for continuous performance task (percent correct) for 
Subject 1 
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Figure D.3  Learning curve for continuous performance task (percent correct) for 
Subject 3 
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Figure D.4 Learning curve for continuous performance task (percent correct) for 
Subject 5 
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Figure D.5  Learning curve for continuous performance task (percent correct) for 
Subject 6 
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Figure D .6  Learning curve for continuous performance task (percent correct) for 
Subject 7 
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Figure D . 7  Learning curve for continuous performance task (percent correct) for 
Subject 8 
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Figure D. 8 Learning curve for continuous performance task (percent correct) for 
Subject 9 
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Learning curve for continuous performance task (average latency) for 
Subject 1 
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Figure D . lO Learning curve for continuous performance task (average latency) for 
Subject 2 
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Figure D. I I  Learning curve for continuous performance task (average latency) for 
Subject 3 
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Figure D. 12  Learning curve for continuous performance task (average latency) for 
Subject 5 
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Figure D. 13  Learning curve for continuous performance task (average latency) for 
Subject 6 
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Figure D. 14  Learning curve for continuous performance task (average latency) for 
Subject 7 
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Figure D.IS Learning curve for continuous performance task (average latency) for 
Subject 8 
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Figure D. 1 6  Learning curve for continuous performance task (average latency) for 
Subject 9 
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Figure D. 1 7  Learning curve for finger tapping (right hand) for Subject 1 
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Figure D . 1 8 Learning curve for finger tapping (right hand) for Subject 2 
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Learning curve for finger tapping (right hand) for Subject 3 
5 10 15  20 25 
TEST BATIERY NUMBER 
Figure 0.20 Learning curve for finger tapping (right hand) for Subject 5 
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Learning curve for finger tapping (right hand) for Subject 6 
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Figure D.22 Learning curve for finger tapping (right hand) for Subject 7 
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Figure D.24 Learning curve for finger tapping (right hand) for Subject 9 
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Figure D.25 Learning curve for finger tapping (left hand) for Subject 1 
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Figure D.26 Learning curve for finger tapping (left hand) for Subject 2 
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Figure D.27 Learning curve for finger tapping (left hand) for Subject 3 
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Figure D.28 Learning curve for finger tapping (left hand) for Subject 5 
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Figure 0 . 30 Learning curve for finger tapping (left hand) for Subject 7 
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Figure D . 3 1  Learning curve for finger tapping (left hand) for Subject 8 
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Figure D.32 Learning curve for finger tapping (left hand) for Subject 9 
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Table E. l Randomization Schedule 
SUBJECT PERIOD 1 PERIOD 2 PERIOD 3 PERIOD 4 
NUMBER 
1 A B C D 
2 B D A C 
3 D C B A 
4 C A D B 
5 A B C D 
6 B D A C 
7 D C B A 
8 C A D B 
9 A B C D 
10  B D A C 
A = 5 MG DOSE ( 1  X 5 MG CAPSULE + 1 X PLACEBO CAPSULE) 
B = PLACEBO (2 X PLACEBO CAPSULES) 
C = 20 MG DOSE (2 X 10 MG CAPSULES) 
D = 10 MG DOSE ( l  X 10 MG CAPSULE + 1 X PLACEBO CAPSULE) 
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Figure F.2  Chromatogram from blank serum of Subject 2 
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Figure F.4 Chromatogram from blank serum of Subject 5 
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Figure G.2 Chromatogram from 2 ng/mL standard - start of run 
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Figure G , 3  Chromatogram from 2 ng/mL standard - end o f  run 
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Figure G.4 Chromatogram from 3 ng/mL standard - start of run 
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Figure G . 5  Chromatogram from 3 ng/mL standard - end of  run 
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Figure G . 6  Chromatogram from 5 ng/mL standard - start of run 
Cl.. 
o ..... 
Lf) 
305 
(T, 
I 
' D  I ( - I I n : I z: cr:  ::l o-
u: .f) I 
I 
RT 
14 .306 
14 . 595 
Area 
8220 
72548 
Width 
0.046 
0.046 
, 
" 
n 
r 
-i 
Figure G.7  Chromatogram from 5 ng/mL standard - end of  run 
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Figure G . 8  Chromatogram from 10 ng/mL standard - start of run 
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Figure G.9  Chromatogram from 1 0  ng/mL standard - end of  run 
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Figure G . 10 Chromatogram from 20 ng/mL standard - start of run 
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Figure G. l l  Chromatogram from 20 ng/mL standard - end of run 
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Figure G. l 3  Chromatogram from 5 0  ng/mL standard - end of run 
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Figure G. 14 Chromatogram from 3 .5  ng/mL control - start of run 
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Figure G. 1 5  Chromatogram from 3 .5  ng/mL control - end o f  run 
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Figure G. 1 6  Chromatogram from 7 . 5  ng/mL control - start of run 
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Figure G . 17  Chromatogram from 7 .5  ng/mL control - end of  run 
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Figure G . 1 8  Chromatogram from 3 5  ng/mL control - start of run 
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Figure H. I Serum amphetamine concentration versus time profile for Subject 1 
100 
::r 
i! Cl � 
z 0 
� � ... z w U 10 z 
0 U 
w Z � 
« 
t;:; 
:r 
Q. 
:::E 
« 
1 
0 5 10 15 20 25 
TIME (HR) 
...... S MG -fi- 10 MG -'JOE- 20 MG - REGRESSION LINES 
Figure H.2 Log serum amphetamine concentration versus time profile for Subject 1 
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Figure H .3  Serum amphetamine concentration versus time profile for Subject 2 
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Figure H.4  Log serum amphetamine concentration versus time profile for Subject 2 
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Figure H .5  Serum amphetamine concentration versus time profile for Subject 3 
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Figure H .6  Log serum amphetamine concentration versus time profile for Subject 3 
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Figure H .7  Serum amphetamine concentration versus time profile for Subject 4 
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Figure H . 8  Log serum amphetamine concentration versus time profile for Subject 4 
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Figure H. 1O Log serum amphetamine concentration versus time profile for Subject 5 
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Figure H. I I  Serum amphetamine concentration versus time profile for Subject 6 
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Figure H. 12  Log serum amphetamine concentration versus time profile for Subject 6 
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Figure H . I 3  Serum amphetamine concentration versus time profUe for Subject 7 
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Figure H. I4  Log serum amphetamine concentration versus time profile for Subject 7 
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Figure H. 15  Serum amphetamine concentration versus time profile for Subject 8 
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Figure H . 1 6  Log serum amphetamine concentration versus time profile for Subject 8 
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Figure H. t 7  Serum amphetamine concentration versus time profile for Subject 9 
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Figure H. t 8  Log serum amphetamine concentration versus time profile for Subject 9 
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Figure H. 19  Serum amphetamine concentration versus time profile for Subject 10  
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Figure H.20 Log serum amphetamine concentration versus time profile for Subject 10  
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Figure 1 . 1 Amphetamine serum concentration/dose versus time for Subject 1 
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Figure 1 .2  Amphetamine serum concentration/dose versus time for Subject 2 
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Figure 1 . 3  Amphetamine serum concentration/dose versus time for Subject 3 
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Figure 1 .4 Amphetamine serum concentration/dose versus time for Subject 4 
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Figure 1 . 5  Amphetamine serum concentration/dose versus time for Subject 5 
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Figure 1 . 6  Amphetamine serum concentration/dose versus time for Subject 6 
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Figure I .  7 Amphetamine serum concentration/dose versus time for Subject 7 
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Figure 1 . 8  Amphetamine serum concentration/dose versus time for Subject 8 
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Figure 1 .9  Amphetamine serum concentration/dose versus time for Subject 9 
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Figure 1 . 10  Amphetamine serum concentration/dose versus time for Subject 10  
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Figure J . 1 Urinary excretion rate of amphetamine versus time plot for Subject 1 
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Figure J .2 Log urinary excretion rate of amphetamine versus time plot for Subject 1 
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Figure 1 . 3  Urinary excretion rate of amphetamine versus time plot for Subject 2 
fl' :I: 
a () 
!. 
w ..... � 
Z 0 
� a: () 
1:) 
10001�-------------------------------------------' 
100 
10+
0
--------�------�--------�------�--------j
25 5 10 15 20 
TIME AT MIDPOINT OF COLLECTION (HR) 
1 ___ 20 MG -- 5 MG I 
335 
Figure 1 .4  Log urinary excretion rate of amphetamine versus time plot for Subject 2 
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Figure J .5  Urinary excretion rate of amphetamine versus time plot for Subject 4 
If' 
� () 
!. 
w � ! 
Z 0 
� a: () 1:S 
1 000�------------------------------------------� 
100 
10+-------�--------�------_r--------._------� 
o 5 10 15 20 
TIME AT MIDPOINT OF COLLECTION (HR) 
1 ___ 20 MG -+- 10 MG --- 5 MG I 
25 
336 
Figure J .  6 Log urinary excretion rate of amphetamine versus time plot for Subject 4 
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Figure J .  7 Urinary excretion rate of amphetamine versus time plot for Subject 6 
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Figure J. 8 Log urinary excretion rate of amphetamine versus time plot for Subject 6 
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Figure J .9 Urinary excretion rate of amphetamine versus time plot for Subject 8 
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Figure J . 1 0 Log urinary excretion rate of amphetamine versus time plot for Subject 8 
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Figure J . 1 1  Urinary excretion rate of amphetamine versus time plot for Subject 9 
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Figure J . 1 2 Log urinary excretion rate of amphetamine versus time plot for Subject 9 
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Figure J . 1 3  Urinary excretion rate of amphetamine versus time plot for Subject 10 
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Figure J . 14 Log urinary excretion rate of amphetamine versus time plot for Subject 10 
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Figure K. I Renal clearance plot for Subject I (5 mg dose) 
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Figure K .3  Renal clearance plot for Subject 1 (20 mg dose) 
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Figure K.4 Renal clearance plot for Subject 2 (5 mg dose) 
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Figure K.5  Renal clearance plot for Subject 2 (20 mg dose) 
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Figure K .6  Renal clearance plot for Subject 4 (5 mg dose) 
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Figure K .7  Renal clearance plot for Subject 4 ( 1 0  mg dose) 
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Figure K .8  Renal clearance plot for Subject 4 (20 mg dose) 
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Figure K .9  Renal clearance plot for Subject 6 (5 mg dose) 
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Figure K. 1O  Renal clearance plot for Subject 6 ( 1 0  mg dose) 
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Figure K. l l  Renal clearance plot for Subject 6 (20 mg dose) 
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Figure K . 12 Renal clearance plot for Subject 8 (5 mg dose) 
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Figure K . 1 3  Renal clearance plot for Subject 8 ( 10  mg dose) 
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Figure K . 14  Renal clearance plot for Subject 8 (20 mg dose) 
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Figure K . 1 5  Renal clearance plot for Subject 9 (5 mg dose) 
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Figure K . 1 6  Renal clearance plot for Subject 9 ( 10  mg dose) 
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Figure K . 1 7  Renal clearance plot for Subject 9 (20 mg dose) 
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Figure K . 1 8  Renal clearance plot for Subject 10  (5 mg dose) 
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Figure K . 19  Renal clearance plot for Subject 10  ( 10  mg dose) 
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Figure K.20 Renal clearance plot for Subject 10  (20 mg dose) 
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Figure L 1 Baseline and placebo corrected total EEG power across all frequency 
bands versus time profile for Subject 1 
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Figure L2 Baseline and placebo corrected total EEG power across all frequency 
bands versus time profile for Subject 2 
354 
40 
30 
N 20 ( 
> 
.5- I a: w � 10 '"-...J « � 0 � 0 
-10 
-20 
0 2 4 6 
TIME (HR) 
1---- 5 MG -+- 10 MG --- 20 MG 
8 10  12 
Figure L.3 Baseline and placebo corrected total EEG power across all frequency 
bands versus time profile for Subject 4 
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Figure L.4 Baseline and placebo corrected total EEG power across all frequency 
bands versus time profile for Subject 6 
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Figure L.5 Baseline and placebo corrected total EEG power across all frequency 
bands versus time profile for Subject 7 
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Figure L.6 Baseline and placebo corrected total EEG power across all frequency 
bands versus time profile for Subject 8 
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Figure L .  7 Baseline and placebo corrected total EEG power across all frequency 
bands versus time profile for Subject 10  
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Figure L. 8 Baseline and placebo corrected total EEG power in the delta frequency 
band versus time profile for Subject 1 
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Figure L.9 Baseline and placebo corrected total EEG power in the delta frequency 
band versus time profile for Subject 2 
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Figure L. 1O  Baseline and placebo corrected total EEG power in the delta frequency 
band versus time proftle for Subject 4 
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Figure L. I I  Baseline and placebo corrected total EEG power in the delta frequency 
band versus time profile for Subject 6 
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Figure L 12 Baseline and placebo corrected total EEG power in the delta frequency 
band versus time profile for Subject 7 
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Figure L 1 3  Baseline and placebo corrected total EEG power in the delta frequency 
band versus time profile for Subject 8 
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Figure L. 14  Baseline and placebo corrected total EEG power in the delta frequency 
band versus time profile for Subject 10  
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Figure L. 15  Baseline and placebo corrected total EEG power in the theta frequency 
band versus time profile for Subject I 
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Figure L. 1 6  Baseline and placebo corrected total EEG power in the theta frequency 
band versus time profile for Subject 2 
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Figure L. I 7  Baseline and placebo corrected total EEG power in the theta frequency 
band versus time profile for Subject 4 
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Figure L. I 8  Baseline and placebo corrected total EEG power in the theta frequency 
band versus time profile for Subject 6 
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Figure L. 19  Baseline and placebo corrected total EEG power in the theta frequency 
band versus time profile for Subject 7 
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Figure L.20 Baseline and placebo corrected total EEG power in the theta frequency 
band versus time profile for Subject 8 
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Figure L.2 l  Baseline and placebo corrected total EEG power in the theta frequency 
band versus time profile for Subject lO  
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Figure L.22 Baseline and placebo corrected total EEG power in the alpha frequency 
band versus time profile for Subject 1 
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Figure L.23 Baseline and placebo corrected total EEG power in the alpha frequency 
band versus time profile for Subject 2 
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Figure L.24 Baseline and placebo corrected total EEG power in the alpha frequency 
band versus time profile for Subject 4 
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Figure L.25 Baseline and placebo corrected total EEG power in the alpha frequency 
band versus time profile for Subject 6 
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Figure L26 Baseline and placebo corrected total EEG power in the alpha frequency 
band versus time profile for Subject 7 
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Figure L27 Baseline and placebo corrected total EEG power in the alpha frequency 
band versus time profile for Subject 8 
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Figure L.28 Baseline and placebo corrected total EEG power in the alpha frequency 
band versus time profile for Subject 10  
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Figure L.29 Baseline and placebo corrected total EEG power in the beta I frequency 
band versus time profile for Subject 1 
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Figure L.30 Baseline and placebo corrected total EEG power in the beta I frequency 
band versus time profile for Subject 2 
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Figure L.3 1  Baseline and placebo corrected total EEG power i n  the beta I frequency 
band versus time profile for Subject 4 
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Figure L.32 Baseline and placebo corrected total EEG power in the beta I frequency 
band versus time profile for Subject 6 
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Figure L. 33 Baseline and placebo corrected total EEG power in the beta I frequency 
band versus time profile for Subject 7 
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Figure L .34 Baseline and placebo corrected total EEG power in the beta I frequency 
band versus time profile for Subject 8 
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Figure L. 35 Baseline and placebo corrected total EEG power in the beta I frequency 
band versus time profile for Subject 10  
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Figure L.36 Baseline and placebo corrected total EEG power in the beta n frequency 
band versus time profile for Subject 1 
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Figure L.37 Baseline and placebo corrected total EEG power in the beta II frequency 
band versus time profile for Subject 2 
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Figure L. 38 Baseline and placebo corrected total EEG power in the beta II frequency 
band versus time profile for Subject 4 
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Figure L. 39 Baseline and placebo corrected total EEG power in the beta II frequency 
band versus time profile for Subject 6 
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Figure LAO Baseline and placebo corrected total EEG power in the beta n frequency 
band versus time profile for Subject 7 
800 
600 
N' 400 
( 
> 
.s 200 = 
< 
tu CD 
: 0 a: w 
� -200 ... 
-' � 
0 ..... -400 
-aoo 
T' --:---.., � V � "" ?---
�/ ,� 
o 2 
--------
6 
TIME (HR) 
8 
1 ___ 5 MG -+- 10 MG --- 20 MG I 
1 0  1 2  
Figure L41 Baseline and placebo corrected total EEG power in the beta n frequency 
band versus time profile for Subject 8 
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Figure L.42 Baseline and placebo corrected total EEG power in the beta II frequency 
band versus time profile for Subject 10  
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Figure M . I Baseline and placebo corrected serum prolactin concentration versus time 
plot for Subject I 
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Figure M . 2  Baseline an d  placebo corrected serum prolactin concentration versus time 
plot for Subject 2 
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Figure M.3  Baseline and placebo corrected serum prolactin concentration versus time 
plot for Subject 4 
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Figure M.4  Baseline and placebo corrected serum prolactin concentration versus time 
plot for Subject 5 
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Figure M.5  Baseline and placebo corrected serum prolactin concentration versus time 
plot for Subject 6 
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Figure M . 6  Baseline and placebo corrected serum prolactin concentration versus time 
plot for Subject 7 
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Figure M _ 7  Baseline and placebo corrected serum prolactin concentration versus time 
plot for Subject 8 
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Figure M_8  Baseline and placebo corrected serum prolactin concentration versus time 
plot for Subject 9 
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Figure M_9  Baseline and placebo corrected serum prolactin concentration versus time 
plot for Subject 10 
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Baseline and placebo corrected self-rated mood scale score versus time 
plot for Subject ) 
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Figure N. 2 Baseline and placebo corrected visual analog mood scale score versus 
time plot for Subject ) 
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Baseline and placebo corrected self-rated mood scale score versus time 
plot for Subject 2 
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Figure NA Baseline and placebo corrected visual analog mood scale score versus 
time plot for Subject 2 
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Baseline and placebo corrected self-rated mood scale score versus time 
plot for Subject 4 
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Figure N. 6 Baseline and placebo corrected visual analog mood scale score versus 
time plot for Subject 4 
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Figure N. 7 Baseline and placebo corrected self-rated mood scale score versus time 
plot for Subject 5 
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Figure N.  8 Baseline and placebo corrected visual analog mood scale score versus 
time plot for Subject 5 
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Figure N. 9 Baseline and placebo corrected self-rated mood scale score versus time 
plot for Subject 6 
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Figure N. 1O  Baseline and placebo corrected visual analog mood scale score versus 
time plot for Subject 6 
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Figure N. 1 1  Baseline and placebo corrected self-rated mood scale score versus time 
plot for Subject 7 
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Figure N. I 2  Baseline and placebo corrected visual analog m ood  scale score versus 
time plot for Subject 7 
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Figure N.  1 3  Baseline and placebo corrected self-rated mood scale score versus time 
plot for Subject 8 
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Figure N. 14 Baseline and placebo corrected visual analog mood scale score versus 
time plot for Subject 8 
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Figure N. 1 5  Baseline and placebo corrected self-rated m ood  scale score versus time 
plot for Subject 9 
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Figure N. 1 6  Baseline and placebo corrected visual analog m ood  scale score versus 
time plot for Subject 9 
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Figure N. 17  Baseline and placebo corrected self-rated mood scale score versus time 
plot for Subject 10  
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Figure N. 1 8  Baseline and placebo corrected visual analog mood scale score versus 
time plot for Subject 10  
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l .... () .... a: a: 
0 () .... z w 
() a: w "-.... "-
() 
1 5,�--------------------------------------------------� 
1 0  
5 
0 
-5 
-101+---------,---------.----------.--------.--------.--------1 10 12 o 2 4 6 
TIME (HR) 
1 ___ 5 MG -- 10 MG --- 20 MG 
8 
Figure 0.2 Baseline and placebo corrected percent correct on the continuous 
performance task for Subject 1 
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Figure 0.4 Baseline and placebo corrected percent correct on the continuous 
performance task for Subject 2 
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Figure 0.6 Baseline and placebo corrected percent correct on the continuous 
performance task for Subject 4 
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Figure 0.7 Baseline and placebo corrected average latency on the continuous 
performance task for Subject 5 
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Figure 0.8  Baseline and placebo corrected percent correct on the continuous 
performance task for Subject 5 
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Figure 0.9 Baseline and placebo corrected average latency on the continuous 
performance task for Subject 6 
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Figure 0. 10  Baseline and placebo corrected percent correct on  the continuous 
performance task for Subject 6 
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Figure 0. 1 1  Baseline and placebo corrected average latency on the continuous 
performance task for Subject 7 
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Figure 0. 12  Baseline and placebo corrected percent correct on  the continuous 
performance task for Subject 7 
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Figure 0. 1 3  Baseline and placebo corrected average latency on the continuous 
performance task for Subject 8 
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Figure 0. 14  Baseline and placebo corrected percent correct on the continuous 
performance task for Subject 8 
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Figure 0. 15  Baseline and placebo corrected average latency on the continuous 
performance task for Subject 9 
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Figure 0. 1 6  Baseline and placebo corrected percent correct on the continuous 
performance task for Subject 9 
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Figure 0. 17  Baseline and placebo corrected average latency on the continuous 
performance task for Subject 10 
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Figure 0. 1 8  Baseline and placebo corrected percent correct on the continuous 
performance task for Subject 10  
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Figure 0_ 19  Baseline and placebo corrected finger tapping rate with the right hand for 
Subject 1 
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Figure 0.20 Baseline and placebo corrected finger tapping rate with the left hand for 
Subject 1 
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Figure 0.2 1 Baseline and placebo corrected fmger tapping rate with the right hand for 
Subject 2 
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Figure 0.22 Baseline and placebo corrected finger tapping rate with the left hand for 
Subject 2 
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Figure 0_23 Baseline and placebo corrected finger tapping rate with the right hand for 
Subject 4 
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Figure 0.24 Baseline and placebo corrected finger tapping rate with the left hand for 
Subject 4 
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Figure 0_25 Baseline and placebo corrected finger tapping rate with the right hand for 
Subject 5 
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Figure 0.26 Baseline and placebo corrected finger tapping rate with the left hand for 
Subject 5 
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Figure 0.27 Baseline and placebo corrected finger tapping rate with the right hand for 
Subject 6 
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Figure 0.28 Baseline and placebo corrected finger tapping rate with the left hand for 
Subject 6 
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Figure 0.29 Baseline and placebo corrected finger tapping rate with the right hand for 
Subject 7 
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Figure 0.30 Baseline and placebo corrected finger tapping rate with the left hand for 
Subject 7 
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Figure 0 _ 3 1  Baseline and placebo corrected finger tapping rate with the right hand for 
Subject 8 
2�----------------------------------------------� 
6 1 .5,+----------------------------j w 
� � 
o z 
� 
S 0.5+--I+�_c::::=-��:::::".,-�;.....,,=�ot:""'===------.:�.......::�----__j -' 
o z 
Ci: 0.. ;5 
a: w 
O.-----------------------------------��--���� 
" z 
..: .{l.5i+--------------------------� 
-1 ----,.----,.-----,------,----,------1 
6 
TIME (HR) 
8 10 12 o 2 4 
1 ___ 5 MG -+- 10 MG --- 20 MG 
Figure 0.32 Baseline and placebo corrected finger tapping rate with the left hand for 
Subject 8 
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Figure 0.33 Baseline and placebo corrected finger tapping rate with the right hand for 
Subject 9 
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Figure 0.34 Baseline and placebo corrected finger tapping rate with the left hand for 
Subject 9 
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Figure 0.35 Baseline and placebo corrected finger tapping rate with the right hand for 
Subject 10  
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Figure 0.36 Baseline and placebo corrected finger tapping rate with the left hand for 
Subject 1 0  
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Figure P. I Baseline and placebo corrected diastolic blood pressure versus time plot 
for Subject I 
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Figure P .3  Baseline and placebo corrected diastolic blood pressure versus time plot 
for Subject 2 
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Figure P .7  Baseline and placebo corrected diastolic blood pressure versus time plot 
for Subject 5 
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Figure P.9 Baseline and placebo corrected diastolic blood pressure versus time plot 
for Subject 6 
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Figure P. 1O  Baseline and placebo corrected systolic blood pressure versus time plot 
for Subject 6 
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Figure P _ 1 1  Baseline and placebo corrected diastolic blood pressure versus time plot 
for Subject 7 
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Figure P _ 1 2  Baseline and placebo corrected systolic blood pressure versus time plot 
for Subject 7 
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Figure P _ 1 3  Baseline and placebo corrected diastolic blood pressure versus time plot 
for Subject 8 
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Figure P . 14  Baseline and placebo corrected systolic blood pressure versus time plot 
for Subject 8 
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Figure P. 15  Baseline and placebo corrected diastolic blood pressure versus time plot 
for Subject 9 
50 
40 
0- JO X 
� 20 � 
w II: ::> 1 0  oo 
oo 
w 
a: 0 "" 
Q 
0 
0 · 1 0  ..... co 
(.) 
� ·20 0 I-
oo 
>-
oo 
-40 
·50 
0 2 4 6 
TIME (HR) 
1 ___ 5 MG -- 10 MG --- 20 MG 
8 10 1 2  
Figure P. 1 6  Baseline and placebo corrected systolic blood pressure versus time plot 
for Subject 9 
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Figure P_ 17  Baseline and placebo corrected diastolic blood pressure versus time plot 
for Subject 10 
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Figure P . 1 8  Baseline and placebo corrected systolic blood pressure versus time plot 
for Subject 10  
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Figure Q. l Baseline and placebo corrected heart rate versus time plot for Subject 1 
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Figure Q.2 Baseline and placebo corrected heart rate versus time plot for Subject 2 
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Figure Q.3  Baseline and placebo corrected heart rate versus time plot for Subject 4 
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Figure Q.4 Baseline and placebo corrected heart rate versus time plot for Subject 5 
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Figure Q.5 Baseline and placebo corrected heart rate versus time plot for Subject 6 
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Figure Q.6  Baseline and placebo corrected heart rate versus time plot for Subject 7 
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Figure Q.7 Baseline and placebo corrected heart rate versus time plot for Subject 8 
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Figure Q .8  Baseline and placebo corrected heart rate versus time plot for Subject 9 
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Figure Q_9 Baseline and placebo corrected heart rate versus time plot for Subject 10 
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